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 ABSTRACT 
The α, ω-dicarboxylic acids HOOC-(CH2)n-COOH (where n = 1-11) reacted smoothly 
with [Ag(CH3COO)] to yield 11 novel silver dicarboxylate complexes.  These silver 
dicarboxylates were reacted with triphenylphosphine (PPh3) in 1:2.5, 1:4 and 1:6 molar 
ratios resulting in the isolation of 30 novel silver dicarboxylate triphenylphosphine 
derivatives.  X-ray crystal structures for nine of these complexes were determined 
showing a variation in the structural motifs across the series with mononuclear, 
dinuclear, polynuclear and polymeric species being generated. When the 11 novel silver 
dicarboxylate complexes were reacted with bis-(diphenylphosphino)methane (dppm) in 
a 1:2 molar ratio 11 novel complexes were isolated.  The complexes were isolated as 
powders and 8 of them formulated as [Ag2(dicarboxylate)(dppm)4] with the remainder 
having just three dppm ligands in their formulae.  The only crystals isolated from this 
series precipitated from the mother liquor of the reaction involving 
dodecanedicarboxylic acid (dddaH2), which formulated as {Ag2(dppm)2(ddda)(H2O)}n  
and whose structure comprises a linear polymer in which centrosymmetric Ag2(dppm)2 
units are linked by diacid anions.     
The 11 novel silver dicarboxylate complexes were reacted with bis-
(diphenylphosphino)ethane (dppe) in a 1:2 molar ratio using the same procedure 
employed for the dppm reactions to yield 11 novel complexes which again were isolated 
as powders and formulated as either [Ag2(dicarboxylate)(dppe)4] or 
[Ag2(dicarboxylate)(dppe)3]. All of the complexes were found to have limited 
solubilities and the phosphine derivatives were all relatively light stable compared to 
simple silver salts such as AgNO3.  
The metal free dicarboxylic acids and phosphine based ligands are relatively poor 
antifungals and display no antibacterial activity.  The 11 silver dicarboxylate complexes 
are potent in-vitro anti-Candida agents but only five of them displayed good 
antibacterial activity, although it was significantly less than that of AgNO3. 
Furthermore, unlike the activity of AgNO3 these five complexes displayed some 
discrimination towards the Grampositive (S. aureus /MRSA) and Gramnegative (E.coli) 
bacteria suggesting that these complexes do not act on microbial cells in the same way 
as AgNO3.  All of the PPh3 complexes exhibited significant antifungal activity against 
  
  
the Candida albicans cells although their activity is, on average, over ten times less than 
that of the equivalent silver dicarboxylate. Only 5 of these complexes are active against 
the bacterial cells tested.  Three of these complexes display higher antibacterial activity 
(comparable to that of AgNO3) than antifungal activity, a trend not previously observed.  
The dppm and dppe derivatives all exhibited significant antifungal activity against the 
Candida albicans cells.  However, most of their activities are again significantly less 
than that of the equivalent silver dicarboxylate. Only three of these complexes display 
any activity against the bacterial cells tested and one of them exhibits good activity 
against the Grampositive MRSA but it is inactive against the Gramnegative E.coli.
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ndaH2                    Nonanedioic acid 
ddaH2                    Decanedioic acid 
uddaH2          Undecondioic acid 
dddaH2          Dodecanedioic acid 
uddcaH2          Undecondicaboxylic acid 
      Wavenumber  
   Degrees 
C   Degrees Celsius 
DMSO   Dimethylsulphoxide 
IR   Infrared 
Sym   Symmetric 
Asym   Asymmetric 
α   Alpha  
 IC50               Drug concentration eliciting 50% of max. inhibition 
ca.   Circa 
14DM   14α-demethylase 
DNA   Deoxyribosenucleic acid 
PBS   Phosphate buffer saline 
RNA   Ribonucleic acid 
RPMI   Roswell Park Memorial Institute 
SDA   Sabouraud dextrose agar 
Å   Angstrom 
EtOH   Ethanol 
H, min, s  Hours, minutes, seconds 
  
  
K   Kelvin 
MeOH   Methanol 
R   Alkyl, aryl, aromatic substituent 
Hasp   Acetasalicyclic acid 
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I General Introduction 
During the last two decades the frequency and types of life-threatening fungal and 
bacterial infections has increased dramatically. This has been as a result of changes in 
both medical practice and in the diseases to which humans are exposed. The yeast 
Candida albicans, is considered to be the most opportunistic fungal pathogen as it 
presents itself in immunocompromised patients, and over 75% of women suffer from 
vaginal candidosis at some stage in their lifetime.  Candida infections are diverse in 
their manifestations, varying from superficial skin problems, chronic infection of the 
nails, mouth, throat or vagina to frequently fatal systemic diseases that involve the 
lungs, heart, gastrointestinal tract, central nervous system and other organs.  These 
infections are considered to be opportunistic in nature since some aspect of the host's 
defence system is impaired in some way. C. albicans is a dimorphic yeast, existing in a 
yeast phase (blastospore) and having the ability to form germ tubes that elongate into 
hyphae (hyphal phase). The definitions of the two phases are given below. 
A blastospore is defined as the unicellular form of the fungus, the yeast cell.It is 
distinguished by a specific process of mitotic cell division known as budding (Figure 1).  
Budding involves the growth of new cellular material from selected sites on the 
blastospore surface. The new bud grows for a period of time until it is one third the size 
of the parent blastospore, and then stops.  Nuclear division follows and a septum is laid 
down between the parent and the daughter cell.  The two cell units separate and form 
two blastospores. 1 
 
Figure 1: A yeast cell budding2 
 
 
 
 
 
 
 
 
 
3 
 
In mycology, germination refers to a process in which a hardy dominant spore 
undergoes a complex set of metabolic rearrangements and cell wall alterations to 
generate a new hyphal cell.  This cell emerges through a pore in the wall of the spore as 
a germ tube of different molecular architecture from the spore. This nomenclature is 
being used in all studies of C. albicans to define a process where a novel hypha emerges 
by a simple evagination of the cell wall. Septae are laid down along the extending 
hyphae.  The term "germ tube" is used to refer to newly evaginating hypha up to the 
time that the first septum is laid down. 
 
Figure 2: Yeast cells, pseudohyphal cells and true hyphal cells3 
 
Candida albicans can exist in three forms that have distinct shapes: yeast cells (also 
known as blastospores), pseudohyphal cells and true hyphal cells (Figure 2). Yeast cells 
are round to ovoid in shape and separate readily from each other. Pseudohyphae 
resemble elongated, ellipsoid yeast cells that remain attached to one another at the 
constricted septation site and usually grow in a branching pattern that is thought to 
facilitate foraging for nutrients away from the parental cell and colony. True hyphal 
cells are long and highly polarized, with parallel sides and no obvious constrictions 
4 
 
between cells. All three cell types have a single nucleus per cell before mitosis. 
Important differences between yeast, pseudohyphal and true hyphal cells include the 
degree of polarized growth, the positioning of the septin ring (green in Figure 2 and 
micrographs, and black in light microscope images) and of the true septum relative to 
the mother cell, the movement of the nucleus (blue line in Figure 2 and in micrographs) 
relative to the mother cell and the degree to which daughter cells are able to separate 
into individuals. 
Many of the current antifungal agents that are used in therapy are generating resistance 
or have adverse side effects.  For example, the anti-Candida agent, fluconazole can 
cause nausea, headache or provoke liver damage. As a result of this increase in 
resistance, infections caused by other Candida species such as Candida glabrata, 
Candida kreusi and Candida dublineinsis are becoming more common. 
Antibacterial drug discovery reached its apex in the 1950’s and of the majority of these 
compound classes are still in use today.4 After the introduction of streptogramins and 
quinolones in the early 1960’s, no novel class of antibacterial agent was introduced into 
clinical practice until linezolid was launched in 2000. Due to the diversity of bacterial 
structures, drug discovery in this area requires agents with specific biomolecular targets 
or pathways. Bacterial microorganisms have made use of antibacterial xenobiotics and 
selective pressure to evolve an elaborate arsenal of defences to protect themselves from 
attack. As a result, some researchers suggest the superior role of natural products, due to 
evolutionary conditions, in producing an array of antibiotic producing microorganism, 
compared with synthetic libraries.5 However, these antibiotics function by targeting 
specific biomolecular pathways and as a result have a propensity for the development of 
resistance to prophylactic treatment.  
The major types of bacterial organisms which cause community and hospital acquired 
infections are (i) Methicillin-resistant Staphylococcus aureus (MRSA), (ii) Clostridium-
difficile (C.difficile) and (iii) Escherichia-coli (E-Coli). 
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Methicillin-resistant Staphylococcus aureus (MRSA) 
MRSA has been pandemic for over a decade and is causing a major increase in serious 
staphylococcal infections.6 It is a variety of Staphylococcus aureus (SA) which exists 
on the skin and nose of about 30% of the population without causing any serious health 
effects but can cause wound infections and severe bloodstream infections.7 Penicillin 
was introduced in 1940 to fight against these infections but within a short period of time 
nearly all strains of SA became resistant to it. Methicillin was then introduced to 
overcome this resisitance but about 60% of SA strains have now become resistant to it. 
The antibiotic drug vancomycin, is currently used to treat these infections but it is not 
effective and resistance to this drug is also beginning to emerge.8 
 
Clostridium-difficile (C.difficile) 
Clostridium difficile (C.difficile) is an anaerobic bacterium which is usually found in the 
large intestine and it can be found in a small portion of healthy adult population. It is 
traditionally a nosocomial pathogen and is one of the leading causes of diarrhoea. It 
usually occurs in patients that have had their natural intestinal bacteria destroyed by 
antibiotics. In the absence of normal bacteria it multiplies and produces toxins that 
damage the lining of the intestine resulting in diarrhoea.9 C.difficile spores can persist in 
dust or on surfaces for months and can be transmitted to other patients or to healthcare 
workers. The spores cannot be destroyed by usual detergents and survive hand 
disinfections with alcoholic preparations. Therefore it is important to try and establish 
an effective strategy for controlling the spread of this infection.10 
 
Escherichia-coli (E-Coli) 
Escherichia-coli (E-Coli) is an anaerobic Gramnegative bacterium that is found in the 
intestinal tracts of healthy animals.11 It can adhere to the mucus overlying the large 
intestine and once established it can persist there for months or years. It becomes 
problematic for a patient if the natural flora in the gut is disturbed particularly after a 
course of antimicrobial chemotherapy.12 It is one of the leading causes of urinary tract 
infections and can form biofilms on catheters.  
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I.1 GENERAL CHEMISTRY OF SILVER 
Silver is a white metal, more malleable and ductile than other metal except gold.  
Silver, one of the “coinage metals” was almost certainly one of the first three metals 
known to man along with the other “coinage metals”, gold and copper.  It has been 
known and valued as an ornamental and coinage metal since ancient times and silver 
mines in Asia Minor were probably worked before 2500 BC. The alchemists called 
the metal Luna or Diana after the goddess of the moon and ascribed to it the symbol 
of a crescent moon. It’s principle ore is argentite or “horn Silver”. Silver has the 
electron configuration [Kr] 4d10 5s1.  Its hardness ranges between 2.5 and 2.7; it is 
harder than gold but softer than copper.  Silver melts at about 962 °C, boils at about 
2212° C and has a specific gravity of 10.5. The atomic weight of silver is 107.868 g 
mol-1. 
I.1.1 The silver(I) oxidation state 
Ag(I) is by far the most important oxidation state and is the most commonly known, 
with the electron configuration [Kr] 4d10.  Ag+ forms a large variety of complexes. Most 
simple ligands have a coordination number of two e.g. the silverdiammine complex 
[Ag(NH3)2]+, [Ag(CN)2]- and [Ag(S2O3)2]3- and are therefore linear in shape.  However 
complexes of coordination number three, four and six are also found, with trigonal, 
planar, square planar, tetrahedral and octahedral structures commonly seen. Ligands 
capable of  bonding, such as phosphine derivatives, may form both two- and four-
coordinate complexes.  A few silver(I) complexes with colourless anions are coloured. 
AgI, Ag2CO3 and Ag3PO4 are yellow and Ag2S is black.  This is due to the small and 
highly polarising silver(I) ion and the anion, eg. I, being large and highly polarisable. 
This leads to some covalent character. 
I.1.2 The silver(II) oxidation state 
The silver(II) ion has the electron configuration [Kr] 4d9. Numerous complexes of 
Ag(II) are known, and are usually prepared by oxidizing a solution of silver(I) 
containing the complexing ligand with potassium persulphate. These complexes are 
usually square planar and paramagnetic. With neutral ligands cationic species such as 
[Ag(pyridine)4]2+, [Ag(bipyridine)2]2+ and [Ag(ortho- phenanthroline)2]2+ form 
crystalline salts.  The magnetic moments of Ag(II) complexes range from eff =1.75 to 
2.2 BM, consistent with a d9 configuration.   
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I.1.3 The silver(III) oxidation state 
The silver(III) oxidation state is very uncommon.  The flourination of a fused mixture of 
alkali metal halide and silver halide will give M+[AgIIIF4]-, and the electrolytic oxidation 
of silver(I) can give impure Ag2O3.  Oxidation of alkaline Ag2O with persulphate gives 
mixed oxide AgIAgIIO2.  Persulphate in the presence of periodate or tellurate ions gives 
compounds such as K6H[AgIII(IO6)2] and Na6H[AgIII(TeO6)2].  These compounds are all 
unstable and are strong oxidising agents.  
I.1.4 Complexes of silver(I) 
I.1.4.1 Silver(I) and its coordination modes 
Silver(I) has an outer electron configuration of [Kr]d10 and is diamagnetic. It forms 
good complexes with nitrogen, sulphur and halogen donor ligands. Silver(I) has a low 
affinity for oxygen donors although complexes containing carboxylate ions and crown 
ethers are known. Numerous phosphine complexes of silver(I) are also known. There 
are a number of coordination modes and geometries of silver(I) complexes. The most 
common are linear (coordination number 2), trigonal planar (coordination number 3), 
tetrahedral (coordination number 4) and octahedral (coordination number 6).13 
Examples of these are shown in Figure 3. 
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Figure 3:  Structures of the most common coordination modes and geometries of 
silver(I): (i) linear, (ii) trigonal planar, (iii) tetrahedral and (iv) octahederal13 
I.1.4.2 Complexes with Nitrogen Ligands 
Many of the silver complexes with nitrogen ligands readily form in aqueous solution. 13 
NH3 is most important of the nitrogen ligands. There is a preference for linear 
coordination, the linear [H3N-Ag-NH3]+ ion has been observed crystallographically in 
several compounds. Formation of this ion is dependent on [Ag+] and [NH3], it can be 
used for the separation of silverhalides.The solubility of AgCl gives [Ag(NH3)2]Cl on 
treatment with aqueous ammonium carbonate, while AgBr dissolves only in aqueous 
ammonia, in which AgI is poorly soluble. 
Aqueous pyridine and substituted pyridines form [Ag(py)2]+ and [Ag(py)2]+ ions, but in 
non-aqueous conditions tetrahedral complexes, such as [Ag(py)4]ClO4, may be 
obtained. The tetrahedral acetonitrile adduct [Ag(NCMe)4]+ is also known and is quite 
stable. There are a number of argentite(I) complexes such as [Ag(NCO)2]- and 
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[Ag(ONO2)2]-; they are linear, with 2-coordinate Ag+. Linear coordination is also found 
in the tetrameric silver amide [Ag{N(SiMe3)2}]4. 
I.1.4.3 Complexes with Halogen Ligands  
The halides AgX react with halide anions X- (where X is I- > Br- > Cl-) to give a series 
of anionic complexes [AgKXl](l-K)-, with relative stabilities I- > Br- > Cl-.13 The type of 
complex anion formed is strongly influenced by the counterion and the nature of the 
halide, and there is considerable structural diversity. The ions [X-Ag-X]- (X = Cl, Br) 
are linear, where as [Ag2X4]2-(X = Cl, Br, I) and [AgI3]- contain 3-coordinate silver. 
Examples of anionic iodo complexes are shown in Figure 4. Cationic species such as 
Ag2X+ and Ag3X2+ are formed when the silver halides are dissolved in aqueous solution 
of AgNO3 and AgClO4. 
 
Figure 4: Structures of the anionic iodoargentate complexes (a) [AgI3]2-; (b) [Ag2I4]2-; 
(c)-(e) isomers of [Ag4I8]4- 13 
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I.1.4.4 Complexes with Phosphine Ligands 
With monophosphines these are mainly of the type (R3P)n AgX, with n=1-4.14 The 1:1 
complexes are tetrameric, with either cubane figure or chair figure structures depending 
on the steric requirements of both X and R3P; Ag4I4(PPh3)4 undergoes cube-chair 
isomerisation, and the two structural types may be obtained by crystallization from 
different solvents (Figure 5). 
 
Figure 5: The Cube and Chain structures of [Ag4I4(PPh3)4]14 
The complexes (AgXR3)2 are generally dimeric with bridging X. Triphenylphosphine 
forms four coordinate [Ag(PPh3)4]+. Slightly larger phosphines, such as PCyPh2 and 
PCy2Ph give 3-coordinate [AgL3]+, while bulky phosphines such as PBut3 or P(mes)3 
form linear cations[L-Ag-L]+. 
Complexes with bridging bidentate phosphines tend to be dimers or tetramers with 
bridging phosphines, as in Figure 6. Phosphines with a large bite angle, (Figure 6), may 
however form mononuclear chelates. 
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Figure 6: Bridging and Chelating diphosphine derivatives of Silver14  
I.1.4.5 Complexes with other ligands  
Silver(I) has a relatively low affinity for oxygen donors, although compounds and 
complexes containing carboxylate ions, DMSO, DMF, and crown ethers are known. 15 It 
forms numerous complexes with the donor atoms S, Se, P and As. With sulfur the 
thiosulphate complexes, [Ag(S2O3)]- and [Ag(S2O3)2]3- are quite stable. Other important 
sulfur ligands for Ag+ are thiolate anions, which give oligomers, (AgSR)n, 
dithiocarbamate ions, SCN-, thioureas and thioethers. Silver(I) binds to peptides and 
proteins, with a preference for –SR and imidazole nitrogen functionalities. 
The dithiocarbamate ion Pr2NCS2- forms a hexanuclear complex with a trigonal 
antiprismatic array of silver ions. Similar anionic clusters are also formed with the 
related (NC)2C=CS22- ligand, e.g. [Ag6L6]6- and [Ag8L6]4-. Four-, five-, and six- 
coordination is found in Ag+ complexes with sulphur macrocycles. For e.g.,in 
[Ag(16s6)]ClO4 only four of the six S atoms coordinate to give tetrahedral geometry 
(16S6= hexathiacylohexadecane), while [Ag(18S6)]+ and [Ag(9S3)2]+ are octahedral. 
The latter complex can be oxidized to silver (II) compound. The reaction of Ag+ with 
tetrathiometallates MS42- gives polymers [Ag(MS4)]nn-(M=Mo,W).In [NH4]n[Ag(WS4)]n 
this polyanion consists of a chain of S-bridged eight membered rings (Figure 7). 
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Figure 7: Structure of [NH4]n[Ag(WS4)]n 15 
 
I.2 THE SILVER ION AS AN ANTIMICROBIAL AGENT 
 
Elemental silver and silver salts have been used for decades as antimicrobial agents in 
curative and preventive healthcare.16 Silver and its simple salts have found important 
applications in the treatment of chronic ulcers, extensive burns, and difficult-to-heal 
wounds. The silver ion (Ag+) is the active ingredient in these simple systems and is well 
known as an excellent antimicrobial with high efficacy against Grampositive and Gram 
negative bacteria as well as a wide array of fungal microbes, but low toxicity against 
non target organisms.17 Furthermore Ag+ ions also exhibit virucidal properties.18   
Silver salts and compounds that release silver ions have also found applications in 
materials used in medical devices such as intravascular catheters where they prevent the 
growth of pathogens that cause catheter-related bloodstream infections which account 
for a significant proportion of nosocomial infections in intensive care units.19 More 
recently wound dressings containing fabrics impregnated with silver (FIS’s - a new 
silver technology), which have antimicrobial efficacy, have been developed with the 
potential to provide a protective barrier against infection in severe burn wounds. Such 
FIS’s owe their efficacy to the inclusion of discrete silver complexes which have the 
ability to release silver ions in a slow controlled manner. 
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I.3 THE ANTIMICROBIAL MECHANISM OF ACTION OF SILVER ION 
 
It is believed (but not yet fully understood) that the silver ions interfere with cell growth 
by 1. inhibition of transport functions in the cell wall (respiration), 2. interruption of cell 
metabolism (changing enzyme structures) and  3.  inhibition of cell division (interaction 
with DNA) (Figure 8).20 This multimodal efficacy, which occurs at very low 
concentrations, is unique to silver ion antimicrobials and reduces the possibility of 
developing resistant organisms.21  
 
Figure 8:  The antimicrobial mechanism of action of silver ions20 
 
In 2000 Feng et al.22 reported a mechanistic study of inhibition of silver ions against 
two different bacterial species, S. aureus and E. coli. For the experiment, both bacteria 
were inoculated into liquid Luria Bertoni (LB) medium and incubated at 37 °C on a 
rotary shaker (200 rpm) for 16 h. After that 10 µg/ml of silver nitrate was added to the 
liquid culture and allowed to incubate for 4–12 h. Five milliliters of the above culture 
was removed, centrifuged and the subsequent biomass obtained was further studied by 
transmission electron microscopy (TEM) and X-ray micro-analysis to find out the 
morphological changes occurred in the cells after treatment with silver ions. In the case 
of E. coli significant morphological changes were noticed after the treatment of silver 
ions. An electron-light region was observed in the center of E. coli cells containing 
some tightly condensed substance twisted together. A big gap was observed between the 
cytoplasm membrane and the cell wall. Presence of some electron dense granules 
around the cell wall was also noticed. The X-ray microanalysis of these electron dense 
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granules demonstrated the presence of silver and sulfur assuming that the silver ions 
after entering the bacterial cell might have combined with the cell components 
containing sulfur. Similarly, in the case of S.aureus the presence of condensed 
substance in the electron-light region was observed. The cytoplasm membrane was 
shrunken and detached from the cell wall. In the condensed region of S. aureus cells, a 
large amount of phosphorus was found. There were also, slight differences observed 
related to the effect of silver ions on S.aureus when compared with E.coli. The electron-
dense granules observed in S.aureus and the electron-light region was darker than E. 
coli cells. S. aureus has a much stronger defense system compared to E.coli. S.aureus is 
Grampositive bacteria with a thicker peptidoglycan cell wall than Ecoli and there is 
presence of a clearly visible nuclear region in the center of cells where DNA molecules 
are distributed randomly. Thus, this thicker cell wall protects the cell from the 
penetration of silver ions in the cytoplasm.23 By the comparative evaluation of the 
effects of silver ions on both the test organisms, the authors suggested the possible 
mechanism of action of silver ions. The silver ions enter into the bacterial cells by 
penetrating through the cell wall and consequently turn the DNA into condensed form 
which reacts with the thiol group proteins and result in cell death. The silver ions also 
interfere with the replication process. To the 0.05 M aqueous histidine and tryptophan 
solution, 0.05 M silver nitrate was added which resulted in the formation of a white 
precipitate. This precipitate was centrifuged, dried and used for the evaluation of 
antimicrobial activity by double serial dilution method. The toxicity of silver complexes 
of tryptophan and histidine was tested on a group of white mongrel mice. The histidine 
complex with silver compound showed good antimicrobial activity against 
Gramnegative bacteria while, the tryptophan complex with silver compound showed 
higher antimicrobial activity and broad spectrum of action. In the toxicity study, both 
the complexes of histidine and tryptophan show low toxicity. From the above 
experimental work it was found that the tryptophan complex with silver depicted a 
better antimicrobial activity than the histidine silver complex. 
 
 Bromberg et al24 demonstrated the use of silver nitrate for the treatment of periodontal 
pathogens. They found silver nitrate more efficient than antibiotics for the treatment of 
oral cavity of periodontal infections. 
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The mechanism of action of silver is linked with its interaction with thiol group 
compounds found in the respiratory enzymes of bacterial cells. Silver binds to the 
bacterial cell wall and cell membrane and inhibits the respiration process. In the case of 
E.coli, silver acts by inhibiting the uptake of phosphate and releasing phosphate, 
mannitol, succinate, proline and glutamine from E. coli cells. Bactericidal actions of a 
silver ion solution on E.coli, is studied by energy-filtering transmission electron 
microscopy and proteomic analysis. 
 
The mechanism for the antimicrobial action of silver ions is not properly understood 
however, the effect of silver ions on bacteria can be observed by the structural and 
morphological changes. It is suggested that when DNA molecules are in a relaxed state 
the replication of DNA can be effectively conducted. But when the DNA is in a 
condensed form it loses its replication ability hence, when the silver ions penetrate 
inside the bacterial cell the DNA molecule turns into the condensed form and loses its 
replication ability leading to cell death. Also, it has been reported that heavy metals 
react with proteins by getting attached with the thiol group and the proteins get 
inactivated. 
 
Simple biocides such as Ag+ ions generally exhibit indiscriminate microbial activity due 
to their multimodal nature and their ability to penetrate the outer cell layers of a range of 
microorganisms.  
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Table 1: Compositions of outer cell layers of different microorganisms25  
Organism Outer cell layers Example(s) 
Grampositive cocci Cell wall: predominantly 
Peptidoglycan 
Staphylococci 
Gramnegative bacteria Outer membrane: phospholipids, 
Lipopolysaccharide 
P.aeruginosa, 
E.coli 
Mycobacteria Cell wall: mycolate of a arabinogalactan Mycobacterium
tuberculosis 
Bacterial spores Outer spore coat: alkali-resistant (S-S 
bonds) 
Inner spore coat: alkali-soluble (acidic 
polypeptides) 
Cortex: peptidoglycan, including spore 
specific 
Bacillus spp 
Yeasts and moulds Cell wall: chitin + chitosan 
Cell wall: chitin + glucan 
Cell wall: glucan + mannan 
Mucor rouxii 
A.niger 
S.cerevisiae, 
C.albicans 
Intestinal protozoa Cysts have thick outer coverings C.parvum 
Other protozoa Double-walled cysts containing 
cellulose (during encystation) 
A.Castellanii 
Algae Cell wall: cellulose + other  
polysaccharides + other constituents  
green 
(Chlorophyta), 
brown(Phaeop- 
phyta) and red 
(Rhodophyta) 
algae 
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1.4 MICROBIAL RESISTANCE TO SILVER 
 
Silver resistance has been reported in bacteria isolated from both clinical and 
environmental settings. The genetic basis of silver resistance was first reported by 
McHuge et al,26 demonstrating that silver resistance was plasmid encoded and has been 
confirmed by others. The physiological, biochemical, genetic and structural studies of 
the silver resisitance determinant plasmid pMG 101 established the molecular basis of 
silver resisitance. Plasmid pMG 101 is a 182 kb, transferable plasmid encoding 
resistance to silver, mercury, tellurite, ampicillin, chloramphenicol, tetracylin, 
streptomycin and sulphonamide. The silver resistance cassette of genes encodes two 
silver efflux pumps and two periplasmic Ag+ binding proteins. 
I.5 SILVER COMPLEXES AS ANTIMICROBIAL AGENTS 
In addition to simple silver salts a number of complexes have also been used 
clinically.27 Such silver complexes are particularly interesting since the antimicrobial 
activity and other desirable properties can be changed by varying the the number and 
type of ligands coordinated to the silver ion.  Important factors to consider when 
designing novel silver based antimicrobial complexes are: 
 1.  The type of atoms bound to the Ag+ ion (O>N & S>>P) 
 2.  The ease of ligand replacement and control of Ag+ ion release. 
 3.  Chemical and Photo-Stability (Blackening) 
 4.  Cost  
The search for new complexes and materials allowing biocidal Ag+ ions to be delivered 
with increased efficiency is currently an active research area in inorganic medicinal and 
material chemistry.  Silver has been described as ‘oligodynamic’ because of its ability 
to exert a bactericidal effect at minute concentrations28.  In a complex biological system 
such as wound fluid, the maximum level of free (available) Ag+ is approximately 1 
µg/ml. Above this level, Ag+ complexes with anions such as chloride to form minimally 
soluble and inactive salts resulting in costly loss of efficacy.  However developing 
formulations which allow for the application of optimum low concentrations of simple 
silver salts and labile silver complexes under biological conditions can be difficult 
because of problems associated with the photosensitivity of the free Ag+ ion. The rate of 
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metal ion release and the relative stability of any silver-complexes can be controlled 
using variations in the ligand architecture and the overall structural motif of the 
compound. 
Silver sulphadiazine 
Silver-sulphadiazine(AgSD)29 (Figure 9) (which is available commercially in products 
such as Flammazine®)  a compound that has been very successfully applied in the clinic.  
Upon application AgSD releases the two antibacterial agents, free Ag+ ion and the 
sulphonamide antibiotic sulphadiazine which in the drug are combined together in a 
polymeric structure composed of 6 silver atoms bonding to 6 sulphadiazine molecules 
via labile Ag-Nitrogen linkages. The sulphadiazine also reduces the photosensitivity of 
the Ag+  in the complex.   
O
S
N
N
N
NH2
O
Ag
 
Figure 9:  Structure of one unit of Silver-Sulfadiazine29 
Silver sulfadiazine is used as a 1% water-soluble cream. AgSD works as a broad-
spectrum antibiotic. It is used especially for the treatment of burn wounds. AgSD serves 
as a reservoir of silver in the wound and slowly liberates silver ions. All kinds of sulfa- 
drugs have been tested in combination with silver but sulphadiazine was found to be 
most effective. AgSD binds to cell components including DNA and cause membrane 
damage. It achieves bacterial inhibition by binding to the base pairs in the DNA helix 
and thus inhibits transcription. In a similar way it also binds to phage DNA. 
In deep dermal and full-thickness burns, antiseptic agents, which can penetrate into 
deeper layers, such as silver-sulfadiazine should be applied. The released silver ions 
bind to the microbial genes (DNA) and inhibit the reproduction of bacteria and fungi. 
Sulfadiazine inhibits the production of folic acid which is necessary for the reproduction 
of bacteria. In case of later surgical debridement an unfavourable effect of silver-
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sulfadiazine is that it softens the necrosis thus complicating a tangential excision. If 
applied broadly, the systemic resorption of silver ions may cause an impaired acid-base 
balance, leukopenia as well as liver and kidney damage. 
A number of groups in various labs around the world are synthesizing silver complexes 
and testing for biological activity. A number of silver complexes have been synthesized 
that have been found to have chemotherapeutic potential as antimicrobial or cytotoxic 
agents. The antimicrobial complexes are of interest to the pharmaceutical industry for 
potential use as topical agents, oral antibiotics and antimicrobial coatings for medical 
devices. With the emergence of ubiquitous antimicrobial resistance to antibiotics and 
antiseptics Ag+ ion technologies have re-emerged as attractive biocides for medical and 
industrial applications.  
A number of silver complexes have also been shown to display significant cytotoxicity 
against selected cancer cell30 lines and such complexes are of interest to medicinal 
chemists.  A selection of these biologically active complexes are discussed below. 
1.6 SILVER BASED BIOCIDAL PRODUCTS 
As mentioned, silver sulfadiazine cream is used for treating burns and this is available 
commercially as a topical cream known as Silvadine.31 There are also a number of 
antimicrobial wound dressings that contain silver such as ActicoatTM 32, SilverIon33, 
Contreet34 and Silvercel35. Several companies have manufactured silver antimicrobial 
agents intended for use in many applications. For example Agion from Agion36, JMAC 
from Johnson Matthey37 and Biomaster from Addmaster.38 
AgIon 
AgIon incorporates silver ions into a zeolite carrier and works by ion exchange. Silver 
ions exchange with other positive ions present in the moisture in the atmosphere. 
JMAC 
This is silver chloride deposited on inert titanium dioxide and it is finding applications 
as coatings on sutures, wound dressings, catheters and internal feeding tubes. 
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Biomaster 
Biosilver is a product from the Biomaster range and it consisits of titanium dioxide 
coated with silver chloride and it is available in powder and liquid forms. It can be used 
for incorporation into textiles, paints and coatings. 
There are also some companies which have developed silver based paints. These 
include Bioni Hygenic39 and Stershield40. Bioni Hygenic utilizes nanosilver as the 
antimicrobial agent which is trapped inside a polymer matrix. This paint is currently 
applied in severel hospitals in Germany. Stershield use Biosilver as the antimicrobial 
additive in their paint and is marketed by Dulux. The use of an antimicrobial paint in 
hospital wards may help reduce the spread of infection. There are also a number of 
companies which market catheters impregnated with a form of silver. 
I.7 SILVER COMPLEXES EXHIBITING BIOLOGICAL ACTIVITY 
Despite the fact that silver has a low affinity for oxygen donor ligands, such complexes 
are known. Silver complexes of oxygen donor ligands such as, [Ag(hino)]2 (where 
hino = 4-isopropyltopolone) and water-soluble silver (I) complexes of (R)-(+)- and (S)-
(−)-2-pyrollidone-2-carboxylic acid  displayed wide ranging and effective activities 
against some bacteria, yeasts and moulds. It has been found that the silver–oxygen 
bonding properties rather than the chiral helical or achiral polymer structure play a role 
in exhibiting antimicrobial activities. The antimicrobial activities of Silver(I)–oxygen 
bonding complexes are independent of whether the ligand itself possesses antimicrobial 
activities. Examples of such complexes containing acetasalicyclic acid (Hasp) are; 
{[Ag(L-Hasp)]2} and {[Ag(L-Hasp)]2}n, where the ligand showed no activity. Similarly, 
salicylic acid (salH) did not prevent the growth of a fungal pathogen, while the silver 
complexes, [Ag(salH)]2 and [Ag(NH3)(salH)]2 greatly inhibited cell reproduction. These 
complexes also produced a cytotoxic response against human cancer cells. 
The biological action of the silver (I) oxygen complexes comes from a weaker bonding 
property of the Ag–O bond. In the biological system, the ease of ligand replacement of 
the silver (I) complexes would result in further replacement with biological ligands. The 
Ag–O bonding complexes can readily undergo ligand replacement with O-, N- or S-
donor atoms. The antimicrobial activities of silver (I)–oxygen bonded complexes are 
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due to the silver (I) ion itself, i.e., due to a direct interaction between the silver (I) ion 
and the biological ligands such as protein, enzymes and membrane. The coordinating 
ligands of the silver (I) complexes play the role of carrier for the silver (I) ion to the 
biological system. The magnitude of antimicrobial properties of silver complexes is 
related to the ease with which they participate in ligand exchange reactions. For 
example, it has been speculated that the weak Ag–O and Ag–N bond strengths might 
play an important role in exhibiting a wider spectrum of antimicrobial and antifungal 
activities and that the potential target sites for inhibition of bacterial and yeast growth 
by silver complexes might be the sulfur containing residues of proteins. Generally, Ag–
S complexes have been shown to have a narrower spectrum of antibacterial activity than 
Ag–N complexes but no antifungal activity. In contrast, the compounds with Ag–P 
bonds have shown no activity against bacteria, yeast or moulds. 
A sulfur coordinated, water soluble silver (I) complex of thiomalic acid showed 
remarkable antimicrobial activity against some bacteria, yeast and moulds. Although 
aqueous silver nitrate itself has similar activities for bacteria, the complexation of silver 
(I) with thiomalate leads to appreciably high activities for some moulds. Antimicrobial 
activities have been observed for sulfur bonded silver complexes of 2-mercaptonicotinic 
acid, [Ag(Hmna)]6 · 4H2O and 2-mercaptobenzoic acid, [Ag(Hmba)]n and 
[Na{Ag(Hmba)} · H2O]n. The spectra of antimicrobial activities observed in Ag–S 
bonded compounds have so far been narrower than those in the Ag–N bonded 
compounds such as [Ag(im)]n (im = imidazole) and [Ag(triaz)]n (triaz = 1,2,4-triazole). 
The key factor determining the spectrum of antimicrobial activity is the nature of atom 
coordinated to the silver (I) atom and its bonding properties, (i.e., the ease of ligand 
replacement), rather than the solid state structure, solubility, charge and degree of 
polymerization of the complexes. 
In 2003 McCann et al41 reported reaction of (Z)-3-(1H-imidazol-l-yl)-
2phenylpropenenitrile (imppn) with AgClO4 producing the [Ag2(imppn)4(ClO4)2] 
(Figure 10) complex. In the dimeric Ag(I) complex each metal is coordinated to the 
imine nitrogens of two imppn ligands in an almost linear fashion and the two 
[Ag(imppn)2]+ units are linked by an Ag-Ag bond, supported by two trans bridging 
bidentate perchlorate groups and by π-π interactions between the ligands. In vitro tests 
on the ability of compounds to inhibit the growth of pathogenic yeast Candida albicans 
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showed that imppn and its metal complexes were markedly less effective than the 
prescription drug, Ketoconazole. 
 
 
Figure 10: Structure of [Ag2(imppn)4(ClO4)2] 41  
In 2004 Coyle et al 42 synthesized [Ag2(NH3)2(SalH)2] from salicyclic acid and Ag2O in 
concentrated aqueous NH3 and the dimeric Ag(I) complex was characterised using X-
ray crystallography (Figure 11). The complex is centrosymmetric with each metal 
coordinated to a salicylate carboxylate oxygen and to an ammonia nitrogen atom in an 
almost linear fashion. The two [Ag(NH3)(salH)] units in the complex are linked by an  
Ag-Ag bond. 
 
Figure 11: X-ray crystal structure of [Ag2(NH3)2(salH)2]42 
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SalH2, [Ag2(salH)2] and [Ag2(NH3)2 (SalH)2] were screened for their ability to inhibit 
the growth of Candida albicans, whilst metal-free salH2 was essentially ineffective at 
controlling the growth of the organism, [Ag2(salH)2] did show quite marked activity. 
However, the ammonia complex [Ag2(NH3)2(salH)2] displayed an approximately 
tenfold superior activity at controlling yeast cell proliferation. 
In 2004, Liu et al 43 reported the reaction of Ag2O and sulfamic acid in a 30% ammonia 
and 4% NaOH solution resulting in a 
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VM7-4DTP5W1-
5&_user=2322584&_coverDate=12%2F01%2F2004&_alid=771923479&_rdoc=234&
_fmt=high&_orig=search&_cdi=6143&_st=5&_docanchor=&view=c&_ct=446&_acct
=C000056897&_version=1&_urlVersion=0&_userid=2322584&md5=3fb49f49e3c49f0
091bfa8cb963d0ed0 - 
hit1silverhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VM7-
4DTP5W1-
5&_user=2322584&_coverDate=12%2F01%2F2004&_alid=771923479&_rdoc=234&
_fmt=high&_orig=search&_cdi=6143&_st=5&_docanchor=&view=c&_ct=446&_acct
=C000056897&_version=1&_urlVersion=0&_userid=2322584&md5=3fb49f49e3c49f0
091bfa8cb963d0ed0 - hit3(I) polymer, Na[Ag(NH2SO3)2]n (Figure 12). The X-ray 
crystal structure analysis indicates that the complex is a 
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VM7-4DTP5W1-
5&_user=2322584&_coverDate=12%2F01%2F2004&_alid=771923479&_rdoc=234&
_fmt=high&_orig=search&_cdi=6143&_st=5&_docanchor=&view=c&_ct=446&_acct
=C000056897&_version=1&_urlVersion=0&_userid=2322584&md5=3fb49f49e3c49f0
091bfa8cb963d0ed0 - 
hit2silverhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VM7-
4DTP5W1-
5&_user=2322584&_coverDate=12%2F01%2F2004&_alid=771923479&_rdoc=234&
_fmt=high&_orig=search&_cdi=6143&_st=5&_docanchor=&view=c&_ct=446&_acct
=C000056897&_version=1&_urlVersion=0&_userid=2322584&md5=3fb49f49e3c49f0
091bfa8cb963d0ed0 - hit4 polymer through Na–O bonds forming a 3D framework. And 
the complex shows high cytotoxicity properties to normal cells and carcinoma cells. 
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Figure 12: The structure of Na[Ag(NH2SO3)2]n43 
In 2004 five Ag(I) complexes containing the ligands bis(imidazol-2-yl)methane (2-
BIM) and its derivatives were reported by Abuskhuna et al44 and [Ag2(2BIM)2]ClO4)2 
and [Ag2(2-BIM(Bz)OH)2](ClO4)2.EtOH were characterized using X-ray 
crystallography. In each dimer the two Ag(I) ions are two-co-ordinate and there are 
small but definite argentophilic Ag-Ag(d10-d10) interactions. All of the complexes 
display antifungal activity when tested in vitro against the fungal pathogen Candida 
albicans. 
The X-ray crystal structure of [Ag2(2-BIM)2](ClO4)2 (Figure 13) showed the complex to 
be centrosymmetric, containing two Ag(2-BIM)+ units. The two metal ions are two-
coordinate and have identical atoms in the plane of the chelating ligand. Using its two 
imine N atoms each 2-BIM ligand bridges the pair of Ag(I) ions. All four N atoms (N1, 
N4A, N4, N1A) are coplanar and the two imidazole groups in each 2-BIM ligand have 
an interplanar angle of 75.52(8)°. 
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Figure 13:  X-ray crystal structure of [Ag2(2-BIM)2](ClO4)244 
The X-ray crystal structure of [Ag2(2-BIM(Bz)-OH)2](ClO4)2.EtOH (Figure 14) shows 
the asymmetric unit containing one [Ag2(2-BIM(Bz)-OH)2]2+ unit, two perchlorate 
anions and a solvate ethanol. The two Ag(I) ions are again bridged by the two ligands 
and each metal is approximately linearly coordinated to a pair of imine nitrogens. There 
are additional longer interactions with the perchlorate anions. The metal-metal distance 
of 3.018(4)Å is considerably shorter than for the [Ag2(2-BIM)2](ClO4)2.EtOH complex 
and there appears to be some degree of intermolecular π-π interaction between the 
imidazole and phenyl rings of the opposing two 2-BIM(Bz)OH ligands in the dimer. 
 
Figure 14: X-ray crystal structure of [Ag2(2-BIM(Bz)-OH)2](ClO4)2.EtOH.44 
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All of the metal-free ligands were found to be inactive against the fungal cells. As 
aqueous suspensions, the silver complexes were moderately active with MIC value 
ranges indicated in brackets:[Ag2(2-BIM)2](ClO4)2 (10-20µg/cm3); [Ag2(2-
BIM(Bz)OH)2](ClO4)2.EtOH (50-100µg/cm3); [Ag2{2-BIM(Me)}2](ClO4)2 (20-50 
µg/cm3) [Ag2{2-BIM(CN)}2](ClO4)2 (20-50 µg/cm3). 
A considerable improvement in antifungal activity was observed upon testing the 
complexes as DMSO/water solutions as opposed to aqueous suspensions: [Ag2(2-
BIM)2](ClO4)2 (5-10µg/cm3); [Ag2(2-BIM(Bz)OH)2](ClO4)2.EtOH (2.5-5µg/cm3); 
[Ag2{2-BIM(Me)}2](ClO4)2 (2.5-5µg/cm3); [Ag2{2-BIM(CN)}2](ClO4)2 (5-10 µg/cm3). 
The highly fluorinated tris(pyrazolyl)borate ligand [HB(3,5-(CF3)2Pz)3]- has been used 
in the isolation of the air- and light stable silver complex, [HB(3,5-
(CF3)2Pz)3]Ag(OSMe2) as reported by Rasika Dias et al45 in 2006. It is a monomeric 
tetrahedral silver complex with O-bonded dimethylsulfoxode ligand (Figure 15). The 
silver adduct [HB(3,5-(Cf3)2Pz)3]Ag(OSMe2) and the related [HB(3,5-
(CF3)2Pz)3]Ag(THF) (where OSMe2= dimethyl sulfoxide; THF= tetrahydrofuran) show 
good antibacterial activity, and their antibacterial efficacy against staphylococcus aureus 
is greater than those of AgNO3 and silver sulphadiazine. 
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Figure 15: X-ray crystal structure of  [HB(3,5-(Cf3)2Pz)3]Ag(OSMe2)45 
 In 2007, Lei Zhang et al46 reported two new polymeric silver (I)-fluconazole 
complexes: [Ag(HFlu)(NO3)]n and {[Ag(HFlu)2](ClO4)}n (Figures 16 and 17). The 
crystal structure of [Ag(HFlu)(NO3)]n consists of infinite 1D single strand helical 
coordination arrays with alternative...pmpm... arrangements, which are interlinked 
through hydrogen bonding interactions to generate a 3D network. The shortest 
intrachain Ag Ag distance bridged by HFlu ligand is 8.287(1) Å. In 
{[Ag(HFlu)2](ClO4)}n, each Ag(I) ion is coordinated by four triazole N atoms from four 
HFlu ligands to form a 2D coordination layer, which has a helical arrangement along 
the direction. The results of anti-fungal studies demonstrate that both silver (I) 
complexes are more active in comparison to the fluconazole drug. 
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Figure 16: The structure of [Ag(HFlu)(NO3)]n46 
 
Figure 17: The structure of {[Ag(HFlu)2](ClO4)}n46 
Ag4(9-aca)4(NH3)2] 47 was shown to be over 30 times more active against C. albicans 
than the commonly used antifungal agent ketoconazole (Table 2). Although [Ag2(9-
aca)2]n appears to be only half as active as [Ag4(9-aca)4(NH3)2], when their MIC100 
values are equated to their silver ion content (58 μM and 56 μM, respectively) then both 
complexes display approximately equal activity. Against MRSA and E. coli [Ag2(9-
aca)2]n and [Ag4(9-aca)4(NH3)2] both appeared to perform significantly better than the 
topical antibacterial agent silver(I) sulfadiazine. These two complexes also exhibited 
significant cytotoxic activity against liver and lung cancer derived cells (HepG and 
A.498 repectively). 
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Table 2: Antimicrobial activity (μM concentrations)47 
Drug 
C.albicans 
MIC100 
MRSA 
MIC50 
E.coli 
MIC50 
Hep-G2 
IC50 
A-498 
IC50 
[Ag2(9-aca)2]n 0.29 55.91 61.53 27.8 30.0 
[Ag4(9-aca)4(NH3)2] 0.14 28.36 40.73 3.6 5.5 
Ketoconazole 4.70     
Silver(I) sulfadiazine  120.40 154.00   
Cisplatin    15.0 14.0 
Organo silver complex exhibiting biological activityare rare in the literature. The simple 
alkyl complexes AgR are thermally unstable.48 The stability decreases with increasing 
chain length of R, thermolysis gives a mixture of alkenes and alkanes. Vinyl and aryl 
silver compounds are more readily accessible, usually by the reaction of a mild agent 
(ZnR2, PbR4) with silver nitrate: 
AgNO3   +   ZnAr2 AgAr + ArZn(NO)3  
They are sensitive to light, air and moisture. Alkyl compounds stabilized by donor 
ligands are significantly more stable, for example Figure 18. The linear L-Ag-C 
arrangement is typical. 
 
Figure 18: Alkyl compounds stabilized by donor ligands 48 
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Silver perfluoroalkyl compounds are thermally much more stable. For example, 
(CF3)2CFAg(NCMe) decomposes above 60ºC. The adducts CF3AgPR3 are 
photosensitive but are oxidized by air to stable Ag3+ anion [Ag(CF3)4]-. Complexes with 
the strongly electron- withdrawing pentaflouro- and pentachlorophenyl ligands are 
stable to water and oxygen, e.g., the yeild adduct (C6F5)Ag(CH2PPh3). 
Alkynyl silver compounds are readily accessible from AgNO3 and HC=CR in methanol 
or water in the presence of base and they are thermally stable. Like many heavy metal 
acetylides, silver compounds of unsubstituted acetylene are shock sensitive and 
explosive. 
With an excess of alkylating agents linear argentite(I) anions are formed, [R-Ag-R]-. 
These may associate to clusters, such that as in [Li2Ag3Ph6]-, where three [Ph-Ag-Ph]- 
units are held together by Ph...Li interactions. 
Complexes with alkenes and arenes are formed when the hydrocarbons are shaken with 
aqueous solutions of silver(I) salts. Di- or polyalkenes often give crystalline compounds 
with Ag+ bound to one to three double bonds. The formation of alkene complexes of 
varying stability may be used for the purification of alkenes, or for the separation of 
isomeric mixtures (e.g., 1,3-, 1,4-, and 1,5- cyclooctadienes), or of the optical isomers 
of α- and β-pinene. There is very little back-bonding contribution in the formation of 
AgI π-complexes. For example, the planar complex (hfa)Ag(Ph-C=C-Ph)47 (hfa= 
hexafluoroacetylacetonate) contains an almost linear acetylene ligand with a C=C bond 
that is only marginally longer than in free diphenylacetylene, while the Ag-C bonds are 
long (2.26Å).  
Until recently, isolable CO complexes of silver were unknown. However, if the 
counteranion possesses only very weak basicity, fairly stable CO adducts are obtained. 
Carbon monoxide acts in these compounds as a σ-donor ligand only. Back-bonding is 
virtually absent and the C-O stretching frequencies are substantially higher than that of 
free CO (2143 cm-1). The compounds [Ag(CO)]+X- (νco= 2204 cm-1) and [OC-Ag-
CO]+X- (νco= 2198 cm-1) [X=B(OTeF5)4] were characterized by X-ray diffraction. The 
[Ag(CO)3]+ ion is formed under CO pressure. 
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As shown in Table 3, the carbene–silver complexes, 2a and 2b, shown in Figure 19 
showed better bacteriostatic effect (lower MIC value) than silver nitrate at about 2.7 
times lower initial silver ion concentration.49 This result showed that although the 
theoretical amounts of the silver cations released from carbene–silver complexes were 
lower than silver nitrate, more silver cations were in the solution from carbene–silver 
complexes. Most of the silver cations from silver nitrate were precipitated as silver 
chloride and lost activity. The amount of 0.1% chloride anions in the culture medium is 
close to physiological concentrations of chloride (0.15 M sodium chloride). Under these 
conditions, carbene–silver complexes were more stable than silver nitrate. Moreover, 
when the solutions demonstrating the lowest MIC value were inoculated onto agar 
plates, the growth of organisms treated with carbene–silver complexes was delayed for 
a longer time than was the growth of organisms treated with silver nitrate. The observed 
results can be explained by the slow decomposition of the silver–NHC complexes in the 
aqueous culture medium to imidazolim cation and biologically active silver species. 
Carbene–silver complexes were observed to decompose over a period of weeks in 
deionized water. 
 
Figure 19: Structure of complex 2a and 2b49 
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Table 3: MIC results of the silver compounds49 
Test compounds Ag (mg/mL) E. coli P. aeruginosa S. aureus 
  
Day 1
 
Day 2
 
Day 1
 
Day 2 
 
Day 1 
 
Day 2 
 
2a 1186 − − − − − − 
1DF  − + − − − + 
2DF  − + − + +  
3DF  +  +  +  
4DF  +  +  +  
2b 1125 − − − − − − 
1DF  − + − + − + 
2DF  − + − + −  
3DF  +  +  +  
4DF  +  +  +  
AgNO3 3176 − + − + +  
1DF  +  +  +  
2DF  +  +  +  
3DF  +  +  +  
4DF  +  +  +  
DF: dilution factor (1 mL); growth (+); no growth (−). 
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I.8 SILVER COMPLEXES CONTAINING PHOSPHINE  
I.8.1 Silver Phosphine Complexes exhibiting Biological Activity 
Three novel silver(I) complexes consisting of both hard Lewis bases (O and N atoms) 
and one soft Lewis base (P atom) ((DL-a-alaninato)(triphenylphosphine)silver(I) (1), 
(DL-asparaginato)(triphenylphosphine)silver(I) (2) and 
(Lasparaginato)(triphenylphosphine)silver(I) (3)) were prepared from stoichiometric 
reactions of amino acid–silver(I) complexes with PPh3 in a 1:1 molar ratio in a mixed 
organic solvent. 
The antimicrobial activities of the silver (I) complexes {[Ag(dl-ala)(PPh3)]2 · 2H2O}, 
{[Ag(dl-asn)(PPh3)]2 · 2EtOH · 2H2O},{[Ag(l-asn)(PPh3)]2 · 2EtOH · H2O}are listed in 
Table 4.50 Water-insoluble Ag2O showed modest activity against two bacteria, whereas 
the aqueous Ag+ ion in AgNO3 solution, showed effective activity against Gramnegative 
bacteria (Escherichia coli and Pseudomonas aeruginosa), modest activity against 
Grampositive bacteria (Bacillus subtilis), and no activity against yeasts and moulds. 
Complex {[Ag(dl-ala)(PPh3)]2 · 2H2O}showed moderate antimicrobial activities against 
the selected bacterium (Staphylococcus aureus), and modest antimicrobial activities 
against bacteria (E. coli, B. subtilis and P. aeruginosa) and yeasts (Candida albicans 
and Saccharomyces cerevisiae); however, its effectiveness was less than that of (DL-
alaninato) silver(I). Complexes {[Ag(DL-asn)(PPh3)]2 · 2EtOH · 2H2O}, and {[Ag(l-
asn)(PPh3)]2 · 2EtOH · H2O}showed favourable antimicrobial activities against four 
selected bacteria and moderate to modest activities against two selected yeasts. The 
MIC values of complexes 2 and 3 are comparable to those of the precursors, except for 
moulds. These results support the conclusion that the number of coordinating PPh3 
ligands per silver(I) atom in the complexes significantly influences the antimicrobial 
activities and presumably the ligand-exchangeability of the silver (I) complexes. 
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Table 4: Antimicrobial activities of silver(I) complexes 1–3 evaluated by using 
minimum inhibitory concentration (MIC; µg/ml)50 
 
Organism 
{[Ag(DL-
ala)(PPh3)]2. 
2H2O} (1) 
{[Ag(DL-
asn)(PPh3)]2 
2EtOH. 2H2O} (2) 
{[Ag(L-
asn)(PPh3)]2 
2EtOH. H2O} (3) 
Escherichia coli 125 62.5 31.3 
Bacillus subtilis 125 31.3 15.7 
Staphylococcus aureus 62.5 62.5 62.5 
Pseudomonas aeruginosa 500 125 62.5 
Candida albicans 500 250 62.5 
Saccharomyces cerevisiae 500 125 31.3 
Aspergillus niger >1000 >1000 125 
Penicillium citrinum 1000 >1000 125 
 
 
Antibacterial and antifungal activities of [Ag(tetz)]n, [Ag(tetz)(PPh3)2]n, 
[Au(tetz)(PPh3)]  and the free ligand Htetz (where Htetz= tetrazole), were evaluated by 
MIC.51   
Antimicrobial activity of the complex [Ag(tetz)(PPh3)2]n was estimated as >1000 μg 
ml−1 for bacteria, yeast and mould, showing no activity. The free Htetz ligand and 
complex [Au(tetz)(PPh3)] showed only poor activities against Grampositive bacteria (B. 
subtilis, S. aureus). On the other hand, the precursor [Ag(tetz)]n has shown effective 
activities against Grampositive and negative bacteria, and yeast, but no activities against 
mould. These facts are consistent with the recently observed results; the polymeric 
silver (I) complexes without a PPh3 ligand such as [Ag(im)]n] (im=imidazole), [Ag(1,-
triz)]n(triz= triazole) and [Ag(1,2,4-triz)]n have shown effective antimicrobial activities, 
while almost all of their triphenylphosphine derivatives such as [Ag(im)(PPh3)3],  have 
shown no activity (>1000 μgml−1). These facts have been attributed to the restricted 
ligand exchange ability of the Ag---P bonding complexes. From a viewpoint of metal-
based drug design, no activity of the PPh3 derivatives is also crucial.   
In 2003, Tao WuF et al52 synthesized a novel trinuclear silver (I)- triphenylphosphine 
complex with nitrogen-containing hetrocyclic ligand benzimidazole (Hbim). [Ag3(μ-
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bim)3(PPh3)5], was synthesized by  the reaction of the precursor complex [Ag(bim)]n 
with two equivalents of PPh3 in dichloromethane. The complex has been identified by 
IR, UV/VIS, EA, and X-ray diffraction crystallography. Three silver ions are bridged by 
three bim- ligands to form an asymmetric twelve–membered ring structure with rare 
twisted conformation (Figure 20). Each silver (I) ion occupied a three- or four co-
ordination environment bound to one or two triphenylphosphine(s).  
 
Figure 20: Molecular structure of [Ag3(μ-bim)3(PPh3)5] 51 
In 2005 Li et al53 reported four new luminescent silver(I) sulfonate complexes with 
PPh3, namely Ag(L1)(PPh3)2, Ag(L2)(PPh3)3, g2(L3)(PPh3)4(H2O)].1.5CH3CN.0.5H2O 
and [Ag4(L4)(PPh3)10].8H2O, where L1= p-toluenesulfonate, L2= 1-
naphthalenesulfonate, L3= 3-carboxylate- 4- hydroxybenzenesulfonate,L4= 1, 3,6, 8-
pyrenetetrasulfonate (structure of L1-L4 shown in Figure 21) and PPh3= 
triphenylphosphine. The crystal structures were determined by single crystal X-ray 
diffraction method. The complexes adopt discrete structures (Figure 22-25) rather than 
polymeric structures. Compounds Ag(L1)(PPh3)2, and Ag(L2)(PPh3)3 show 
mononuclear structure while Ag2(L3)(PPh3)4(H2O)].1.5CH3CN.0.5H2O and 
[Ag4(L4)(PPh3)10].8H2O are dinuclear and tetranuclear molecules, respectively. 
Moreover the numbers of PPh3 molecules coordinating to one silver center are two or 
three. 
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Figure 21: The structures of the sulfonate ligands53 
 
Figure 22: Molecular structure of [Ag(L1)(PPh3)2] 53 
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Figure 23: Molecular structure of [Ag(L2)(PPh3)3]53 
 
Figure 24: Molecular structure of [Ag2L3(PPh3)4(H2O)].1.5CH3CN.0.5H2O53 
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Figure 25: Molecular structure of [AgL4(PPh3)10].8.H2O53 
In 2005 Noguchi et al54 reported a novel tetranuclear silver(I) cluster, 
[Ag2(Himdc)(PPh3)2]2  (H3imdc = imidazole-4-5-dicarboxylic acid) which was obtained 
by a reaction of the Ag-O bonding precussor [Ag(R-Hpyrrld)]2 (H2pyrrld= 2-
pyrrolidone-5-carboxylic acid), PPh3 and H3imdc. The mononuclear complex, 
[Ag(H2imdc)PPh3)2] , was also formed by the reactions using increased amounts of 
PPh3 . In the solid state, the complex [Ag2(Himdc)(PPh3)2]2 was “bivalve”- like the Ag4 
cluster (Figure 26), while complex [Ag(H2imdc)PPh3)2] (Figure 27) showed a 
supramolecular arrangement of 4-coordinate AgP2(N2O) unit via an intermolecular 
hydrogen bonding interaction. 
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Figure 26: Molecular structure of [Ag2(Himdc)(PPh3)2]254 
 
Figure 27: Crystal and molecular structure of [Ag(H2imdc)PPh3)2]254 
 
In 2008 Ardizzoia et al55 reported the crystal structure of a compound composed of 
dimers of [Ag(H2L1)(PPh3)]2 formula  lying on a crystallographic twofold axis, the 
asymmetric unit being composed by one silver (I) ion, one H2L1 and one PPh3 ligand 
(Figure 28). Each metal centre possesses a slightly distorted trigonal stereochemistry 
and is coordinated to two triazole nitrogen atoms of two distinct H2L1 moieties and to 
the phosphorous atom of one phosphine ligand. The two H2L1 ligands, acting in the 
N,N′-exobidentate mode, bridge metal centres 3.72 Å apart, and form dimers in which 
the six-membered rings composed by the four coordinated nitrogen atoms and the two 
silver (I) centres adopt a boat-shape disposition. The oxygen atoms of the –OH groups 
are not involved in the coordination to the metal centres, as expected for a metal with 
soft nature like Ag(I). Nevertheless, intermolecular hydrogen bonds of moderate 
strength (H–D A 2.63 Å) are present between the hydroxy groups and the 
neighbouring iminic nitrogen atoms. 
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Figure 28: The structure of [Ag(H2L2)(PPh3)]2 55 
In 2008, Zhang et al56 reported the X-ray single crystal structure of 
[(Ph3PAgO3SCH3)4·4CH2Cl2] (Figure 29) and [(Ph3P)2AgO3SCH3·CH2Cl2]. Because of 
the different molar ratio of triphenylphosphine with silver methylsulofonate, the 
complex [(Ph3P)2AgO3SCH3·CH2Cl2] is a monomer (Figure 30) with each silver atom 
coordinated by two PPh3 groups. Complex [(Ph3PAgO3SCH3)4 · 4CH2Cl2], however, is 
a tetramer with the silver atom coordinated by one PPh3 group.  
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Figure 29: Crystal structure of [(Ph3PAgO3SCH3)4·4CH2Cl2] 56 
 
 
Figure 30: Crystal structure of [(Ph3P)2AgO3SCH3·CH2Cl2]56 
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I.9 METAL CARBOXYLATE CHEMISTRY 
I.9.1 Coordination modes of monocarboxylic acids 
Carboxylates serve as an important class of ligand in inorganic and bioinorganic 
chemistry.57 The versatility of the RCO2- ligand is attributed to the wide range of 
coordination modes that it can adopt.  The coordination chemistry of monocarboxylic 
acids is well established, and a large number of carboxylate complexes have been 
structurally characterized.  In metal carboxylates the positively charged metal centres 
(Mn+) are found in combination with negatively charged carboxylate groups (RCO2-), 
and the bonding between the metals and the carboxylate group ranges from ionic to 
polar covalent.  For a given type of compound (i.e. a given metal, oxidation state and 
structural type) a wide variety of physical and chemical properties can be conferred by 
varying the nature of the R group. 
The carboxylate functional group has four lone pairs of electrons available for metal 
binding.  These lone pairs subtend to an angle of 120o and are referred to as the syn- and 
anti-lone pairs (Figure 31).  On the basis of stereoelectronic arguments it has been 
suggested that the syn-lone pairs are more basic than those in the anti position.  
C
O
O
:
:..
..
syn 
anti 
anti 
R
 
Figure 31:  The carboxylate functional group57 
 
The various coordination modes of the RCO2- ligand are listed below: 
 
(i) Ionic.  The carboxylate salts of Na, K, Rb, and Cs have been shown to be ionic, with 
only coulombic interactions between the metal and the carboxylate ions. 
 
(ii) Monodentate.  In lithium acetate the metal is coordinated to one of the carboxylate 
oxygens. 
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 (iii) Bidentate Chelating.  Carboxylates may chelate either in a symmetrical mode, with 
both metal-oxygen bonds being of equal length, or in the asymmetrical mode (Figure 
32(d)) where one metal-oxygen bond is shorter than the other.  In zinc(II) acetate 
dihydrate the bonding mode of the acetate is symmetrical bidentate chelating, while in 
the mixed-ligand complex [Zn(phen)2(O2CCH3)][ClO4] it is asymmetrical bidentate 
chelating.  It has been found that the “bite angle” (i.e. the O-M-O angle) for a chelating 
carboxylate is ca. 60o which, being fairly small, distorts the octahedral geometry of 
many metal complexes. 
 
(iv) Bidentate Bridging.  The planar carboxylate ion is ideally suited to the formation of 
complexes in which the carboxylate bridges two metal atoms (Figure 32(e-g)).  The 
syn-syn mode is of particular interest since it is the type of bridging observed in the 
“lantern shaped” (paddlewheel) bimetallic carboxylates such as copper(II) acetate 
dihydrate.  The syn-syn coordination mode is the only one which allows the ligand to 
bridge the short metal-metal bonds found in these binuclear complexes. Several 
binuclear ruthenium complexes57 have carboxylate bridges in which the anti-anti mode 
of binding is found. 
 
(v) Monodentate Terminal Bridging.  This is one of the rarer binding modes (Figure 
33(h)) and it has been suggested to be important biologically, and it is thought to act as 
an intermediate between other carboxylate bridging modes.58  
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Figure 32: Coordination modes of monocarboxylic acids58 
 
I.9.2 Coordination modes of dicarboxylic acids 
Dicarboxylic acids contain two -CO2- functional groups, both of which can coordinate 
to a metal centre.  This class of ligand can generate a myriad of structural motifs and has 
been chosen for this project to promote variation in structure and nuclearity.  The 
unique versatility in the range of binding modes that dicarboxylic acids can adopt are 
broadly divided into three classes (Figure 32).59  
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(i) Unidentate.  The simple dibasic acid, ethanedioic acid (H2OCCO2H) behaves as a 
unidentate ligand in the octahedral cobalt(III) complex [Co(en)2(X)(O2CCO2)] (en = 
ethylenediamine; X = OH- or halide). 
 
(ii) Chelating.  The dicarboxylic acid group can chelate to the metal centre in a 
symmetrical or asymmetrical fashion, in which only one of the carboxylate groups is 
used for coordination. Small dibasic acids can utilise the close proximity of the two 
RCO2- groups to act as chelating ligands where only one carboxylate oxygen from each 
of the RCO2- groups binds the metal centre. An example in which the latter type of 
diacid coordination is present is the ethanedioic dicopper(II,II) complex 
[tmen(H2O)Cu(O2CCO2)Cu(H2O)tmen](ClO4)2(tmen=1,1,4,4tetramethylethylenediamin
e) 
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Figure 33:  Unidentate and chelating coordination modes for dicarboxylic acids.59 
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(iii) Bridging (Figure 34). This mode of binding is divided into three categories 
depending on the number of oxygen atoms that are complexed to the metal centre(s); 
bidentate (bridging via two oxygen atoms), tridentate (bridging via three oxygen atoms), 
and tetradentate (bridging via four oxygen atoms). 
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Figure 34: Mode of binding of dicarboxylate ligands59 
 
 
 I.9.3 Infra-red spectra of carboxylate complexes 
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Infrared spectroscopy is a useful tool for assigning structural detail to carboxylate 
complexes. Upon complexation to a metal centre the C=O absorption band of the -CO2H 
group in the free acid disappears, and two new bands relating to the antisymmetric 
(OCOasym) and symmetric (OCOsym) stretch appear around 1630-1585 cm-1 and 1355-
1330 cm-1, respectively.  The magnitude of separation between these two bands (OCO 
cm-1) has been used as a diagnostic aid in the determination of the nature of the 
carboxylate coordination. OCO = (OCOasym - OCOsym) cm-1. 
Deacon and Phillips60 compiled guidelines for diagnosing the type of carboxylate 
coordination based on a metal complex’s infra-red spectrum.  Their findings were based 
on spectral data obtained for eighty four complexed acetates and halogenoacetates, and 
are summarised below: 
(i) Ionic acetates, such as those of the alkali metals, have OCO values of ca. 165 cm-1.  
For ionic trifluoroacetates the OCO value was ca. 235 cm-1. 
(ii) OCO values < 105 cm-1 indicated symmetric chelating carboxylate coordination.  
Complexes in which the carboxylates bridge short metal-metal bonds may also show 
such low values. 
(iii) OCO values substantially less than the ionic values (i.e. < 150 cm-1 for acetates) 
indicate the presence of chelating or bridging carboxylate.  Unidentate carboxylates 
which are strongly hydrogen-bonded (“pseudo-bridging”) may also fall into this 
category. 
(iv) For complexes with OCO values similar to those for ionic carboxylates the 
assignments were counted as untrustworthy.  Deacon and Phillips found many examples 
of each type of coordination mode (except for symmetric chelating) in this category. 
(v) Unidentate coordination was suggested for complexes where the OCO value was 
substantially greater than those for the ionic carboxylates (i.e. > 200 cm-1 for acetates)  
An explanation for this difference in energy may be that the bonding of one oxygen to a 
metal, with the other oxygen free, increases the energy of the antisymmetric stretching 
mode.The above observations are summarised in Table 5. For a variety of reasons there 
can be many contradictions in the OCO proposed band assignments. For example anion 
exchange from the alkali halide infra-red discs can occur, and there can also be 
uncertainties in locating exactly the OCOsym stretching band. 
Table 5:  Infra-red spectral data (OCO) for coordinated acetate ligands61 
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OCO(CH3CO2-) (cm-1) Coordination mode 
< 105 symmetric chelating or short bridging 
< 150 chelating or bridging 
ca. 165 untrustworthy assignments 
> 200 Unidentate 
 
Caution should be applied to using these estimates as phenomena such as hydrogen 
bonding can significantly distort the OCO values.  
 
I.10 SILVER(I) CARBOXYLATE COMPLEXES 
 
I.10.1 Silver(I) carboxylate complexes 
In the solid state, silver(I) carboxylates mostly form bridged dimers as in 
[Ag2(OOCC6H5)2].62 They also exhibit aggregation of these dimers into a ladder 
forming a polymeric network. Their poor solubility and light-sensitivity make their 
structural characterization difficult.  
 
I.10.2 Silver(I) carboxylate complexes with tertiary Phosphines  
Reactions of silver(I) carboxylates with tertiary phosphines such as triphenylphosphine 
can lead to complexes which contain monodentate, bridging  or chelating carboxylate 
ligands62 and the number of phosphines attached to the silver can vary from one to three 
(Figure 35). 
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(a) Monodentate carboxylate 
 
   (b) Bridging carboxylate  
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  (c) Chelating carboxylate  
Figure 35: The structures of [Ag(OOCC2F5){(PPh3)3}] (a), [Ag(OOCC2F5)(PPh3)]2 (b)  
and [Ag(OOC(CH2)16CH3)(PPh3)2] (c)62  
 
In 2005 Han et al63 reported a series of triphenylphosphine co-ordinated silver α,β-
unsaturated carboxylates of type [Ag(O2CR)(PPh3)n:n=1, R=CH3CH=CH(2a), 
(CH3)2C=CH(2b), CH3CH2CH=CH(2c), CH3CH2CH2CH=CH(2d), PhCH=CH(2e), 
CH2=CH(2f), n=2, CH3CH=CH(3a), (CH3)2C=CH(3b), CH3CH2CH=CH(3c), 
CH3CH2CH2CH=CH(3d) were prepared by reaction of relative silver carboxylates (1a-
1f) with triphenylphosphine in chloroform. These complexes were obtained in high 
yields and characterised by elemental analysis, 1H NMR, 13C NMR, 31P NMR and IR 
spectroscopy. The molecular structure of [Ag((O2CCH=C(CH3)2))(PPh3)2] (3b) (Figure 
36,37) shows that the senecioato ligand is chelated to the silver atom and generates, a 
distorted tetrahedron. Complex 3b exists as a monomer in crystal structure. The Silver 
atom is bonded to two oxygen atoms of the carboxyl at the same time. The angle P1-
Ag1-P2 is 130.62o. The angle of P1-Ag1-P2 is much more than the expected value of 
ideal tetrahedron geometry. This is due to the presence of six phenyl groups, which 
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creates a relatively more crowded environment around silver. 
` 
Figure 36: The crystal structure of [Ag((O2CCH=C(CH3)2))(PPh3)2]63 
The use of smaller phosphines such as PMe3 leads to the formation of polymeric chain 
structures such as that of [Ag(OOCC2F5)(PMe3)]n 
 
 
Figure 37:  The chain-like structure of [Ag(OOCC2F5)(PMe3)]n62  
 
I.10.3 Silver(I) carboxylate complexes with diphosphines 
 
Diphosphines effectively stabilize Ag(I) carboxylate complexes through possible 
chelate and bridge binding,  a feature which makes them attractive for generating 
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possible silver-based antimicrobial agents. These ligands stabilize silver(I) in its 
tetrahedral and trigonal planar geometries, and influence the nuclearity of the 
complexes. In comparison to monophosphines more complicated dinuclear, tetranuclear 
or polynuclear structures are observed. The Ag(I) carboxylate complexes with 
diphenylphosphinoferrocene (dppf)  illustrate the variability of carboxylate bonding and 
nuclearity that can be achieved by this type of ligand when the type of carboxylate is 
varied  (Figure 38) .   
 
 
 
     (a) Carboxylate = formate   
 
 
  (b)  Carboxylate = benzoate  (c) Carboxylate = acetate 
 
Figure 38:  The variation  in structures of  [Ag(OOCCH)2(dppf)3].2CH2Cl2 (a)  
[Ag2(OOCC6H5)2(μ-dppf)] (b) and [Ag4(OOCCH3)4(dppf)2] (c)62 
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The versatility of carboxylates when used in conjunction with diphosphine ligands is 
also demonstrated for the stable diphenylphosphinomethane (dppm) complexes shown 
in Figure 39.  
 
 (a) carboxylate = acetate    (b) carboxylate = acetate 
 
(c) carboxylate = pentaflouroacetate 
 
Figure 39: The variation  in structures of  [Ag4(OOCCH3)4{(μ-dppm)2].2H2O (a) 
[Ag2(OOCCH3)2{(μ-dppm)2]. 2CHCl3 (b) and [Ag4(OOCC2H5)4{(μ-dppm)2] (c)62  
 
I.10.4 Silver(I) dicarboxylate complexes with phosphines 
 
Silver(I) dicarboxylate complexes with phosphine ligands are relatively scarce.63  It has 
been proposed that silver(I) dicarboxylates form complexes with triphenylphosphines in 
which two silver atoms are bridged by the dicarboxylate ligand and each metal either 
has two or three phosphine attached to them (Figure40,41).64    
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Figure 40: The proposed structure of silver(I)dicarboxylate triphenylphosphine 
complexes.64
 
Figure 41: Structure of [Cu2(terph)(PPh3)4] (terphH2 = terephthalic acid).65 
  
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
 
 
RATIONALE 
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Silver(I) salts and simple silver(I) complexes are generally excellent antimicrobial 
agents.  However it can be difficult to control the rate of silver ion release from these 
systems and they are often indiscriminate antimicrobials.  A further problem arises from 
the fact that generally they are not photostable.  The purpose of this study was to 
generate a series of light stable silver complexes as potential antimicrobial agents.  The 
strategy employed the use of the aliphatic α, ω-dicarboxylic acids HOOC-(CH2)n-
COOH (where n = 1-11) as primary ligands and counter ions with the intention of 
generating a series of novel compounds capable of releasing silver ions.  These versatile 
dicarboxylate ligands have previously been shown, in this laboratory, to promote 
variations in structure and nuclearity (chain length dependent) when employed to make 
copper(II), manganese(II) and cobalt(II) complexes in the presence of auxiliary nitrogen 
donor ligands.66 Because of the known instability of silver(I) carboxylate complexes the 
neutral donor phosphines PPh3, dppm and dppe were employed as auxiliary ligands, as 
they are known to stabilize Ag (I) complexes and modify their silver ion release 
capabilities.  It was hoped that the series of complexes generated using this approach 
would be stable,  exhibit variation in structure and antimicrobial properties and that 
some interesting lead compounds with potential applications as novel antimicrobials 
would be identified.  
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D.1 SYNTHESIS AND CHARACTERISATION OF SILVER (I) 
DICARBOXYLATE COMPLEXES 
The synthetic route to the silver dicarboxylate complexes [Ag2(prda)] (1), [Ag2(bda)] 
(2), [Ag2(pda)] (3), [Ag2(hxda)] (4), [Ag2(hpda)](5), [Ag2(oda)] (6), [Ag2(nda)] (7), 
[Ag2(dda)] (8), [Ag2(udda)] (9), [Ag2(ddda)] (10) and [Ag2(uddca)] (11) is shown in 
Scheme 1. The 11 complexes were generated by the reaction of [Ag(CH3COO)] with 
the relevant dicarboxylic acid.  
 
HOOC-(CH2)n-COOH    +       2[Ag(CH3COO)] 
AgOOC-(CH2)n-COOAg     +    CH3COOH
Toluene
30ml
Reflux
2.5hrs
 
 
n =1-11 
Scheme 1: The synthetic route to the silver dicarboxylate complexes 
 
The reaction was facilitated by removal of the condenser which removed the acetic acid 
byproduct and essentially drove the reaction forward. 
Complex 1-11 were obtained as off-white powders. They were formulated as shown 
below in Table 6. 
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Table 6: Elementary Analysis of complexes 1-11 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H C H 
[Ag2(prda)] (1) 11.34 0.63 11.32 0.64 
[Ag2(bda)] (2) 14.48 1.22 14.22 1.68 
[Ag2(pda)] (3) 17.36 1.75 17.22 1.6 
[Ag2(hxda)] (4) 20.03 2.24 20.59 2.16 
[Ag2(hpda)] (5) 22.49 2.7 22.43 2.26 
Ag2(oda)] (6) 24.77 3.12 24.27 3.17 
[Ag2[(nda)] (7) 26.89 3.51 26.39 3.01 
[Ag2(dda)] (8) 28.87 3.88 28.11 3.5 
[Ag2(udda)] (9) 28.87 3.66 28.34 3.84 
[Ag2(ddda)] (10) 32.46 4.54 32.22 4.94 
[Ag2(uddca)] (11) 34.09 4.84 34.44 4.77 
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Table 7: Characteristic IR bands (cm-1, KBr discs) of the complexes 1– 11 
 
         (1)          (2)         (3)          (4)         (5)         (6)          (7)         (8)                    (9)                        (10)              (11)     
 
ν(C-H)aliphatic 
 
Carboxylate band 
 
ν(asym)(OCO) 
 
ν(sym)(OCO) 
 
∆OCO 
 
 
        
         *             *        2959     2925       2932      2930      2934    2930,2851     2930,2913,2846        2918             2848 
 
 
 
     1570       1566     1569      1564       1564       1566      1567      1567                 1585                    1568            1562 
 
     1356      1410     1400      1409        1407       1410     1408       1408                 1408                    1409            1409    
 
      214       156       169         155          157         156       159         159                   177                      159              153       
* Bands precluded by others in the infrared spectrum. 
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The IR spectra of complexes 1-11 are shown in the Appendix 1. Complexes 1-11 all 
have very similar IR spectra (Table 7) reflecting similar structural characteristics of this 
family of complexes. The important feature of the IR spectra of these complexes is the 
presence of the νasym(OCO) and  νsym(OCO) bands which are indicative of the presence 
of the carboxylate ligand (Table 7). These bands are not split and therefore it is most 
likely that the two carboxylate groups are bound to the silver centres in the same mode 
for each dicarboxylate ligand. The ∆OCO values for all complexes (153-214 cm-1) are 
indicative of carboxylate groups bound to a metal centre in a monodentate coordination 
mode.60 The presence of bands in the 2000-2950 cm-1 of the IR spectra for these 
complexes further supports the presence of the dicarboxylate ligands and the increasing 
intensity of these bands results from the increase in fatty nature of the dicarboxylate 
ligands as the molecular weight of the ligands increases. 
 
It is worth noting that early attempts to generate complexes 1-11 via the ligand 
exchange reaction between the diacids and the silver acetate (Scheme 1) yielded 
colourless powders which were difficult to formulate and had IR spectra that exhibited ν 
asym(OCO) and ν sym(OCO) groups that were split. Furthermore, the IR spectrum of 
silver acetate (Appendix1) is very similar to the spectra of complexes 1-11 in the 
carboxylate region. It transpired that these early products were mixtures of 
dicarboxylate and acetate silver salts and it was discovered that the critical element in 
the protocol for achieving pure samples of 1-11 was the removal of the condenser 
periodically during the reaction process. This allowed excess acetic acid to evolve out of 
the reaction vessel and yielded pure products. 
 
 Complexes 1-11 were found to have very limited solubility in the organic solvents. All 
attempts to obtain NMR spectra and conductivity of the complexes were unsuccessful 
due to the insolubility of the compounds. 
 
A proposed structure that fits the physico-chemical properties of the complexes 1-11 is 
shown in Figure 42. 
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n= 1-11
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Figure 42: A proposed structure of the complexes 1-11 
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D.2 SYNTHESIS AND CHARACTERISATION OF SILVER (I) 
DICARBOXYLATE COMPLEXES WITH TRIPHENYLPHOSPHINE (PPh3) 
LIGAND  
Complexes 1-11 were reacted with PPh3 in 1:2.5, 1:4 and 1:6 molar ratios.  
The synthetic route to the silver dicarboxylate triphenylphosphine complexes 
[Ag2(prda)(PPh3)3] (12), [Ag2(bda)(PPh3)3].C7H8 (13), [Ag2(pda)(PPh3)3].2H2O  (14), 
[Ag(hxdaH)(PPh3)2] (15){Ag(hpdaH)(PPh3)3.2H2O }n(16),{Ag2(oda)(PPh3)3.2H2O}n 
(17), [Ag(ndaH)(PPh3)2](18), [Ag2(dda)(PPh3)4].2C7H8(19), [Ag2(udda)(PPh3)2] (20), 
[Ag(ddda)(PPh3)3] (21) and [Ag(uddcaH)(PPh3)2] (22) is shown in Scheme 2. Complex 
12-22 resulted from the reaction of the relevant Ag(I) dicarboxylate salt with 2.5 
equivalents of PPh3 as shown in Scheme 2. 
  
[Ag2(OOC-(CH2)n-COO)]       +      2.5PPh3
[Agx(OOC-(CH2)n-COOHy)(PPh3)z]
n=1-11
Toluene
30ml
Reflux
2.5hrs
 
x = 1or 2, y = 0 or 1 and z = 2 – 4 
 
Scheme 2: The synthetic route to the silver dicarboxylate triphenylphosphine complexes 
 
Complex 12 to 21 were obtained as off-white powders. Complex 22 was obtained as 
colourless crystals. They were formulated as shown below in Table 8. 
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Table 8: Elementary Analysis of complexes 12 to 22 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H P C H P 
[Ag(prdaH)(PPh3)2].C7H8 (12) 63.69 4.52 8.42 64.49 4.61 7.22 
[Ag2(bda)(PPh3)3].C7H8 (13) 64.48 4.74 7.67 64.98 4.98 7.89 
[Ag2(pda)(PPh3)3].2H2O (14) 60.63 4.74 7.95 60.51 4.43 7.86 
[Ag2(hxda)(PPh3)2] (15) 57.04 4.33 7.00 57.04 4.30 6.43 
[Ag2(hpda)(PPh3)2].2H2O (16) 61.12 5.13 7.75 61.60 4.87 7.27 
{[Ag2(oda)(PPh3)3].2H2O}n (17) 61.40 5.24 7.66 61.02 5.07 7.44 
[Ag(ndaH)PPh3)2] (18) 65.94 5.53 7.56 66.95 5.16 8.50 
[Ag2(dda)(PPh3)4].2C7H8 (19) 69.82 5.74 7.50 69.23 5.21 7.58 
[Ag2(udda)(PPh3)2] (20) 59.01 5.27 6.48 59.46 5.00 6.63 
[Ag2(ddda)(PPh3)3] (21) 64.40 5.33 7.55 64.55 5.53 7.43 
[Ag(uddcaH)(PPh3)2] (22) 67.20 6.10 7.07 66.83 6.02 7.31 
 
Complexes 12-22 formulate in three categories (i) {Ag2(O2C-(CH2)nCO2)(PPh3)3}n ; 
(ii)[Ag(O2C-(CH2)n-COOH)(PPh3)2]; and (iii) {Ag2(O2C-(CH2)n-CO2(PPh3)4}n. 
Complexes 12, 13, 14, 17 and 21 fall into category (i), complexs 15, 16, 18 and 22 fall 
into category (ii) and complexes 19 and 20 formulate as shown in category (iii). 
Furthermore, early attempts to react the PPh3 with complex 1-11 in a 2.5 : 1 ratio were 
flawed as a result of using the mixtures of [Ag(CH3COO)] and [Ag2(dicarboxylate)] 
inadvertently. This point was demonstrated when crystals from the intial reaction of 2.5 
PPh3 and what was believed to be [Ag2(O2C-(CH2)5-CO2)] were isolated. These turned 
out to be a co-crystallised product ( ie 2 complexes present in one crystal lattice). The 
crystal comprised two components [Ag(PPh3)2(CH3COO)] and 
{Ag(hpdaH)(PPh3)2}n.These structures are shown in Figures 43, 44 and 45 and selected 
bond lengths and angles for them are listed in Tables 9 and 10. 
 
The [Ag(PPh3)2(CH3COO)] (Figure 44) component is reasonably well-behaved and 
does not show any very striking interactions with the other species present (though there 
are many weak interactions involving the phenyl groups- see (Figure 45). The other 
silver species forms a {Ag(PPh3)2(OOC(CH2)5COOH)}n polymeric chain running 
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parallel to the b axis in which the silver ions are bridged by OOC(CH2)5COOH anions, 
Figure 45. This link is reinforced by H-bonding between the chains. There is some 
disorder in this component – in which the silver ion and one of the PPh3 groups take up 
alternate positions.67 Since the minor component is quite small (estimated 15%) only the 
Ag and P positions have been modelled. A second data set shows this disorder more 
clearly.The toluene solvate is disordered and modelled with equal occupancy of two 
overlapping sites. 
 
 
Figure 43: Structure of the [Ag(PPh3)2(CH3COO)] component of the co-crystallised 
product from the reaction of impure [Ag2(hpda)] complex with PPh3 
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Figure 44: The polymeric structure of {Ag(hpdaH)(PPh3)2}n component of the co-
crystallised product from the reaction of the impure [Ag2(hpda)] complex with PPh3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Packing diagram for the co-crystallised 
[Ag(PPh3)2(CH3COO)]/{Ag(hpdaH)(PPh3)2}n product. 
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Table 9: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(PPh3)2(OAc)] component of the co-crystallised product from the 
reaction of impure [Ag2(hpda)] complex with PPh3 
 
Complex (16A) 
Bond lengths Å 
Ag(1)-O(2)  2.417(2) 
Ag(1)-P(2)  2.4232(8) 
Ag(1)-P(1)  2.4394(8) 
Ag(1)-O(1)  2.441(2) 
Bond angles  
O(2)-Ag(1)-P(2) 115.91(6) 
O(2)-Ag(1)-P(1) 105.10(6) 
P(2)-Ag(1)-P(1) 129.58(3) 
O(2)-Ag(1)-O(1) 53.99(7) 
P(2)-Ag(1)-O(1) 112.18(6) 
P(1)-Ag(1)-O(1) 115.34(6) 
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Table 10: Selected bond lengths [Å] and angles [] around the silver centres in 
the{Ag(hpdaH)(PPh3)2}n1  component of the co-crystallised product from the 
reaction of impure [Ag2(hpda)] complex with PPh3 
 
Complex (16) 
Bond lengths Å 
Ag(1)-O(1)  2.386(9)           
Ag(1)-P(1)  2.419(2) 
Ag(1)-P(2)  2.4524(19)  
Ag(1)-O(3)#1  2.500(9)         
Ag(1')-P(2)  2.320(5) 
Ag(1')-P(1')  2.530(11) 
Bond angles  
O(1)-Ag(1)-P(1)                               111.0(3)     
O(1)-Ag(1)-P(2)                               109.6(2) 
P(1)-Ag(1)-P(2)                               125.86(7) 
O(1)-Ag(1)-O(3)#1                         100.4(5) 
P(1)-Ag(1)-O(3)#1                          110.1(3) 
P(2)-Ag(1)-O(3)#1                          95.9(2) 
 
When pure [Ag2(hpda)] was reacted with 2.5 equivalents of PPh3 the complex 
[Ag2(hpda)(PPh3)2].2H2O 16 was isolated. 
Crystals of 17 suitable for X-ray structural analysis were obtained when the mother 
liquor was left to stand for several weeks.  The structure of 17 is shown in Figures 45 
and 46 and selected bond lengths and angles are listed in Table 11. 
The polymeric structure results from the bridging nature of the dicarboxylate anions 
(Figure 46). The repeating unit comprises two silver ions linked by two oxygen bridges, 
Note that the metal ions have different coordination numbers.68 Quite likely some of 
this is driven by the packing interactions between the phenyl groups (Figure 47). There 
is possibly a weak interaction between Ag2 and the second carboxylate oxygen. The 
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Ag1-Ag2 distance is 3.7254(2) Å. and therefore no significant Ag…..Ag interaction is 
found in the complex. 
 
 
 
Figure 46: The polymeric structure of {Ag2(oda)(PPh3)3}n  (17) 
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Figure 47: Packing diagram for {Ag2(oda)(PPh3)3}n  (17) 
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Table 11: Selected bond lengths [Å] and angles [] around the silver centres in 
{Ag2(oda)(PPh3)3}n   (17)  
Complex 17 
Bond lengths Å 
Ag(1)-O(1)  2.3214(12) 
Ag(1)-P(1)  2.4245(5) 
Ag(1)-P(2)  2.4293(4) 
Ag(1)-O(3)#1  2.4680(13) 
Ag(2)-O(3)#1  2.2205(13) 
Ag(2)-O(1)  2.2726(12) 
Ag(2)-P(3)  2.3314(4) 
Bond angles  
O(1)-Ag(1)-P(1) 112.70(4) 
O(1)-Ag(1)-P(2) 113.23(4) 
P(1)-Ag(1)-P(2) 129.402(15) 
O(1)-Ag(1)-O(3)#1 70.41(4) 
P(1)-Ag(1)-O(3)#1 109.53(4) 
P(2)-Ag(1)-O(3)#1 104.81(4) 
O(3)#1-Ag(2)-O(1) 75.91(4) 
O(3)#1-Ag(2)-P(3) 145.61(4) 
O(1)-Ag(2)-P(3) 137.50(3) 
 
Crystals of 18 suitable for X-ray structural analysis were obtained when the mother 
liquor was left to stand for several weeks.  The structure of 18 is shown in Figures 48 
and 49 and selected bond lengths and angles are listed in Tables 12 and 13. 
The carboxylic acid is mono-deprotonated; the carboxylate end acts as a bidentate 
ligand to the silver while the carboxylic acid end is linked to a neighbouring complex by 
hydrogen bonding (Figure 49).69 The result is H-bonded chains running through the 
structure parallel to the b axis. 
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Figure 48: The structure of [Ag(ndaH)(PPh3)2] (18) 
 
Figure 49: Packing diagram for [Ag(ndaH)(PPh3)2] (18) 
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Table 12: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(ndaH)(PPh3)2] (18)  
Complex 18 
Bond lengths Å 
Ag(1)-O(1)  2.3736(14) 
Ag(1)-P(2)  2.4255(5) 
Ag(1)-P(1)  2.4319(6) 
Ag(1)-O(2)  2.5409(15) 
Bond angles  
O(1)-Ag(1)-P(2) 109.75(4) 
O(1)-Ag(1)-P(1) 114.44(4) 
P(2)-Ag(1)-P(1) 131.221(19) 
O(1)-Ag(1)-O(2) 53.19(5) 
P(2)-Ag(1)-O(2) 118.08(4) 
P(1)-Ag(1)-O(2) 104.62(4) 
 
Table 13: Hydrogen bonds for [Ag(ndaH)(PPh3)2] (18) 
 
 [Å and °]. 
______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________ 
 O(3)-H(3)...O(2)#1 0.95 1.70 2.627(2) 166.1 
______________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 x,y+1,z      
 
Crystals of 22 suitable for X-ray structural analysis were obtained when the mother 
liquor was left to stand for several weeks.  The structure of 22 is shown in Figures 50 
and 51 and selected bond lengths and angles are listed in Table 14 and 15. 
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Each silver ion is coordinated to two PPh3 ligands and to a bidentate carboxylate group. 
The second acid group of the diacid is not deprotonated but hydrogen-bonded to a 
neighbouring coordinated carboxylate (under symmetry operation -x+1,-y+1,-z+1).70 This 
results in the formation of H-bonded centrosymmetric dimers. There is a slight disorder 
in part of the alkyl chain modelled as 90:10 occupancy of two related positions. 
 
Figure 50: The structure of [Ag(uddcaH)(PPh3)2] (22) showing the hydrogen bonding 
between molecules  
 
It is worth noting the significant difference in the way the dicarboxylate group behaves 
in 22 compared to those in complex 18. The –(CH2)n- chain length in the dicarboxylate 
acid has a profound effect on the way the complexes pack into the crystal. 
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Figure 51: Packing diagram for [Ag(uddcaH)(PPh3)2] (22) 
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Table 14: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(uddcaH)(PPh3)2] (22) 
 
Complex (22) 
Bond lengths Å 
Ag(1)-O(1)  2.3697(15) 
Ag(1)-P(1)  2.3958(6) 
Ag(1)-P(2)  2.4500(6) 
1Ag(1)-O(2)  2.5095(16) 
Bond angles  
O(1)-Ag(1)-P(1) 124.66(4) 
O(1)-Ag(1)-P(2) 103.77(4) 
P(1)-Ag(1)-P(2) 129.48(2) 
O(1)-Ag(1)-O(2) 53.42(5) 
P(1)-Ag(1)-O(2) 122.17(4) 
P(2)-Ag(1)-O(2) 96.63(5) 
 
Table 15:  Hydrogen bonds for [Ag(uddcaH)(PPh3)2] (22) [Å and °]. 
______________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________  
 O(4)-H(4)...O(1)#1 0.83(3) 1.72(3) 2.553(2) 175(3) 
______________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:    #1 -x+1,-y+1,-z+1       
 
The IR spectra of complexes 12-22 are shown in the Appendix 1.The IR spectral data 
that are indicative of the structural features of the complexes 12-22 are shown in Table 
14. The spectra of the complexes 13, 14, 15 and 21 are all similar to that of complex 17 
and therefore it is likely that they share a similar structure. Complex 12 formulates as 
having one Ag, two PPh3 groups and a mono deprotonated dicarboxylic acid ligand and 
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the IR spectral data support a structure similar to those of the structurally characterised 
complexes 18 and 22.60 Furthermore, the presence of the COOH group in 12, 18 and 22 
is supported by C=O stretches in their IR spectra (Table16). 
Complexes 19 and 20 formulate as [Ag2(dicarboxylate)(PPh3)4] and the IR spectral 
features are the same for both complexes. A structure that fit’s the physico-chemical 
properties of 19 and 20 is shown in Figure 52. 
 
PPh3
Ag
PPh3
O
C
O
(CH2)n C
O Ag
PPh3
PPh3
O
 
Figure 52: Possible structure for complexes 19 and 20 
 
Complexes 12-22 were found to have very limited solubility in organic solvents and all 
attempts to obtain NMR spectra and the conductivity of the complexes were 
unsuccessful.
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Table 16: Characteristic IR bands (cm-1, KBr discs) of the complexes (12)-(22) along with the free ligand 
 PPh3 (12)           (13)           (14)        (15)         (16)          (17)          (18)           (19)             (20)             (21)               (22) 
ν (C-H) aromatic  3053         3053         3052      3049          3052          3053      3053.22          *              3051           3051            3054 
                                                                
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate 
band 
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
 
744 
692 
 *            *        2962,2920      2934       2941      2930,2851     2938        2921            2922        2924,2851       2922 
                                                             
1731                                                                                           1736                                                                    1703 
                                                                                           
 
1598        1549       1549         1620       1548           1593         1546           1478             1547             1560        1562           
1370        1393      1393          1366       1400          1407          1403           1433             1397             1406        1402 
228          156         156            254         148            186            143              45               150                154         160 
 
 
 
753.18   745.25    745.26      746.58       748.28       746.56       746              752                  745          745         745 
694.60   693.43    693.62      693.08      694.52       693.60        694             693.85           694.55            695     694 
* Bands precluded by others in the infrared spectrum. 
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D.3 SYNTHESIS AND CHARACTERISATION OF SILVER (I) 
DICARBOXYLATE COMPLEXES WITH TRIPHENYLPHOSPHINE (PPh3) 
The synthetic route  to the silver dicarboxylate triphenylphosphine complexes 
[Ag2(prda)(PPh3)3].H2O (23), [Ag2(bda)(PPh3)4] (24), [Ag2(pda)(PPh3)4] (25), 
[Ag(hxda)(PPh3)4] .2H2O(26), [Ag2(hpda)(PPh3)4].C7H8(27), 
[Ag2(oda)(PPh3)4].2.C7H8(28), [Ag2(oda)(PPh3)4] (28A), [Ag2(ndaH)(PPh3)4].2H2O 
(29), [Ag2(dda)(PPh3)4].H2O (30), [Ag2 (udda) (PPh3)3] (31), [Ag2 (udda) 
(PPh3)4](31A), [Ag(ddda)(PPh3)3]n (32) and Ag(PPh3)2(HOOC(CH2)9COO)(33) is 
shown in Scheme 3.  
Complex 23-33 resulted from the reaction of the relevant Ag(I)dicarboxylate salt with 4 
equivalents of PPh3 as shown in Scheme 3 
 
[Ag2(OOC-(CH2)n-COO)]       +      4PPh3
[Agx(OOC-(CH2)n-COOHy)(PPh3)z]
n=1- 11
Toluene
30ml
Reflux
2.5hrs
 
X=1or2, y = 0 or 1 and z = 2-4 
 
Scheme 3: The synthetic route to the silver dicarboxylate triphenylphosphine complexes 
 
Complex 23 to 33 were obtained as off-white powders. They were formulated as shown 
below in Table 17. 
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Table 17: Elementary Analysis of complexes 23 to 33 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H P C H P 
[Ag2(prda)(PPh3)3].H2O (23) 60.98 4.4 8.28 60.95 4.29 8.18 
[Ag2(bda)(PPh3)4] (24) 66.1 4.67 8.97 66.05 4.76 8.44 
[Ag2(pda)(PPh3)4] (25) 66.3 4.77 8.88 66.96 4.75 8.88 
[Ag(hxdaH)(PPh3)4].3H2O (26) 65.88 5.53 8.49 65.22 4.98 8.39 
[Ag2(hpda)(PPh3)4].C7H8 (27) 68.17 5.19 8.18 68.72 5.20 8.14 
[Ag(odaH)(PPh3)2].C7H8 (28) 68.23 5.73 6.90 69.96 5.43 7.86 
[Ag(ndaH)(PPh3)2] (29) 65.94 5.53 7.56 65.59 4.92 8.71 
[Ag2(dda)(PPh3)4].H2O (30) 66.41 5.3 8.35 66.05 5.66 8.47 
[Ag2 (udda) (PPh3)3] (31) 64.16 5.22 7.64 64.52 5.03 7.69 
[Ag2(udda)(PPh3)4] (31A) 67.75 5.61 8.21 67.08 5.92 7.96 
[Ag(dddaH)(PPh3)2] (32) 66.90 5.97 7.19 66.38 5.72 8.06 
[Ag2(uddca)(PPh3)5] (33) 71.53 5.56 9.15 71.33 5.55 9.10 
 
Complexes 23-33 formulate in four categories. 
(i) {Ag2(O2C-(CH2)n-CO2(PPh3)3}n; 
(ii) [Ag(O2C-(CH2)n-CO2H)(PPh3)2];  
(iii) [Ag2(O2C-(CH2)n-CO2)(PPh3)4] and 
(iv) [Ag(O2C-CH2)n-CO2H(PPh3)3] 
 
Complexes 23 and 31 fall into category (i), complex 28, 29 and 33 fall into category (ii), 
complexes 24, 25, 27, 30 and 31A fall into category (iii) and complex 26 and 32 fall 
into category (iv). 
Crystals of 28 suitable for X-ray structural analysis were obtained when the reaction 
was carried out in toluene and the mother liquor left to stand for several weeks.  The 
structure of 28 is shown in Figures 53 and 54 and selected bond lengths and angles are 
listed in Table 18 and 19. 
  
H-bonding links the Ag(odaH)(PPh3)2 units into a zig-zag one dimensional chain along 
the b direction (O4 ···· O2 2.573(2)Å, under –x, y-½, -z+½).71 One toluene solvate 
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molecule is present for each formula unit and is disordered, it was modelled with 50% 
occupancy each of two overlapping sites. 
The structure is similar to that of complexes 18 (Figure 48) and 22 (Figure 51) with the 
dicarboxylate only singly deprotonated.The deprotonated group is bound to the silver 
centre in a chelating mode. The metal is overall four coordinate with the two PPh3 
groups completing the ligation around the silver ion. Once again the hydrogen bonding 
links individual molecules to their neighbours through out the crystal lattice. 
 
Figure 53: Crystal Structure of [Ag(odaH)(PPh3)2].C7H8 (28) 
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Figure 54: Packing diagram for [Ag(odaH)(PPh3)2].C7H8 (28) 
 
Table 18: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(odaH)(PPh3)2].C7H8 (28) 
 
Bond lengths Å 
Ag(1)-P(1)  2.4187(5) 
Ag(1)-P(2)  2.4369(5) 
Ag(1)-O(2)  2.4690(16) 
Ag(1)-O(1)  2.4760(15) 
Bond angles  
P(1)-Ag(1)-P(2) 129.516(19) 
P(1)-Ag(1)-O(2) 109.02(5) 
P(2)-Ag(1)-O(2) 118.53(5) 
P(1)-Ag(1)-O(1) 117.29(4) 
P(2)-Ag(1)-O(1) 104.81(4) 
O(2)-Ag(1)-O(1) 52.72(5) 
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Table 19:  Hydrogen bonds for {Ag(oda)(PPh3)2]C7H9}n [Å and °] 
______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________ 
 O(4)-H(4)...O(2)#1 0.84 1.81 2.573(2) 150.3 
______________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 -x,y-1/2,-z+1/2      
 
When the mother liquor from the reaction for complex 31 was allowed to stand, crystals 
of 31A were obtained after several weeks. 31A and 31 do not formulate the same and 
the x-ray crystal structure of 31A revealed it to be [Ag2(udda)(pph3)4] 
The structure of 31A is shown in Figures 55 and 56 and selected bond lengths and 
angles are listed in Table 20.  
The asymmetric unit contains 1½ independent molecules. The [Ag2(PPh3)4(O2C-R-
CO2)] molecule containing Ag1 and Ag2 has no crystallographically imposed 
symmetry, while that containing Ag3 has a crystallographic 2-fold axis passing through 
C17 and bisecting the Ag3 ….Ag3A vector.72 Despite this difference, the structures of 
the two molecules are similar, in each case two Ag(PPh3)2 units are linked by a 
dicarboxylate chain. The carboxylate binds to Ag1 in a reasonably symmetric manner, 
but this is not the case for Ag2 or Ag3.  
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Asymmetric unit – 1½ molecules
 
Figure 55: Crystal Structure [Ag2 (udda) (PPh3)4](31A) 
 
Figure 56: Packing diagram for [Ag2 (udda) (PPh3)4] (31A) 
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Complex 31A formulates the same as complexes 19 and 20 and it is likely that they all 
share a similar structure. 
 
Table 20: Selected bond lengths [Å] and angles [] around the silver centres in [Ag2 
(udda) (PPh3)4] (31A) 
 
 
Bond lengths Å 
Ag(1)-O(1) 2.448(6) 
Ag(1)-P(2) 2.4495(18) 
Ag(1)-P(1) 2.4535(19) 
Ag(1)-O(2) 2.526(6) 
Ag(2)-O(3) 2.287(5) 
Ag(2)-P(4) 2.4082(19) 
Ag(2)-P(3) 2.4425(18) 
Ag(2)-O(4) 2.619(6) 
Ag(3)-O(5) 2.354(5) 
Ag(3)-P(6) 2.4240(18) 
Ag(3)-P(5) 2.4547(18) 
Ag(3)-O(6) 2.600(5) 
Bond angles  
O(1)-Ag(1)-P(2) 107.51(14) 
O(1)-Ag(1)-P(1) 125.12(14) 
P(2)-Ag(1)-P(1) 123.99(6) 
O(1)-Ag(1)-O(2) 52.06(18) 
P(2)-Ag(1)-O(2) 123.83(13) 
P(1)-Ag(1)-O(2) 104.36(13) 
O(3)-Ag(2)-P(4) 120.79(15) 
O(3)-Ag(2)-P(3) 107.35(15) 
P(4)-Ag(2)-P(3) 131.28(7) 
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O(3)-Ag(2)-O(4) 52.04(18) 
P(4)-Ag(2)-O(4) 114.09(16) 
P(3)-Ag(2)-O(4) 100.47(17) 
O(5)-Ag(3)-P(6) 120.92(13) 
O(5)-Ag(3)-P(5) 98.71(13) 
P(6)-Ag(3)-P(5) 128.95(7) 
O(5)-Ag(3)-O(6) 52.69(17) 
P(6)-Ag(3)-O(6) 105.58(13) 
P(5)-Ag(3)-O(6) 124.53(13) 
 
Crystals of 32 suitable for X-ray structural analysis were obtained when the mother 
liquor was left to stand for several weeks. It should be noted that no powder was 
obtained from this reaction. The structure of 32 is shown in Figures 57 and 58 and 
selected bond lengths and angles are listed in Tables 21 and 22. 
H-bonding links the units into a one dimensional chain along the a direction (O4 ···· O2 
2.502(2)Å, under x+1, y, z). 
 
 
Figure 57: Crystal Structure for [Ag(dddaH)(PPh3)3]  (32) 
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Figure 58: Packing diagram for [Ag(dddaH)(PPh3)3] (32) 
 
The structure of 32 (Figure 58) reveals that the dicarboxylic acid has only singly 
deprotonated and that the deprotonated carboxylate group is bound to the silver in a 
monodentate fashion. The silver ion is four coordinate with three PPh3 groups 
completing the ligation. The tetrahedral silver complexes are hydrogen bonded to 
neighbours through the hydroxyl hydrogen of the COOH groups in one molecule and 
the uncoordinated carboxylate oxygen (O2A) of another molecule (Figures 59 and 60) 
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Table 21: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(dddaH)(PPh3)3]  (32) 
 
Complex (32) 
Bond lengths Å 
Ag(1)-O(1)  2.3488(13) 
Ag(1)-P(2)  2.4792(5) 
Ag(1)-P(3)  2.5035(5) 
Ag(1)-P(1)  2.5820(5) 
Bond angles  
O(1)-Ag(1)-P(2) 109.29(4) 
O(1)-Ag(1)-P(3) 107.63(4) 
P(2)-Ag(1)-P(3) 119.209(15) 
O(1)-Ag(1)-P(1) 90.20(4) 
P(2)-Ag(1)-P(1) 116.060(15) 
P(3)-Ag(1)-P(1) 110.240(15) 
 
Table 22:  Hydrogen bonds for [Ag(dddaH)(PPh3)3] (32) 
 
 [Å and °] 
______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________ 
 O(4)-H(4)...O(2)#1 0.84 1.69 2.502(2) 162.6 
______________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 x+1,y,z      
 
Crystals of 33 suitable for X-ray structural analysis were obtained when the mother 
liquor was left to stand for several weeks. Again no powder was obtained from this 
reaction. The structure of 33 is shown in Figures 59 and 60 and selected bond lengths 
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and angles are listed in Tables 23 and 24. H-bonds link the 
Ag(PPh3)2(HOOC(CH2)11COO) units into centrosymmetric dimers (O1-O4A 2.552(2) 
Å).(Figure 58) 
 
 
Figure 59: Crystal Structure for [Ag(uddcaH)(PPh3)2] (33) 
 
Figure 60:  Packing diagram for [Ag(uddcaH)(PPh3)2] (33) 
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Table 23: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag(uddcaH)(PPh3)2] (33) 
 
 
Bond lengths Å 
Ag(1)-O(1)  2.3675(17) 
Ag(1)-P(2)  2.3966(6) 
Ag(1)-P(1)  2.4505(6) 
Ag(1)-O(2)  2.5114(18) 
Bond angles  
O(1)-Ag(1)-P(2) 124.63(4) 
O(1)-Ag(1)-P(1) 103.79(4) 
P(2)-Ag(1)-P(1) 129.51(2) 
O(1)-Ag(1)-O(2) 53.38(6) 
P(2)-Ag(1)-O(2) 122.21(5) 
P(1)-Ag(1)-O(2) 96.60(5) 
 
Table 24:  Hydrogen bonds for [Ag(uddcaH)(PPh3)2] (33) 
  [Å and °]. 
______________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________  
 O(4)-H(4O)...O(1)#1 0.84 1.72 2.552(2) 173.6 
______________________________________________________________________  
Symmetry transformations used to generate equivalent atoms: #1 -x+1,-y+1,-z+1   
 
Complex 33 formulates the same as complexes 18 and 22 and has a very similar 
hydrogen bonded dimeric structure to that of 22 (Figure 50). 
The IR spectra of complex 23-33 are shown in the Appendix 1. The IR spectral data that 
are indicative of structural features of complexes 23-33 are shown in Table 25, 26.The 
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spectral features of complexes 29 and 33 are similar to those of the structurally 
characterized 28 and it is likely they share similar structural features based on 
formulation and IR spectral features.60 Complexes 24, 25, 27 and 30 are probably quite 
similar to 31A in structure. Complex 26 formulates as [Ag(hxdaH)(PPh3)3].3H2O and its 
IR spectrum suggests that it has a similar structure to that of 32. The presence of a C=O 
stretch in the IR spectra of complexes 26, 28, 29, 32 and 33 supports the presence of un-
dissociated-COOH groups in their formulae. 
Complexes 23 and 31 are unusual as they formulate as [Ag2(dicarboxylate)(PPh3)3]. The 
structurally characterized complex 17 has the same formulation and its IR spectrum is 
similar to those of 23 and 31. It is possible that 23 and 31 are similar in structure to 17 
(Figure 46). 
Complexes 23-33 were found to have very limited solubility in organic solvents and all 
attempts to obtain NMR spectra and conductivity readings of the complexes were 
unsuccessful due to the insolubility of the compounds. 
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Table 25: Characteristic IR bands(cm-1, KBr discs) of the complexes (23)-(31) along with the free ligand PPh3 
 PPh3                   (23)           (24)           (25)        (26)          (27)            (28)              (29)                 (30)                 (31)      
ν (C-H) 
aeromatic 
 *               3051            *         3057          3048              *                3053                3051               * 
ν (C-H) 
aliphatic 
 
ν (C=O) 
 
Carboxylate 
band 
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine 
bands νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
 
 
744 
692 
*               *                  *          2931             *       2921,2851            2931           2921,2850          * 
 
 
                                                  1708                       1704                1700                                          * 
 
 
              
               1546        1542              1548        1555         1546       1547             1551              1479                 1557      
               1317       1386               1391        1395         1394        1399             1389              1283                 1384  
                229         156                 157         160            152         148              162                  196                  173       
              
        
                742         743                743           745           747        747               744                  752                  743 
                694         694                 693           694          693        694                694                694                    694 
* Bands precluded by others in the infrared spectrum. 
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Table 26: Characteristic IR bands (cm-1, KBr discs) of the complexes 31-33 along with 
the free ligand 
 PPh3       (31A)         (32)        (33) 
ν (C-H) aeromatic         3052        3052        3054 
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate band
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
  744 
  692 
  2921,2853       2923   2922,2851 
 
      1717          1703 
 
 
    1557           1585       1574 
    1395          1409       1401 
   162              176         173 
 
 
   743             744         745               
   694             694        695 
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D.4 SYNTHESIS OF SILVER (I) DICARBOXYLATE COMPLEXES WITH 
TRIPHENYLPHOSPHINE (PPh3)  
Attempts to react complexes 1-11 with PPh3 in a 1:6 ratio yielded the same product as 
obtained when 4 equivalents of PPh3 were employed and where the dicarboxylate 
ligands were propanedioate (prda), butanedioate (bda), pentanedioate (pda), 
nonanedioate (nda) and decanedioate (dda). The synthetic route to the six novel 
complexes [Ag(hxdaH)(PPh3)3].C7H8 (34), Ag2(hpda)(PPh3)5].C7H8 (35) 
[Ag2(oda)(PPh3)5].2C7H8 (36) [Ag2(udda)(PPh3)4] (37), [Ag2(uddca)(PPh3)5] (38), 
[Ag2(uddca)(PPh3)6] (38A) is shown in Scheme 4.  
[Ag2(OOC-(CH2)n-COO)] + 6PPh3
Reflux
2.5hrs
Toluene
30ml
[Agx(OOC-(CH2)n-COOHy)(PPh3)2]
where n= 4-6 and 9,11;  x= 2; y= 0 or 1 and z= 3-6  
Scheme 4: The synthetic route to silver(I) dicarboxylate complexes with 
triphenylphosphine. 
 
Compounds 34 to 38 were obtained as white powders and were formulated as shown 
below in Table 27. 
Table 27: Elementary Analysis of  complexes 34 to 38 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H P C H P 
[Ag(hxdaH)(PPh3)2].C7H8 (34) 64.87 5.06 7.97 64.78 5.13 7.80 
[Ag2(hpda)(PPh3)5].C7H8 (35) 70.28 5.27 8.71 70.64 5.17 9.67 
[Ag2(oda)(PPh3)4].2C7H8 (36) 69.63 5.47 7.64 69.02 5.44 7.86 
[Ag2(udda)(PPh3)4] (37)  67.40 5.32 8.38 67.28 5.27 8.51 
[Ag2(uddca)(PPh3)5] C7H8  (38) 70.97 5.69 8.32 70.87 5.57 9.03 
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When the mother liquor from the reaction for complex 38 was set aside crystals of 
[Ag2(uddca)(PPh3)6]  38A deposited after several weeks. These crystals were suitable 
for x-ray crystallographic analysis. The structure of 38A is shown in Figures 61 and 62 
and selected bond lengths and angles are listed in Table 28.  
The structure consists of centrosymmetric dimers linked by a dicarboxylate chain.73 The 
chain is disordered and this has been modelled using two overlapping chains of equal  
occupancy. The disorder is not resolved by refinement in the lower symmetry space 
group.
 
Figure 61: Crystal Structure of  [Ag2(uddca)(PPh3)5].C7H8  38A 
 
The structure of 38A is dinuclear with two pseudo-penta coordinated silver ions. The 
carboxylate groups are almost chelating the metal centres with one definite bonding Ag-
oxygen interaction (2.37Å for Ag1-O1) (Table 28).The second oxygen O2 is weakly 
bound to the silver with a bonding distance of 3.03 Å (Table 23). The geometry around 
each silver is completed by phosphorous atoms from three PPh3 groups. It is most likely 
the resultant steric crowding that prevents the carboxylate group from chelating fully to 
the silver ions as seen for [Ag2(udda)(PPh3)4] 31A (Figure 55 and Table 20). The 
molecules of 38A do not associate by any hydrogen bonding in the crystal (Figure 62) 
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Figure 62: Packing diagram for [Ag2(uddca)(PPh3)6] 38A 
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Table 28: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag2(uddca)(PPh3)6] 38A 
 
 
Bond lengths Å 
Ag(1)-O(1')#1  2.341(9) 
Ag(1)-O(1)  2.370(6) 
Ag(1)-P(2)  2.5216(5) 
Ag(1)-P(3)  2.5468(5) 
Ag(1)-P(1)  2.6753(5) 
Ag(1)-O(2)  3.030(5) 
Bond angles  
O(1')#1-Ag(1)-O(1) 2.6(4) 
O(1')#1-Ag(1)-P(2) 116.7(3) 
O(1)-Ag(1)-P(2) 119.10(14) 
O(1')#1-Ag(1)-P(3) 110.1(2) 
O(1)-Ag(1)-P(3) 108.95(15) 
P(2)-Ag(1)-P(3) 116.569(15) 
O(1')#1-Ag(1)-P(1) 83.9(2) 
O(1)-Ag(1)-P(1) 82.16(9) 
P(2)-Ag(1)-P(1) 112.274(15) 
P(3)-Ag(1)-P(1) 113.035(15) 
O(1')#1-Ag(1)-O(2) 45.6(3) 
O(1)-Ag(1)-O(2) 46.76(12) 
P(2)-Ag(1)-O(2) 103.76(9) 
P(3)-Ag(1)-O(2) 80.46(11) 
P(1)-Ag(1)-O(2) 127.66(9) 
The IR spectra for complexes 34-38 are shown in the Appendix 1. The IR spectral data 
that are indicative of structural features of complexes 34-38 are shown in Table 29. The 
spectra of all five complexes contain νasym(OCO)  and  νsym(OCO) bands which are 
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characteristic of complexes in which carboxylate groups are found bound to a metal 
centre. The Δoco values (148-173 cm-1) are in the region expected for chelating or 
bridging COO groups.60 Complex 34 formulates as having an undissociated carboxylic 
acid group with a silver atom and three PPh3 ligands. This is the same formulation as 
[Ag(ddaH)(PPh3)3] (32) and the spectral data for 34 suggest that it has a similar 
structure to 32 (Figure 57). 
Complex 37 formulates similarly to complex 31A and the similarities in the IR spectra 
support the hypothesis that 37 has a similar structure to that of 31A (Figure 56). The 
remaining complexes 35, 36 and 38 all formulate as [Ag2(dicarboxylate)(PPh3)5 ]. 
Splitting of the carboxylate bands in the IR spectra of 35, 36 and 38 supports the 
presence of two different binding modes for the carboxylate groups in each compound. 
Complexes 34-38 and 38A were found to have very limited solubility in organic 
solvents and all attempts to obtain NMR spectra and the conductivity of the complexes 
were unsuccessful.
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Table 29: Characteristic IR bands (cm-1, KBr discs) of the complexes (34)-(38) along with the free PPh3 ligand 
 PPh3                (34)               (35)                  (36)                 (37)                  (38)      
ν (C-H) aeromatic                    *                 3045               3054                3052               3052 
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate 
band 
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
 
744 
692 
                  *                2921                 2931              2923                2920 
   
               1723                 
 
 
 
               1547          1555                     1547               1556                1585 
               1398          1382                    1399                1395                1434 
                149           173                        148                 161                 151 
                     
 
                746           743                       747                 743                   744 
                695           693                       695                 694                   694 
     * Bands precluded by others in the infrared spectrum.
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D.5 SYNTHESIS AND CHARACTERISATION OF SILVER(I) 
DIPHENYLPHOSPHINEMETHANE COMPLEXES 
Complexes 1-11 were reacted with bis (diphenylphosphino) methane (dppm) in a 1:2 
molar ratio. The synthetic route to the silver dicarboxylate dppm complexes 
[Ag2(prda)(dppm)3]C7H8 (39), [Ag2(bda)(dppm)3].C7H8 (40), [Ag2(pda)(dppm)4] (41), 
[Ag2(hxda)(dppm)4] (42), [Ag2(hpda)(dppm)4] (43), [Ag2(oda)(dppm)4] (44), 
[Ag2(nda)(dppm)4] (45), [Ag(ddaH)(dppm)3].3H2O (46), [Ag2(udda)(dppm)4] (47), 
[Ag2(ddda)(dppm)4].H2O (48),  [Ag2(uddca)(dppm)4].2H2O (49), [Ag2(dppm)2(OAc)2].3 
C7H8 (49A) is shown in Scheme 5 
[Ag2(OOC-(CH2)n-COO)] +2dppm
{Agx(OOC-(CH2)n-COOHy)(dppm)z}
where n=1-11, x=1or 2, y= 0 or 1 and z=3 or 4
Reflux
2.5hrs
Tolune
30ml
 
Scheme 5: The synthetic route to the silver dicarboxylate dppm complexes 
 
Complexes 39 to 49 were obtained as off white powders.The mother liquor from the 
reaction of complex 48 yielded colourless crystals of {Ag2(OOC-(CH2)10COO) 
(dppm)2}n.H2O}48A. Complexes 39-49 were formulated as below in Table 30 
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Table 30: Elementary Analysis of complexes 39 to 49 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H P C H P 
[Ag2(prda)(dppm)3].C7H8 (39) 58.24 4.89 9.19 58.72 4.50 9.98 
[Ag2(bda)(dppm)3]. C7H8 (40) 58.61 5.02 9.07 57.40 4.31 9.97 
[Ag2(pda)(dppm)4] (41) 59.05 4.87 11.08 58.07 4.47 10.41 
[Ag2(hxda)(dppm)4] (42) 60.02 5.21 10.87 59.00 4.66 10.26 
Ag2(hpda)(dppm)4] (43) 60.32 5.32 10.55 59.46 4.65 11.02 
[Ag2(oda)(dppm)4] (44) 60.62 5.43 10.42 60.47 4.99 10.00 
[Ag2(nda)(dppm)4] (45) 60.91 5.53 10.30 59.67 4.93 10.82 
[Ag(ddaH)(dppm)3] .3H2O (46) 61.06 6.48 9.64 60.61 5.29 9.88 
[Ag2(udda)(dppm)4] (47) 61.48 5.73 10.07 60.84 5.15 10.46 
[Ag2(ddda)(dppm)4].H2O (48) 61.57 6.32 9.48 61.43 5.61 9.36 
[Ag2(uddca)(dppm)4].2H2O (49) 60.29 6.07 9.57 59.71 5.25 9.93 
    
The crystals of 48A were suitable for X-ray crystallographic analysis. 
 The structure of 48A is shown in Figures 63 and 64 and selected bond lengths and 
angles are listed in Tables 31 and 32. 
The structure is a linear polymer in which centrosymmetric Ag2(dppm)2 units are linked 
by diacid anions.74 The chains are linked via H-bonding through the water solvate 
molecule (one of the hydrogen atoms on the water is necessarily disordered).  
 
Figure 63: Crystal Structure for {Ag2(dppm)2(ddda)(H2O)}n  48A 
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Figure 64: Packing diagram for {Ag2(dppm)2(ddda)(H2O)}n 48A 
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Table 31: Selected bond lengths [Å] and angles [] around the silver centres in 
{Ag2(dppm)2(ddda)(H2O)}n 48A 
 
Complex (48A) 
Bond lengths Å 
Ag(1)-O(2)  2.303(3) 
Ag(1)-P(1)  2.4235(9) 
Ag(1)-P(2)#1  2.4295(10) 
Ag(1)-Ag(1)#1  3.0430(7) 
Bond angles  
O(2)-Ag(1)-P(1) 106.66(8) 
O(2)-Ag(1)-P(2)#1 98.96(9) 
P(1)-Ag(1)-P(2)#1 150.47(4) 
O(2)-Ag(1)-Ag(1)#1 132.06(9) 
P(1)-Ag(1)-Ag(1)#1 92.80(2) 
P(2)#1-Ag(1)-Ag(1)#1 80.36(3) 
 
Table 32:  Hydrogen bonds for {Ag2(dppm)2(ddda)(H2O)}n  48A 
 [Å and °] 
______________________________________________________________________
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________ 
 O(1W)-H(1WA)...O(1) 0.86 1.92 2.782(6) 179.2 
 O(1W)-H(1WB)...O(1W)#30.85 1.96 2.815(11) 179.4 
______________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms: #1 -x+1,-y+1,-z+1    #2 -
x,-y,-z+2    #3 -x,-y+1,-z+2  
 
Crystals of [Ag2(dppm)2(OAc)2].3C7H8, suitable for X-ray structural analysis were 
obtained when impure complex 10 was reacted with dppm and the reaction was carried 
out in toluene and the mother liquor left to stand for several weeks.  The structure of 
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[Ag2(dppm)2(OAc)2].3C7H8, is shown in Figures 65 and 66 and selected bond lengths and 
angles are listed in Table 33. 
The dimeric silver molecule lies on a centre of symmetry, so that the asymmetric unit 
contains half of the molecule. The asymmetric unit also contains 1.5 toluene molecules; 
one is disordered about a centre of symmetry and the second is disordered over two 
overlapping positions. The geometry of the phenyl rings of the latter toluene was 
restrained to that of a regular hexagon. The acetate bonding is asymmetric but probably 
best thought of as bidentate.75 There are some  and edge-to-face interactions but that 
is not unusual for these types of molecules. 
 
Figure 65: Crystal Structure for [Ag2(dppm)2(OAc)2].3 C7H8 49A 
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Figure 66: Packing diagram for [Ag2(dppm)2(OAc)2].3C7H8 49A 
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Table 33: Selected bond lengths [Å] and angles [] around the silver centres in 
[Ag2(dppm)2(OAc)2].3C7H8 
 
Complex(54A) 
Bond lengths Å 
Ag(1)-P(1) 2.4232(5) 
Ag(1)-O(1) 2.4376(14) 
Ag(1)-Ag(1)#1 3.2509(3) 
Ag(1)-P(2)#1 2.4504(4) 
Ag(1)-O(2) 2.7053(17) 
Bond angles  
P(1)-Ag(1)-O(1) 107.40(3) 
P(1)-Ag(1)-P(2)#1 146.021(15) 
O(1)-Ag(1)-P(2)#1 102.25(4) 
P(1)-Ag(1)-O(2) 130.70(3) 
O(1)-Ag(1)-O(2) 50.46(5) 
P(2)#1-Ag(1)-O(2) 81.50(3) 
P(1)-Ag(1)-Ag(1)#1 89.779(11) 
O(1)-Ag(1)-Ag(1)#1 140.14(4) 
P(2)#1-Ag(1)-Ag(1)#1 77.551(11) 
O(2)-Ag(1)-Ag(1)#1 90.95(3) 
 
 The   formulations for complexes 39-49 are such that it is not likely that they share the 
same structure as that of 48A. Indeed complxes 39-49 formulate in three categories (i) 
[Ag2(O2C-CH2)n-CO2)(dppm)3], (ii) [Ag2(O2C-(CH2)n-CO2)(dppm)4] and (iii) [Ag(O2C-
CH2)n-CO2H)(dppm)3] . The complexes 39 and 40 formulate as shown in category (i), 
complexes 41-45 and 47-49 formulate as shown in category (ii) and complex 46 is 
unusual as it formulates as shown in category (iii). 
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The IR spectra of complexes 39-49 (with that of 48A) are shown in Appendix1. The IR 
spectral data that are indicative of the structural features of the complexes are shown in 
Tables 34 and 35. Although the complexes 39 and 40 formulate somewhat similarly 
they do not appear to have similar structures as evidenced by their IR spectra. In the 
spectrum of 39 the νasym OCO band is split indicating that two carboxylate ligands are 
bound to the metal centres in different modes.60 In the IR spectrum of 40 the νasym OCO 
is not split (Table 34). Furthermore, the elemental analytical results for 40 are slightly 
inconclusive. The spectral bands indicative of the presence of the dppm group (750-680 
cm-1) are split in the spectra of both 39 and 40 and the shape and position of the bands is 
different for each complex suggesting that the dppm ligands may be bound to the metal 
centre in different co-ordination modes for each complex. 
The IR spectra for complexes 41-45 and 47-49 are all very similar. The carboxylate 
νasym OCO and νsym OCO bands are not split. The spectra of these complexes also 
contain bands that are indicative of the presence of the dppm ligands and again the 
shape and values for these bands suggests that they are bound to the silver centres in 
similar modes for all eight complexes. A structure that fits the physico-chemical data of 
complexes 41-45 and 47-49 is shown in Figure 67. This structural motif is known for 
silver dppe complexes where the counter ion is NO-3. 
Ph2
P
P
Ph2
Ag
Ph2
P
Ag
P
Ph2
Ph2P PPh2
Ph2P PPh2
2+
-O2C -(CH2)n - CO2-
 
 
Figure 67: Possible structure for complexes 41-45 and 47-49. 
 
Complex 46 is unusual in that it appears to have a dicarboxylate group which is only 
mono- deprotonated. The IR spectrum clearly shows the presence of the C=O band at 
1714 cm-1 (Table 34) and it formulates as [Ag (ddaH)(dppm)3].3H2O (although the % 
hydrogen is low and therefore this formulation may be erroneous like complexes 49 and 
40 it is difficult to assign a structure to complex 46.  
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Complex 39-49 (and complex 48A) were found to have very limited solubility in 
organic solvents and all attempts to obtain NMR spectra and the conductivity of 
complexes were unsuccessful.
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Table 34: Characteristic IR bands(cm-1, KBr discs) of the complexes 39-49 along with the free ligand 
 PPh3         (39)           (40)           (41)        (42)         (43)          (44)         (45)          (46)            (47)       (48)           (49) 
ν (C-H) aeromatic         3049        3052           3050        3049      3050         3050         3051        3051            3050      3052     3051,3019 
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate band
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
744 
692 
        *                *                  *          2922      2937         2940        2930         2924           2922      2923         2920 
                                                                                                                          2850           2850      2850         2850 
       *                 *                  *             *             *             *              *             1714              *             *              * 
        
     
    1537           1547          1557         1555       1559        1561        1553         1555          1552      1563         1560 
    1434          1385           1382         1390       1395        1390        1392         1387          1395      1386        1397   
     103            162             175           165         164          171         161           168            157         177          163 
 
     
    737             736             737           739         738          740         741           740             740       740          740 
    692             693             696           695          694         694        694            695            693        695          694 
* Bands precluded by others in the infrared spectrum. 
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Table 35: Characteristic IR bands (cm-1, KBr discs) of the complexes (54A) along with 
the free ligand 
 PPh3 (48A)    
ν (C-H) aeromatic  3052 
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate band 
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
744 
692 
2920 
 
1717 
 
 
1585 
1401 
184 
 
 
744 
694 
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D.6 SYNTHESIS OF SILVERDICARBOXYLATE DIPHENYLPHOSPHINE 
ETHANE COMPLEXES 
Complexes 1-11 were reacted with bis(diphenylphosphino)ethane(dppe) in a 1:2 molar ratio 
using the same procedure employed for the dppm reactions to yield the complexes 
[Ag2(prda)(dppe)4].H2O (50), [Ag2(bda)(dppe)4](51), [Ag2(pda)(dppe)3].4H2O(52), 
[Ag2(hxda)(dppe)4] (53), [Ag2(hpda)(dppe)3] (54), [Ag2(oda)(dppe)4](55), 
[Ag2(nda)(dppe)4].2H2O (56), [Ag2(dda)(dppe)4] (57), [Ag2(udda)(dppe)4].H2O (58), 
[Ag2(ddda)(dppe)4] (59), [Ag2(uddca)(dppe)4](60)  
Complexes 50-60 were obtained as off white powders and they were formulated as shown in  
Table 36. 
Table 36: Elementary Analysis of complexes 50 to 60 
Elementary Analysis 
% Calculated % Found 
 
Complex 
C H P C H P 
[Ag2(prda)(dppe)4].H2O (50) 59.41 5.41 10.39 58.24 4.48 11.32 
[Ag2(bda)(dppe)4] (51) 60.62 5.43 10.42 59.63 4.75 10.98 
[Ag2(pda)(dppe)3].4H2O (52) 53.22 5.61 8.76 52.17 4.21 9.46 
[Ag2(hxda)(dppe)4] (53) 61.20 5.63 10.18 61.78 5.10 10.53 
[Ag2(hpda)(dppe)3] (54) 57.89 5.45 9.14 56.84 4.80 10.26 
[Ag2(oda)(dppe)4] (55) 61.75 5.83 9.95 60.13 5.02 10.25 
[Ag2(nda)(dppe)4].2H2O (56) 60.29 6.07 9.57 60.43 5.17 10.71 
[Ag2(dda)(dppe)4] (57) 62.27 6.02 9.73 62.52 5.57 10.29 
[Ag2(udda)(dppe)4].H2O (58) 61.67 6.18 9.49 61.49 5.51 9.29 
[Ag2(ddda)(dppe)4] (59) 62.78 6.20 9.52 63.62 5.74 9.59 
[Ag2(uddca)(dppe)4] (60) 63.02 6.29 9.42 62.40 5.66 9.89 
    
Complexes 50-60 formulate into two categories (i) [Ag2(O2C-(CH2)n-CO2)(dppe)3] and 
(ii) [Ag2(O2C(CH2)n-CO2)(dppe)4]. Complexes 52 and 55 formulate in category (i) 
whilst the remaining nine complexes formulate in category (ii). 
The IR spectra of complexes 50-60 are shown in the Appendix 1 and the IR spectral 
bands indicative of structural features are listed in Table 37. The spectra are all very 
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similar with the carboxylate bands (νasym OCO and νsym OCO) for all complexes being 
unsplit. Furthermore, all of the IR spectra of the complexes contain bands that are 
characteristic of the presence of the dppe ligands (790-680 cm-1). It is most likely that 
complexes 50, 51, 53 and 55-60 have structures similar to their dppm counterparts 
(complexes 41-45 and 47-49) and that of the published nitrate silver dppe complex salt 
(Figure 68). 
 
P P
Ag Ag
Ph Ph
PP
PhPh
P
P
Ph
Ph
P
P
Ph
Ph
Ph Ph
Ph Ph
Ph
PhPh
Ph
2+
-O2C-(CH2)n-CO2-
 
Figure 68: Possible structure for complexes 50, 51, 53, and 55-60 
 
Complexes 50-60 were found to have very limited solubility in organic solvents and all 
attempts to obtain NMR spectra and the conductivity of the complexes were 
unsuccessful due to the insolubility of the compounds. 
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    Table 37: Characteristic IR bands(cm-1, KBr discs) of the complexes 50-60 along with the free ligand 
     * Bands precluded by others in the infrared spectrum
 PPh3         (50)           (51)           (52)        (53)        (54)          (55)         (56)           (57)           (58)        (59)           (60) 
ν (C-H) aeromatic         3052        3052           3050        3049      3049           *           3050          3052          3052      3052          3052 
ν (C-H) aliphatic 
 
ν (C=O) 
 
Carboxylate band 
ν (asym)(OCO) 
ν (sym)(OCO) 
Δ OCO 
Phosphine bands 
νC-P  
νasym 
νsym 
 
 
 
 
 
 
 
 
 
 
744 
692 
        *             2915              *          2919       2927         2935       2923          2924          2923      2920         2923 
                                                                                                                          2851          2850      2849         2850 
       *                 *                 *            *         *             *              *                  *              *             *              * 
        
     
    1556           1552          1552        1555      1548        1545        1561         1556          1550      1555           1551 
    1434          1405           1400        1403      1401       1398        1399          1404          1399      1403           1400   
     122            147             152          152        147          147         162           152            151         152            151 
 
     
     742             744             741         741        743          740         742            745             *            743            743 
    694             694             694         692         693         693         695            695            695         695            695 
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D.7 ANTIMICROBIAL ACTIVITY OF THE SILVER (I) DICARBOXYLATE 
 
The onset of antibacterial resistance to these therapeutic treatments exerted considerable 
pressure on scientists and clinicians to develop novel, targeted multi-modal antibacterial 
agents with minimal cytotoxicity to mammalian cells.  
 
The decline in the number of available antibacterial therapies for the treatment of multi-
drug resistant pathogens, has resulted in a reversion to older antimicrobial metallic 
agents, such as silver. In clinical terms, silver is the antimicrobial metal best known for 
its broad spectrum activity against intractable infectious microorganisms, including 
antibiotic resistant strains.76 The multiple modes of action of the silver ion include 
binding with cell DNA, inhibiting enzymes that mediate respiration and reacting with 
sensitive thiol groups on bacterial proteins - thereby destroying the normal biological 
activity of the protein. A key advantage of employing silver based inorganic 
antimicrobials instead of traditional silver nitrate is the potential for controlled release 
of silver ions and reduced photosensitivity. The success of these silver based 
antimicrobials depends on the appropriate ancillary ligands and the stabilization of 
specific oxidation states. In addition, they play a pivotal role in modifying reactivity and 
lipophilicity. It has been reported that the primary challenge in designing silver based 
antimicrobial drugs lies in the slow and sustained release of Ag+ ions over a period of 
time.77 However if the ligands are too tightly bound to the metal centre, this can impede 
the release of the silver ions. This can result in compromised and reduced antibacterial 
activity with the potential for silver resistant microorganisms.  
 
D.7.1 Antifungal agents in clinical use 
There are four major classes of systemic antifungal compounds currently in clinical use: 
the polyene antibiotics, the azole derivatives, the allyamines and thiocarbamates, and 
the morpholines.78 The first three are targeted against ergosterol, the major fungal sterol 
in the plasma membrane. Echinocandins (a recent discovery) are successors to 
cilofungin, which was abandoned in the 1980s. The echinocandins inhibit synthesis of 
fungal β-1,3 glucan, and this represents the first novel target in 20 years of antifungal 
drug discovery in terms of clinically useful drugs. Of these the polyene antibiotics and 
the azole derivatives are the most effective. 
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All of the novel silver complexes 1-60 generated during this project were assessed for 
anti-microbial activity against fungal (Candida albicans) and bacterial (Grampositive 
and Gramnegative) cells over a range of concentrations.  
 
D.7.2 Antifungal activity of the complexes 
The complexes were assessed for their ability to inhibit growth of an isolate of 
C.albicans over a range of concentrations in minimal media (Tables 38-41). The 
antifungal activity of these complexes was compared to that of (i) Silver Nitrate (Ag 
NO3) and Silver acetate [Ag(CH3COO)] {known sources of simple Ag+ ions}(Table 38) 
(ii) Amphotericin B (Amp B) a well known antifungal drug (Table 41)  and (iii) the 
metal free dicarboxylic acid, PPh3, dppm and dppe ligands (Table 41).  Tables 38-41 
also list the IC50 values for each of the compounds. 
 
The experiments were carried out as described in the experimental section, each sample 
was tested in tripclicate and each experiment was repeated three times. The results 
shown represent the average of these results. The percentage growth of strain of 
C.albicans ATCC 10231on AgNO3 was 79% at 0.08 µg/ml and 18% at 1µg/ml with an 
IC50 (concentration that causes 50% reduction in cell viability) of 0.1µg/ml. For silver 
acetate the sensitivity is similar with 80% at 0.08 µg/ml and 20% at 1µg/ml with IC50 0f 
0.1µg/ml. For Amphotericin B the percentage growth was 6% at 1.0 µg/ml. 
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Table 38: Anti-Candida activity and IC50 values of silver dicarboxylate complexes 1-11 
and AgNO3 & [AgCH3COO] 
% growth at concentration 
(µg/ml) 
 Compound 
1.0 0.5 0.1 0.09 0.08 IC50 (µg /ml) IC50 (µM) 
[Ag2(prda)](1) 23 54 70 81 89 0.5 1.57 
[Ag2(bda)](2) 16 28 35 50 77 0.09 0.27 
[Ag2(pda)](3) 22 35 41 59 69 0.09 0.26 
[Ag2(hxda)](4) 07 16 25 36 52 0.08 0.22 
[Ag2(hpda)](5) 11 45 55 65 89 0.1 0.26 
[Ag2(oda)](6) 09 16 34 47 50 0.08 0.20 
[Ag2(nda)](7) 12 36 51 65 78 0.1 0.24 
[Ag2(dda)](8) 05 25 35 46 80 0.09 0.21 
[Ag2(udda)](9) 06 52 58 75 89 0.5 1.16 
[Ag2(ddda)](10) 17 29 38 50 76 0.09 0.20 
[Ag2(uddca)](11) 15 34 48 68 82 0.1 0.21 
Ag NO3 18 25 45 60 79 0.1 0.58 
[Ag(CH3COO)] 20 38 52 65 80 0.1 0.59 
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Table 39: Anti-Candida activity and IC50 values of PPh3 complexes 12-38 
% growth at concentration 
(µg /ml) 
 Compound 
20 10 5 2.5 1.0 IC50 
(µg 
/ml) 
IC50 (µM) 
[Ag2(prdaH)(PPh3)2].C7H8 (12) 16 45 53 94 - 5 5.3 
[Ag2(bda)(PPh3)3].C7H8 (13) 18 45 56 92 - 5 4.1 
[Ag2(pda)(PPh3)3].2H2O  (14) 15 28 50 59 65 5 4.2 
[Ag2(hxda)(PPh3)2] (15) 19 25 38 50 75 2.5 2.8 
[Ag2(hpda)(PPh3)2].2H2O (16) 15 29 37 48 86 2.5 2.6 
{[Ag2(oda)(PPh3)3].2H2O}n(17) 13 26 40 52 68 2.5 2.1 
[Ag(ndaH)PPh3)2] (18) 18 34 46 50 75 2.5 3.1 
[Ag2(dda)(PPh3)4].2C7H8 (19) 06 26 38 45 85 2.5 1.5 
[Ag2(udda)(PPh3)2] (20) 12 34 52 68 76 5 5.2 
[Ag2(ddda)(PPh3)3](21) 09 26 37 52 65 2.5 2.0 
[Ag(uddcaH)(PPh3)2] (22) 12 24 39 50 68 2.5 2.8 
[Ag2(prda)(PPh3)3].H2O (23) 25 45 56 86 - 5 4.4 
[Ag2(bda)(PPh3)4] (24) 24 46 51 85 96 5 3.6 
[Ag2(pda)(PPh3)4] (25) 12 15 36 51 96 2.5 1.8 
[Ag(hxdaH)(PPh3)4].3H2O(26) 15 28 34 54 98 2.5 1.8 
[Ag2(hpda)(PPh3)4].C7H8 (27) 12 29 40 57 92 2.5 1.6 
[Ag(odaH)(PPh3)2].C7H8(28) 15 19 28 35 50 1.0 1.1 
[Ag(ndaH)(PPh3)2] (29) 12 19 29 50 68 2.5 3.1 
[Ag2(dda)(PPh3)4].H2O (30) 16 18 35 50 64 2.5 1.7 
[Ag2 (udda) (PPh3)3] (31) 15 28 34 56 69 2.5 2.1 
[Ag(dddaH)(PPh3)2](32) 16 28 37 50 96 2.5 2.9 
[Ag2(uddca)(PPh3)5](33) 16 26 45 50 69 2.5 1.4 
[Ag(hxdaH)(PPh3)2].C7H8 (34) 06 26 38 46 85 2.5 2.8 
[Ag2(hpda)(PPh3)5].C7H8 (35) 15 35 50 64 87 5.0 2.8 
[Ag2(oda)(PPh3)4].2C7H8 (36)  12 35 48 53 89 5.0 3.1 
Ag2(udda)(PPh3)4] (37) 16 48 59 75 96 5.0 3.4 
[Ag2(uddca)(PPh3)5].C7H8(38) 12 56 85 96 - 10.0 5.3 
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Table 40: Anti-Candida activity and IC50 values of dppm and dppe complexes 39-60 
% growth at concentration 
(µg /ml) 
 Compound 
20 10 5 2.5 1.0 IC50  
(µg 
/ml) 
IC50  
(µM) 
[Ag2(prda)(dppm)3].C7H8 (39) 16 22 35 45 56 1.0 0.9 
[Ag2(bda)(dppm)3].C7H8 (40) 04 15 29 35 46 1.0 0.9 
[Ag2(pda)(dppm)4] (41) 06 15 38 47 75 2.5 2.2 
[Ag2(hxda)(dppm)4] (42) 08 25 37 45 68 2.5 2.1 
[Ag2(hpda)(dppm)4] (43) 09 35 46 58 72 2.5 2.1 
[Ag2(oda)(dppm)4] (44) 05 15 46 86 - 5.0 4.2 
[Ag2(nda)(dppm)4] (45) 16 28 58 95 - 5.0 4.1 
[Ag(ddaH)(dppm)3].3H2O (46) 15 25 35 46 50 1.0 1.0 
[Ag2(udda)(dppm)4](47) 12 16 28 35 50 1.0 0.8 
[Ag2(ddda)(dppm)4].H2O (48) 24 56 69 73 85 10.0 7.9 
[Ag2(uddca)(dppm)4].2H2O (49) 19 45 62 89 90 10.0 7.7 
[Ag2(prda)(dppe)4].H2O (50) 12 25 30 46 59 2.5 2.1 
[Ag2(bda)(dppe)4] (51) 13 27 39 48 59 2.5 2.1 
[Ag2(pda)(dppe)3].4H2O (52) 18 38 49 75 89 5.0 4.7 
[Ag2(hxda)(dppe)4] (53) 12 35 48 65 89 5.0 4.1 
[Ag2(hpda)(dppe)3] (54) 15 29 30 52 69 2.5 2.4 
[Ag2(oda)(dppe)4] (55) 16 38 46 86 - 5.0 4.0 
[Ag2(nda)(dppe)4].2H2O (56) 17 29 56 66 85 5.0 3.9 
[Ag2(dda)(dppe)4] (57) 3 12 29 40 50 1.0 0.8 
[Ag2(udda)(dppe)4].H2O (58) 6 18 29 34 46 1.0 0.7 
[Ag2(ddda)(dppe)4] (59) 9 16 18 29 48 1.0 0.8 
[Ag2(uddca)(dppe)4] (60) 26 37 52 75 89 5.0 3.8 
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Table 41: Anti-Candida activity and IC50 values of Amp B and the free ligands 
(dicarboxylic acids, PPh3, dppm and dppe) 
% growth at concentration (µg /ml) IC50 (µM) Compound 
20 10 5 2.5 1.0          IC50 (µg /ml)  
Amphotericin B 00 00 00 00 6 1.0 0.9 
prdaH2 50 90 - - - 20.0 192 
bda H2 40 57 - - - 10.0 84 
pda H2 25 56 - - - 10.0 75 
hxda H2 38 48 - - - 10.0 68 
hpdaH2 26 50 - - - 10.0 62 
odaH2 35 52 - - - 10.0 57 
ndaH2 56 90 - - - 20.0 106 
ddaH2 38 51 - - - 10.0 49 
uddaH2 48 95 - - - 20.0 92 
dddaH2 50 94 - - - 20.0 86 
uddcaH2 46 96 - - - 20.0 82 
PPh3 39 51 - - - 10.0 38 
dppm 50 95 - - - 20.0 100 
dppe 52 96 - -  20.0 93 
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The silver dicarboxylate complexes 1-11 exhibit potent anti-Candida activity at 
extremely low concentrations (1.0 g/ml, 0.5 g/ml, 0.25 g/ml and 0.1 g/ml) which 
compare favourably with the activities of AgNO3 and [Ag(CH3COO)] (Table 38).  
Clearly the inclusion of the PPh3 groups as auxiliary ligands in the silver complexes 12-
38 has reduced their activity by between 10 and 100 times that of simple dicarboxylates 
1-11.  These triphenylphosphine (PPh3) derivatives of complexes 1-11 are all effectively 
inactive towards the Candida albicans at concentrations below 1g/ml (Table 38).  At 
10 g/ml these complexes are good to moderate antifungal agents and when the 
concentration is increased to 20 g/ml the compounds all exhibit excellent activity 
(Table 39)  
Like the PPh3 derivatives the dppm and dppe complexes 39-60 are significantly less 
active than the simple silver carboxylate complexes 1-11 with their activity reduced by 
between 10 and 100 fold (Table 40). When compared to the PPh3 complexes (12-38) the 
dppm and dppe derivatives show a similar activity profile at 20 g/ml, 10 g/ml and 5 
g/ml but when the concentration drops to 1µg/ml a number of the complexes are still 
moderately active (Table 39).   It is clear that the dppm and dppe derivatives have a 
concentration dependent activity profile and at 10 g/ml and 20 g/ml all of these 
compounds exhibit excellent activity towards the Candida albicans.   
 
D.7.3 Anti-bacterial activity of the complexes 
The antibacterial activity of complexes 1-60, the free ligands and AgNO3 against 
Grampositive and Gramnegative bacteria was determined over seven concentrations (50 
µg /ml , 25 µg /ml, 10 µg /ml, 5 µg /ml, 2.5 µg /ml, 1 µg /ml and 0.1 µg /ml). The 
bacterial strains tested were (i) a clinical isolate of MRSA, (ii) S. aureus (ATCC 25922- 
as reference), (iii) a clinical isolate of E. coli and (iv) E.coli (ATCC 25923-as 
reference).   
The experiments were carried out as described in the experimental section, each sample 
was tested in duplicate and each experiment was repeated three times. The results 
shown represent the average of these results.  The majority of the complexes and all of 
the free ligands were found to be effectively inactive towards the pathogens over the 
concentration range tested. Table 42 lists the IC50 values (µg/ml) for the 13 active 
complexes and the activities for AgNO3.  
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AgNO3 is a very potent antibacterial agent with a similar activity profile against the four 
test microbes.  Of the simple silver dicarboxylates 1-11 only complexes 1, 4, 5, 6 and 7 
exhibit significant activity.  Of the PPh3, dppm and dppe derivatives 12-60 only 
complexes 14, 31, 33, 37, 38, 39, 41 and 52 were found to be active.   
 
Complexes 31, 37 and 38 exhibit exceptional activity against the test microbes and have 
activity comparable to that of the silver nitrate.  
 
Table 42: Anti-bacterial activity as IC50 values of AgNO3 and the complexes that 
exhibited activity 
Compound Code 
S. aureus 
ref. 
ATCC25923 
S.aureus 
clinical 
(MRSA) 
E. coli ref. 
ATCC25922 
E. coli 
clinical 
AgNO3 <0.1 <0.1 <0.1 <0.1 
[Ag2(prda)] (1) 15 13 38 18 
[Ag2(hxda)] (4) 50 50 50 30 
[Ag2(hpda)] (5) 8 30 8 4 
[Ag2(oda)] (6) 6 8 6 8 
[Ag2(nda)] (7) 8 10 12 10 
[Ag2(pda)(PPh3)3].2H2O (14) 30 12 inactive 15 
[Ag2(udda)(PPh3)] (31) <0.1 <0.1 <0.1 <0.1 
[Ag2(uddca)(PPh3)2] (33) 8 50 50 50 
[Ag2(udda)(PPh3)4] (37) <0.1 <0.1 <0.1 <0.1 
[Ag2(uddca)(PPh3)] (38) <0.1 <0.1 <0.1 <0.1 
[Ag2(prda)(dppm)3].C7H8 (39) * 5 10 * 
[Ag2(pda)(dppm)4] (41) * 12  inactive inactive 
[Ag2(pda)(dppe)3].4H2O (52) * 18 28 * 
 
 
The antimicrobial experiments carried out as part of this study have shown that all of 
the metal free dicarboxylic acids and phosphine based ligands are relatively poor 
antifungals and display no antibacterial activity.  The simple dicarboxylate complexes 
1-11 are potent in-vitro anti-Candida agents which display activity superior/comparable 
to the clinically used AgNO3 and the state-of -the -art organic drug Amphothericin B.  
Indeed the majority of complexes 1-11 are twice as active as AgNO3, which may arise 
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from the fact that they contain two silver ions per molecule.  Therefore the assumption 
could be that they elute twice as many silver ions into the media than the simple silver 
nitrate salt.   It has been reported that a higher dose of AgNO3 was required to kill Gram 
positive (S. aureus) than Gramnegative (E. coli) cells. The authors claimed that this 
reflected the fact that the cell wall of the latter species was considerably thinner.  In 
contrast, under the experimental conditions in which the present study was conducted 
the AgNO3 is a potent antibacterial agent and did not discriminate in its activity against 
the Gram positive and Gram negative species. The antibacterial activity of the 
complexes 1-11 showed a surprising deviation from that of the simple silver salt.  
Indeed only five of the silver dicarboxylates (complexes 1, 4, 5, 6 and 7) displayed good 
antibacterial activity, although it was significantly less than that of AgNO3. 
Furthermore, unlike the AgNO3 the activity of these five complexes displayed some 
discrimination in activity towards the Grampositive (S. aureus /MRSA) and Gram 
negative (E.coli) bacteria.  Therefore, it is suggested that the silver dicarboxylate 
complexes 1-11 do not act on microbial cells in the same way as AgNO3 and that the 
ligand must play some role in their mode of antimicrobial action contributing to their 
selectivity between antibacterial and antifungal activity. 
 
 Addition of the PPh3 ligands to silver dicarboxylates 1-11 yielded the photo-stable 
complexes 12-38.  All 27 of these complexes exhibited significant antifungal activity 
against the Candida albicans cells although their activity is, on average, over ten times 
less than that of the equivalent silver dicarboxylate. This may reflect the relative 
stability of the PPh3 derivatives which would not be expected to leach the silver ions 
easily.  Of the 27 PPh3 derivatives only complexes 14, 31, 33, 37 and 38 are active 
against the bacterial cells tested.  Complex 14 is interesting as it displays no activity 
against the reference E.coli (ATCC 25922) cell line but is significantly effective at 
killing the clinical isolate.  Complexes 31, 37 and 38 are the only complexes that 
display higher antibacterial activity than antifungal activity, a trend not previously 
observed for any silver based antimicrobials studied in this and collaborating 
laboratories. Indeed these complexes display antibacterial activity comparable to that of 
AgNO3 but are very photostable, and over 20, 30 and 50 times (respectively) more 
active against the Grampositive and Gramnegative bacterial cells than the fungal cells.   
The fact that complexes 31, 37 and 38 did not manifest similar antifungal activity when 
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incubated with C. albicans suggests that their mode of action is not due simply to 
release of silver ions. The unique structure, which incorporates fatty dicarboxylic acid 
ligands {-OOC-(CH2)n-COO- where n = 9 (complexes 31 and 37) and 11 (complex 38)} 
and the stablising phosphines, of these synthesised complexes may explain these 
observations. Due to cell wall differences, traditional prophylactic treatments differ for 
both bacterial and fungal infections. We propose, from this study, that the ligated 
structures passively diffused through the peptidoglycan cell wall of Grampositive 
bacterial and the lipopolysaccaride cell wall of Gramnegative bacteria.  At this stage, it 
is difficult to elucidate definitely whether the complexes reached the targeted 
compartments of either the perisplasmic space or the cytoplasm. Furthermore, bacterial 
functional groups may exchange with ligands from the metallo-complexes, promoting 
silver ion discharge. Complexes 31, 37 and 38 represent potential therapeutics that 
warrent further investigation as novel antimicrobial agents. Further studies such as 
Graphite Furnace AAS (silver release determination), Raman (silver bonding) and 
Transmission Electron Spectroscopy (TEM, imaging of metal deposition) will help to 
clarify further the observed novel broad-spectrum properties of these three structures.   
 
Addition of the dppm and dppe ligands to the silver dicarboxylates 1-11 yielded the 
photo-stable complexes 39-60 which all exhibited significant antifungal activity against 
the Candida albicans cells.  However, with the exception of complex 39, most of their 
activities are again significantly less than that of the equivalent silver dicarboxylate. 
Again this may reflect the relative stability of the dppm and dppe derivatives which 
would not be expected to leach the silver ions easily.  Of the 22 diphosphine derivatives 
only complexes 39, 41 and 52 display any activity against the bacterial cells tested.  
Complex 41 is interesting as it exhibits good activity against the Grampositive MRSA 
but it is inactive against the Gramnegative E.coli.  Complexes 39 and 52 display some 
discrimination in activity towards the Grampositive (MRSA) and Gramnegative (E.coli) 
bacteria.  Again as all of the dppm and dppe derivatives 36-60 were found to be active 
against the fungal cells and only three of them displayed activity against MRSA and 
E.coli it is suggested that they do not act on microbial cells in the same way as AgNO3 
and that the ligands must play some role in their mode of antimicrobial action 
contributing to their selectivity between antibacterial and antifungal activity. 
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E.1 INSTRUMENTATION 
 
Infrared (IR) spectra were recorded in the region 400- 4000cm-1 on a Nicolet FT-IR 400 
Impact spectrometer. All solids to be tested were prepared in a KBr matrix. 
 
C. Albicans cells were measured using a 20 Genesys Spectrophotometer. All solutions 
were prepared using 5 mls of Phosphate Buffer Saline (PBS). 
 
Antimicrobial susceptibility testing was carried out using BIOTEC EL808 machine used 
for 96 well microtitreplate analysis.   
 
Elemental analysis was carried out by the Microanalytical Laboratory, University 
College Dublin, Ireland.  
 
X-ray crystal structures were carried out by Professor Vickie McKee, Loughborough 
University 
 
E.2 CHEMICALS 
All chemicals were purchased from commercial sources and were used without further 
purification. 
All reported solubility tests were carried out in hot solvent. 
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E.3  SYNTHESIS OF SILVER (I) DICARBOXYLATE COMPLEXES 
 
E.3.1 [Ag2(prda)]  (prdaH2= Propanedioic acid) (1) 
The following procedure was conducted with the exclusion of all light sources. To a 
suspension of prdH2 (0.261 g, 2.5 mmol) in 30 mls of Toluene, 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] was added and refluxed for two and half hours. At regular intervals of 
30 mins the reflux condenser was removed for a minimum of five minutes to allow any 
acetic acid formed in the reaction to evaporate off. After two and half hours the heat 
was switched off and the mixture was left to stir for a further half an hour to cool down. 
The mixture was then filtered and the resulting precipitate was washed using small 
portions of toluene and 5-10 mls of diethyl ether and then air dried.  
Yield:  0 .626 g (57.16%) 
% Calc:  C 11.34, H 0.63, Ag 67.89 
% Found: C 11.32, H 0.64, Ag 65.01 
Melting point: 132-136 ºC 
IR (KBr): 3500, 2360, 1570, 1436, 1403, 1356, 1268, 1190, 668, 589 cm-1. 
Solubility: Not soluble in water, methanol, chloroform, acetone and DMSO. 
 
E.3.2 [Ag2(bda)] (bdaH2= Butanedioic acid) (2) 
0.301g (2.55 mmol) of bdaH2 in 30 mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)]. 
Yield:  0.7336 g (64.63%). 
% Calc: C 14.48, H 1.22, Ag 65.02 
% Found: C 14.22, H 1.68, Ag 64.88 
Melting point: 122-126 ºC 
IR (KBr): 3428, 2349, 1655, 1566, 1410, 1296, 1019, 925, 652, 420cm-1. 
Solubility: Partially soluble in water, not soluble in methanol, chloroform, 
acetone and DMSO.  
 
E.3.3 [Ag2(pda)] (PdaH2= Pentanedioic acid) (3) 
0.336 g (2.55 mmol) of pdaH2 in 30mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)]. 
             Yield : 0.5063 g (43.27%). 
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% Calc: C 17.36, H 1.75, Ag 62.38 
% Found: C 17.22, H 1.6, Ag 63.06 
Melting point: 128-133 ºC 
IR (KBr): 3405, 2959, 2362, 1589, 1400, 1314, 1065, 912, 738, 601cm-1. 
Solubility: Partially soluble in water, not soluble in methanol, chloroform, 
acetone and DMSO.  
 
E.3.4 [Ag2(hxda)] (hxdaH2= Hexanedioic acid) (4) 
0.372 g (2.55 mmol) of hxdaH2 in 30 mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)]. 
Yield:  0.8710 g (72.22%). 
% Calc: C 20.03, H 2.24, Ag 59.95 
% Found: C 20.59, H 2.16, Ag 58.67 
Melting point: 128-132 ºC 
IR (KBr): 3419, 2925, 1650, 1564, 1409, 1199, 1019, 925, 737, 652cm-1. 
Solubility: Partially soluble in water, not soluble in methanol, chloroform, 
acetone and DMSO.  
 
E.3.5 [Ag2(hpda)] (hpdaH2=Heptanedioic acid) (5) 
0.408 g (2.55 mmol) of hpdaH2 in 30 mls of Toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield:  0.5768 g (46.44%) 
% Calc: C 22.49, H 2.7, Ag 57.70 
% Found: C 22.43, H 2.26, Ag 57.89 
Melting point: 131-135 ºC 
IR (KBr): 3419, 2933, 2349, 1651, 1564, 1407, 654cm-1. 
Solubility: Partially soluble in water, not soluble in methanol, chloroform, 
acetone and DMSO.  
 
E.3.6 [Ag2(oda)] (odaH2= Octanedioic acid) (6) 
0.444 g (2.55 mmol) of odaH2 in 30 mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield: 0.6624 g (51.83%). 
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% Calc: C 24.77, H 3.12, Ag 55.61 
% Found: C 24.27, H 3.17, Ag 55.31 
Melting point: 128-132 ºC 
IR (KBr): 2930, 1653, 1566, 1409, 1285, 1192, 1018, 922, 791, 718, 651cm-1. 
Solubility: Partially soluble in water, not soluble in methanol, chloroform, 
acetone and DMSO.  
E.3.7 [Ag2(nda)](ndaH2= Nonanedioic acid) (7) 
0.470 g (2.5 mmol) of ndaH2 in 30mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield:   0.774 g (59.35%). 
% Calc: C 26.89, H 3.51, Ag 53.67 
% Found: C 26.39, H 3.01, Ag 53.41 
Melting point: 130-135 ºC 
IR (KBr): 3396, 2933, 1689, 1567, 1463, 1408, 1287, 1200, 1017, 916, 736cm-1. 
Solubility: Partially soluble in water, not soluble in, methanol, chloroform, 
acetone and DMSO.  
 
E.3.8 [Ag2(dda)] (ddaH2= Decanedioic acid) (8) 
0.515 g (2.55 mmol) of ddaH2 in 30mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield:    0.857 g (63.52%). 
% Calc: C 28.87, H 3.88, Ag 51.86 
% Found: C 28.11, H 3.5, Ag 52.01 
Melting point: 127-132 ºC 
IR (KBr): 3417, 2929, 1679, 1567, 1471, 1408, 1257, 1188, 1018, 924, 753cm-1. 
Solubility: Not soluble in water, methanol, chloroform, acetone and DMSO.  
 
E.3.9 [Ag2(udda)] (uddaH2= Undecanedioic acid) (9) 
0.541g (2.5 mmol) of uddaH2 in 30mls of toluene reacted with 0.834 g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield: 0.9469 g ( 68.86%) 
% Calc: C 28.87, H 3.66, Ag 50.17 
% Found: C 28.34, H 3.84, Ag 50.77 
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Melting point: 133-138 ºC 
IR (KBr): 3407.49, 2929.42, 2913.25, 2846.61, 1584.90, 1466.37, 1409.26, 
1315.53, 1251.31, 721.30 cm-1. 
Solubility: Partially soluble in DMSO, insoluble in methanol, ethanol, 
chloroform, acetone and water.  
 
E.3.10 [Ag2(ddda)] (dddaH2= Dodecanedioic acid) (10) 
0.587 g (2.55 mmol) of dddaH2 in 30 mls of toluene reacted with 0.834g (0.5 mmol) of 
[Ag(CH3COO)] 
Yield: 0.5163 g (36.33%). 
% Calc: C 32.46, H 4.54, Ag 48.59 
% Found: C 32.22, H 4.94, Ag 48.83 
Melting point: 134-138 ºC 
IR (KBr): 3417, 2910, 1688, 1567, 1470, 1408, 1230, 1186, 1018, 923, 651cm-1. 
Solubility: Not soluble in water, methanol, chloroform, acetone and DMSO.  
 
E.3.11 [Ag2(uddca)] (uddcaH2= Undecanedicarboxylic acid) (11) 
0.623 g (2.55 mmol) of uddcaH2 in 30 mls of toluene reacted with 0.8345 g (0.5 mmol) 
of [Ag(CH3COO)] 
Yield:  0.787 g (54.01%) 
% Calc: C 34.09, H 4.84, Ag 47.10 
% Found: C 34.44, H 4.77, Ag 47.67 
Melting point: 131-136 ºC 
IR (KBr): 3417, 2917, 1693, 1562, 1467, 1409, 1272, 1229, 1110, 1019,   
921cm-1.   
Solubility: Not soluble in water, methanol, chloroform, acetone and DMSO. 
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E.4 SYNTHESIS OF SILVER (I) DICARBOXYLATE COMPLEXES WITH 
TRIPHENYLPHOSPHINE (PPh3)  
E.4.1 [Ag(prdaH)(PPh3)2] (12)  
The following procedure was conducted with the exclusion of all light sources. To a 
conical flask containing a suspension of PPh3 (0.669 g, 2.5 mmol) in 30ml of toluene, 
0.319 g (1.0 mmol) of [Ag2(prda)] was added. The flask was then refluxed for two and 
half hours and left to stand for a further half an hour at room temp, allowing the mixture 
to cool. The solution was then filtered off and the resulting precipitate was washed 
using small portions of toluene and 5-10 ml of diethyl ether and then air dried. The flask 
containing the filtrate, were covered with foil and crystals were deposited over several 
weeks.  
Yield: 0.7001 g (70.81%) 
% Calc:    C 63.69, H 4.52, P 8.42, Ag 14.67 
% found:  C 64.49, H 4.61, P 7.22, Ag 14.00 
Melting point: 126-131 ºC 
IR (KBR): 3053.46, 2923.84, 1730.96, 1598.67, 1548.18, 1478.65, 1434.16, 
1402.56, 1370.28, 1181.33, 1158.16, 1095.67, 1070.46, 1026.96, 997.43, 
891.95, 753.18, 694.60, 514.71, 494.09, 466.66, 441.58cm−1. 
Solubility: Partially soluble in methanol, ethanol, DMSO, acetone, chloroform, 
insoluble in water.  
This procedure was used to generate all of the PPh3 derivative of complexes 1-11 (using 
2.5, 4 and 6 equivalents of phosphine ligands) 
 
E.4.2 [Ag2(bda)(PPh3)3].C7H8 (13) 
0.334 g (1.0 mmol) of [Ag2(bda)] in 30mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3.  
Yield:  0.7946 g (79.24%) 
% Calc:    C 64.48, H 4.74, P 7.67, Ag 17.82 
% found:  C 64.98 , H 4.98, P 7.89, Ag 18.53 
 Melting point: 132-137 ºC 
IR (KBR): 3053.28, 2962.96, 2921.08, 1644.58, 1549.09, 1478.64, 1434.22, 
1393.12, 1306.32, 1275.43, 1182.74, 1156.90, 1095.27, 1068.93, 1027.80, 
133 
 
995.96, 888.28, 798.64, 768.78, 745.25, 705.52, 693.43, 618.01, 501.49, 
432.40cm−1. 
Solubility: Partially soluble in chloroform insoluble in water, methanol, ethanol, 
acetone, DMSO.  
 
E.4.3 [Ag2(pda)(PPh3)3].2H2O  (14) 
0.348 g (1.0 mmol) of [Ag2(pda)] in 30mls of toluene reacted with 0.669g (2.5 mmol) of 
PPh3. 
       Yield:     0.4820 g (47.40%) 
    % Calc:     C 60.63, H 4.74, P 7.95, Ag 18.46 
    % found:    C 60.51, H 4.43, P 7.86, Ag 18.87 
Melting point: 129-134 ºC 
IR (KBR): 3052.53, 2962.66, 2920.86, 1961.23, 1887.41, 1816.34, 1770.72, 
1633.75, 1571.00, 1548.82, 1478.78, 1434.22, 1392.67, 1345.85, 1306.33, 
1275.60, 1182.99, 1156.95, 1095.36, 1069.26, 1027.86, 996.14, 942.38, 917.18, 
888.71, 848.54, 798.90, 768.99, 745.26, 705.47, 693.62, 618.17, 501.76, 432.29 
cm−1. 
Solubility: insoluble in water, acetone soluble in methanol, ethanol, chloroform, 
DMSO.  
 
E.4.4 [Ag2(hxda)(PPh3)2] (15) 
0.362 g (1.0mmol) of Ag2(hxda) in 30mls of toluene reacted with 0.669 g (2.5 mmol) of 
PPh3   
   Yield:   0.4178 g (40.53%) 
   % Calc:   C 57.04, H 4.33, P 7.00, Ag 24.34 
   % found:  C 57.04, H 4.30, P 6.43, Ag 22.89 
Melting point: 133-138 ºC 
IR (KBR): 3049.25, 2934.11, 2892.38, 1620.02, 1552.16, 1478.59, 1459.58, 
1435.04, 1414.08, 1365.95, 1309.41, 1193.33, 1095.25, 1071.67, 1025.28, 
997.49, 912.48, 758.21, 746.58, 693.08, 520.36, 505.50, 496.15, 444.96 cm−1 
Solubility: Partially soluble in methanol, ethanol, DMSO, acetone, chloroform, 
water. 
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E.4.5 [Ag2(hpda)(PPh3)2].2H2O (16) 
0.376 g (1.0 mmol) of [Ag2(hpda)] in 30 mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3. 
Yield:   0.3099 g (29.68%) 
   % Calc:   C 61.12, H 5.13, P 7.75, Ag 23.09 
% found:  C 61.60, H 4.87, P 7.27, Ag 23.00 
Melting point: 130-135 ºC 
IR (KBR): 3052.54, 2941.03, 2856.28, 2360.29, 1965.48, 1893.97, 1822.77, 
1646.76, 1548.69, 1496.47, 1478.45, 1463.42, 1400.42, 1330.85, 1309.22, 
1264.68, 1217.31, 1182.73, 1157.75, 1094.35, 1069.35, 1026.56, 996.26, 
973.24, 917.26, 851.32, 748.28, 694.52, 655.38, 617.80, 514.46, 503.93, 466.61, 
439.04 cm−1. 
            Solubility: insoluble in water, ethanol, acetone, DMSO, partially soluble in 
chloroform, methanol. 
 
E.4.6 {[Ag2 (oda)(PPh3)3].2H2O} (17) 
0.390 g (1.0 mmol) of [Ag2(oda)] in 30mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3. 
   Yield:    0.649 g (61.35%) 
   % Calc:   C 61.40, H 5.24, P 7.66, Ag 17.82 
   % found:  C 61.02, H 5.07, P 7.44, Ag 17.34 
Melting point: 131-136 ºC 
IR (KBR): 3053.39, 2930.54, 2851.22, 2349.98, 2284.60, 1593.34, 1570.17,      
1479.36, 1434.64, 1407.48, 1361.56, 1337.93, 1309.06, 1285.20, 1256.11, 
1180.50, 1155.62, 1095.73, 1026.54, 996.84, 746.56, 693.60, 665.85, 618.58, 
515.18, 499.60 cm−1. 
Solubility: insoluble in water, ethanol, partially soluble in methanol, acetone, 
chloroform and DMSO.  
 
E.4.7 [Ag(ndaH)(PPh3)2] (18) 
0.404 g (1.0 mmol) of [Ag2(nda)] in 30mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3 
Yield:  0.578 g (53.91% ) 
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% Calc:   C 65.94, H 5.53, P 7.56, Ag 13.16 
% found: C 65.67, H 5.01, P 7.88, Ag 12.96 
Melting point: 127-132 ºC 
IR (KBR): 2929.70, 2852.90, 2359.54, 1689.02, 1574.72, 1471.55, 
1430.12,1405.66, 1344.10, 1273.17, 1232.96, 1193.77, 1098.25, 923.18, 904.06, 
775.05, 719.11, 696.09, 539.67 cm−1 . 
Solubility: insoluble in water, partially soluble in methanol, ethanol, acetone, 
chloroform and DMSO.  
 
E.4.8 [Ag2(dda)(PPh3)4].2C7H8 (19) 
0.418 g (1.0 mmol) of [Ag2(dda)] in 30 mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3. 
Yield:   0.7142 g (65.71%) 
 % Calc:   C 69.82 , H 5.74, P7.50, Ag 12.86 
% found:  C 69.23,  H 5.21, P 7.58, Ag 12.73 
Melting point: 133-138 ºC 
IR (KBR): 3051.98, 2923.75, 2849.14, 2359.49, 1893.40, 1714.21, 1597.09, 
1569.64, 1479.67, 1466.11, 1434.47, 1407.79, 1357.90, 1307.97, 1267.09, 
1236.04, 1186.45, 1156.84, 1096.38, 1070.92, 1027.06, 997.26, 916.34, 849.91, 
753.70, 744.53, 694.60, 513.41, 502.11, 437.27 cm−1. 
Solubility: partially soluble in water methanol, ethanol, acetone, chloroform and 
DMSO.  
 
E.4.9 [Ag2(udda)(PPh3)2] (20)  
0.432 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3. 
Yield: 0.6402 g (58.15%) 
% Calc:     C 58.01, H 5.32 ,  P 6.63, Ag 22.60 
% Found:  C 59.46, H 5.00,   P 6.63, Ag 22.38 
Melting point: 126-131 ºC 
IR (KBr): 3439.02, 3051.26, 2924.10, 2850.86, 1603.12, 1560.08, 1480.48, 
1434.26, 1406.48, 1434.26, 1406.40, 1364.38, 1258.71, 1096.14, 744.65, 
694.38, 520.06, 502.42 cm-1. 
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Solubility: Partially soluble in chloroform and DMSO, insoluble in methanol, 
acetone, water, ethanol.  
 
E.4.10 [Ag2(ddda)(PPh3)3] (21) 
0.446 g (1.0 mmol) of [Ag2(ddda)] in 30mls of toluene reacted with 0.669 g (2.5 mmol) 
of PPh3. 
Yield:   0.4967 g (45.70%) 
  % Calc:   C 64.40, H 5.33, P 7.55, Ag 17.53 
  % found:   C 64.55, H 5.53, P 7.43, Ag 17.23 
Melting point: 128-133 ºC 
IR (KBR): 3053.06, 2955.07, 2927.15, 2677.98, 2359.55, 2341.68, 1965.49, 
1893.38, 1822.16, 1770.71, 1668.20, 1569.99, 1543.87, 1478.82, 1434.38, 
1387.95, 1328.69, 1309.81, 1268.46, 1182.19, 1157.05, 1096.02, 1070.55, 
1027.25, 996.89, 971.96, 914.78, 876.29, 850.42, 807.43, 744.97, 694.70, 
660.08, 617.89, 513.15, 493.70, 439.68 cm−1. 
Solubility: insoluble in water, partially soluble in methanol, ethanol, acetone, 
chloroform, DMSO. 
 
E.4.11 [Ag(uddcaH)(PPh3)2] (22) 
0.460 g (1.0 mmol) of [Ag2(uddca)] in 30mls of toluene reacted with 0.669 g (2.5 
mmol) of PPh3. 
Yield:   0.487 g (43.13%) 
 % Calc:   C 67.20, H 6.10, P 7.07, Ag 12.32 
  % found:   C 66.83, H 6.02, P 7.31, Ag 12.45 
Melting point: 134-138 ºC 
IR (KBR): 3053,921, 2849, 1703, 1561, 1478, 1402, 1258, 1095, 996, 618, 523, 
444 cm−1. 
Solubility: insoluble in water, partially soluble in methanol, ethanol, acetone, 
chloroform, DMSO. 
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E.5 SYNTHESIS OF SILVER (I) DICARBOXYLATE COMPLEXES WITH 
TRIPHENYLPHOSPHINE (PPh3) 
 
E.5.1 [Ag2(prda)(PPh3)3].H2O (23) 
0.319 g (1.0 mmol) of [Ag2(prda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield: 0.681 g (49.85%) 
% Calc: C 60.98, H 4.4, P 8.28, Ag 19.22 
% Found: C 60.95, H 4.29, P 8.18, Ag 19.22 
Melting point: 132-137 ºC 
IR (KBr): 3427, 1602, 1546, 1477, 1432, 1317, 1093, 1030, 983, 742, 694, 579, 
514, 493 cm-1 
Solubility: Partially soluble in water, chloroform, methanol and DMSO. Not 
soluble in acetone.  
 
E.5.2 [Ag2(bda)(PPh3)4] (24) 
0.334 g (1.0 mmol) of [Ag2(bda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
            Yield: 0.9561 g (69.13%) 
% Calc: C 66.1, H, 4.67, P 8.97, Ag 15.62 
% Found: C 66.05, H, 4.76, P 8.44, Ag 15.53 
Melting point: 131-136 ºC 
IR (KBr): 3441, 3052, 1542, 1477, 1433, 1386, 1179, 1093, 1026, 995, 913, 743, 
693, 659, 507, 491, 441cm-1. 
Solubility: Partially soluble in chloroform, methanol, acetone and DMSO, not 
soluble in water.  
 
E.5.3 [Ag2(pda)(PPh3)4] (25) 
0.348 g (1.0 mmol) of [Ag2(pda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield: 0.6251 g (44.74%) 
% Calc: C 66.3, H 4.77, P 8.88, Ag 15.47 
% Found: C 66.96, H 4.75, P 8.88, Ag 15.83 
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Melting point: 130-135 ºC 
IR (KBr): 3050, 1548, 1477, 1433, 1391, 1305, 1094, 1023, 990, 798, 743, 692, 
499 cm-1.  
Solubility: Partially soluble in water, chloroform and methanol, not soluble in 
acetone and DMSO.  
 
E.5.4 [Ag(hxdaH)(PPh3)3].3H2O (26) 
0.362 g (1.0 mmol) of [Ag2(hxda)] in 30mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield: 0.6425 g (45.53%) 
% Calc: C 65.88, H 5.53, P 8.49, Ag 9.86 
% Found: C 65.22, H, 4.98, P 8.39, Ag 9.12 
Melting point: 126-131 ºC 
IR (KBr): 3053, 3931, 1708, 1572, 1551, 1478, 1434, 1395, 1310, 1246, 1095, 
1026, 996, 745, 693, 612, 512, 501, 426 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
 
E.5.5 [Ag2(hpda)(PPh3)4].C7H8 (27) 
0.376 g (1.0 mmol) of [Ag2(hpda)] in 30mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield:  0.7753 g (54.40%) 
% Calc: C 68.17, H 5.19, P 8.18, Ag 14.24 
% Found: C 68.72, H 5.20, P 8.14, Ag 14.77 
Melting point: 127-132 ºC 
IR (KBr): 3433, 3048, 1546, 1477, 1433, 1393, 1308, 1093, 1025, 994, 883, 837, 
747, 692, 503 cm-1. 
Solubility: Partially soluble in water, chloroform, methanol, acetone and DMSO.  
 
E.5.6 [Ag(odaH)(PPh3)2].C7H8 (28) 
0.390 g (1.0 mmol) of [Ag2(oda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
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Yield: 0.8449 g (58.71%) 
% Calc: C 68.23, H 5.73, P 6.90, Ag 12.02 
% Found: C 69.96, H 5.43, P 7.86, Ag 12.34 
Melting point: 128-132 ºC 
IR (KBr): 2920, 2851, 1704, 1583, 1546, 1494, 1478, 1433, 1399, 1254, 1180, 
1156, 1094, 1025, 995, 746, 694, 515, 493, 417 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
Note: Crystals of 28 deposited when the mother liquor was allowed to stand for 
several weeks. 
 
E.5.7 [Ag(ndaH)(PPh3)2]. (29) 
0.404 g (1.0 mmol) of [Ag2(nda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield: 0.7992 g (55.00%) 
% Calc: C 65.94, H 5.53, P 7.56, Ag 13.16 
% Found: C 65.59, H 4.92, P 8.71, Ag 13.87 
Melting point: 129-134 ºC 
IR (KBr): 3053, 2931, 2360, 2341, 1700, 1572, 1550, 1478, 1434, 1389, 1312, 
1095, 1026, 996, 911, 744, 705, 693, 668, 503, 427cm-1. 
Solubility: Partially soluble in chloroform, methanol, acetone and DMSO, not 
soluble in water.  
 
E.5.8 [Ag2(dda)(PPh3)4].H2O (30) 
0.418 g (1.0 mmol) of [Ag2(dda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
Yield: 0.7499 g (51.11%) 
% Calc: C 66.41, H 5.3, P 8.35, Ag 14.28 
% Found: C 66.05, H 5.66, P 8.47, Ag 14.89 
Melting point: 130-135 ºC 
IR (KBr): 3442, 3051, 2921, 2849, 2360, 1635, 1478, 1433, 1282, 1180, 1095, 
1027, 995, 752, 693, 512, 499 cm-1. 
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Solubility: Partially soluble in water, chloroform, methanol and acetone, not 
soluble in DMSO.  
 
E.5.9 [Ag2(udda)(PPh3)3] (31)  
0.432 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3 
Yield: 0.5171g (34.91%) 
% Calc:    C 64.16, H 5.22, P 7.64, Ag 17.73 
% Found: C 64.52, H 5.03, P 7.69, Ag 17.86 
Melting point: 131-136 ºC 
IR (KBr): 3441.02, 3050.80, 2922.24, 2852.36, 1556.15, 1479.38, 1433.11, 
1394.80, 1304.04, 1183.92, 1157.17, 1094.59, 1068, 1027.29, 997.18, 743.29, 
693.62, 617.78, 512.73, 503.19, 438.61cm-1. 
Solubility: Insoluble in methanol, chloroform, ethanol, acetone, DMSO and 
water.  
Note: Crystals of [Ag2 (udda)(PPh3)4](31A) deposited from the mother liquor after it 
was left standing for several weeks. 
 
E.5.10 [Ag2(dddaH)(PPh3)3] (32) 
0.446 g (1.0 mmol) of [Ag2(ddda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. 
[Ag(dddaH)(PPh3)3] 32 deposited, in very low yield, as crystals. The formulation is 
based on the X-ray crystallographic analysis. 
  
E.5.11 [Ag2(uddcaH)(PPh3)2] (33) 
0.460 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 1.049 g (4.0 mmol) 
of PPh3. [Ag(uddcaH)(PPh3)2] 33 deposited in very low yield as crystals. The 
formulation is based on the x-ray crystallographic analysis. 
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E.6 SYNTHESIS OF SILVER (I) DICARBOXYLATE COMPLEXES WITH 
TRIPHENYLPHOSPHINE (PPh3) 
 
E.6.1 [Ag2(prda))(PPh3)3].H2O (23) 
0.319 g (1.0 mmol) of [Ag2(prda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
Yield: 0.8479 g (44.79%) 
% Calc: C 60.98, H 4.40, P 8.28, Ag 19.22 
% Found: C 62.97, H 4.47, P 8.41, Ag 19.76 
Melting point: 132-137 ºC 
IR (KBr): 3051, 1545, 1477, 1432, 1317, 1182, 1093, 1023, 990, 742, 694, 579, 
514, 493 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
E.6.2 [Ag2(bda)(PPh3)4](24) 
0.334 g (1.0 mmol) of [Ag2(bda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
Yield: 1.0701 g (56.08%) 
% Calc: C 66.1, H 4.67, P 8.97, Ag 15.62 
% Found: C 66.59, H 4.77, P 9.07, 15.01 
Melting point: 133-138 ºC 
IR (KBr): 3052, 1543, 1477, 1433, 1387, 1308, 1093, 1025, 995, 910, 744, 659, 
503 cm-1. 
Solubility: Partially soluble in chloroform, methanol, acetone and DMSO, not 
soluble in water.  
 
E.6.3 [Ag2(pda)(PPh3)4] (25)  
0.348 g (1.0 mmol) of [Ag2(pda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
Yield: 0.9519 g (49.52%) 
% Calc:    C 66.30, H 4.77,  P 8.88, Ag 15.47 
% Found: C 65.74, H 4.75, P 8.71, Ag 15.33 
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Melting point: 134-138 ºC 
IR (KBr): 3050, 1548, 1477, 1433, 1391, 1305, 1181, 1094, 1027, 994, 888, 743, 
705, 692, 500, 431cm-1. 
Solubility: Partially soluble in chloroform, methanol, ethanol, DMSO, insoluble 
in acetone and water.  
 
E.6.4 [Ag2(hxdaH)(PPh3)2].C7H8 (34) 
0.362 g (1.0 mmol) of [Ag2(hxda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
Yield: 1.311 g (67.71%) 
% Calc:    C 64.87, H 5.06,  P 7.97, Ag 22.07 
% Found: C 64.78, H 5.13, P7.80, Ag 22.76 
Melting point: 126-131 ºC 
IR (KBr): 2922, 1723, 1547, 1478, 1434, 1397, 1309, 1242, 1095, 1026, 995, 
745, 694, 440 cm-1. 
Solubility: Partially soluble in chloroform, methanol, ethanol, DMSO, insoluble 
in acetone and water. 
 
E.6.5 [Ag2(hpda)(PPh3)5].C7H8 (35) 
0.376 g (1.0 mmol) of [Ag2(hpda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
            Yield: 1.401g (71.84%) 
% Calc: C 70.28, H 5.27, P 8.71, Ag 12.14 
% Found: C 70.64, H 5.17, P 9.67, Ag 12.86 
Melting point: 127-132 ºC 
IR (KBr): 3045, 1585, 1555, 1478, 1433, 1381, 1080, 1023, 994, 742, 692, 510, 
434 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water,  
acetone and DMSO.  
 
E.6.6 [Ag2(oda)(PPh3)4].2C7H8 (36) 
0.390 g (1.0 mmol) of [Ag2(oda)]  in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3 
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 Yield: 1.3786 g (70.19%) 
% Calc:     C 69.63, H 5.47, P 7.64, Ag 13.31 
% Found: C 69.02, H 5.44, P 7.86, Ag 13.66 
Melting point: 128-133 ºC 
IR (KBr): 3054, 2921, 2851, 1546, 1478, 1434, 1399, 1308, 1095, 1026, 996, 
746, 694, 515, 504, 493,466, 418cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
E.6.7 [Ag(ndaH)(PPh3)2] (29) 
0.404 g (1.0 mmol) of [Ag2(nda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3 
 Yield: 1.206 g (60.97%) 
% Calc:     C 65.94, H 5.53, P 7.56, Ag 13.16 
% Found: C 65.59, H 4.92, P 8.71, Ag 13.91 
Melting point: 129-134 ºC 
IR (KBr): 3053, 2931, 1701, 1550, 1572, 1478, 1434, 1389, 1313, 1247, 1095, 
1026, 996, 911, 744, 693, 612, 503, 427 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
E.6.8 [Ag2(dda)(PPh3)4].H2O (30) 
0.418 g (1.0 mmol) of [Ag2(dda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3. 
 Yield: 1.298 g (65.16%) 
% Calc:     C 66.41, H 5.3, P 8.35, Ag 14.55 
% Found: C 66.05, H 5.66, P 8.47, Ag 14.67 
Melting point: 130-135 ºC 
IR (KBr): 3051, 2921, 2849, 1701, 1635, 1478, 1433, 1309, 1180, 1095, 1027, 
995, 752, 693, 499 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
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E.6.9 [Ag2(udda)(PPh3)4] (37) 
0.432 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 1.574 g (6.0 mmol) 
of PPh3 
 Yield: 1.364 g (67.99%) 
% Calc:     C67.40, H 5.32, P 8.38, Ag 14.59 
% Found: C 67.28, H 5.27, P 8.51, Ag 14.99 
Melting point: 131-136 ºC 
IR (KBr): 3051, 2923, 2852, 1556, 1479, 1433, 1395, 1304, 1094, 1027, 743, 
693, 512, 503, 438 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
 
E.6.10 [Ag2(uddca)(PPh3)5].C7H8 (38) 
0.460 g (1.0 mmol) of [Ag2(uddca)] in 30 mls of toluene reacted with 1.574 g (6.0 
mmol) of PPh3 
 Yield: 1.134 g (55.75%) 
% Calc:     C70.97, H 5.69, P 8.32, Ag 11.59 
% Found: C 70.87, H 5.57, P 9.03, Ag 11.34 
Melting point: 132-137ºC 
IR (KBr): 3051, 2918, 2846, 1563, 1433, 1476, 1380, 1307, 1178, 1091, 1068, 
1026, 996, 742, 617, 512, 420 cm-1. 
Solubility: Partially soluble in chloroform and methanol, not soluble in water, 
acetone and DMSO.  
Note : Crystals of [Ag2(uddca)(PPh3)6] 38A deposited from the mother liquor 
when it was left to stand for several weeks. 
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E.7 SYNTHESIS OF SILVER DIPHENYLPHOSPHINEMETHANE 
COMPLEXES 
E.7.1 [Ag2(prda)(dppm)3].C7H8 (39) 
0.319 g (1.0 mmol) of [Ag2(prda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of Dppm. 
Yield: 0.9759 g (89.77%) 
% Calc: C 58.24, H 4.89, P 9.19, Ag 21.35 
% Found: C 58.72, H 4.50, P 9.98, Ag 21.09 
Melting point: 133-138 ºC 
IR (KBr): 3644.35, 3426.46, 3049.19, 1592.27, 1537.01, 1483.35, 1434.77, 
1336.15, 1241.36, 1164.94, 1100.61, 1025.67, 998.26, 910.64, 794.44, 737.94, 
720.35, 692.76, 515.46, 503.81, 480.05 cm-1. 
Solubility: Partially soluble in methanol, ethanol, DMSO, acetone, chloroform, 
insoluble in water 
 
E.7.2 [Ag2(bda)(dppm)3].C7H8 (40) 
0.334 g (1.0 mmol) of [Ag2(bda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of Dppm. 
Yield: 0.9164 g (83.15%) 
% Calc: C 58.61, H 5.02, P 9.07, Ag 21.06 
% Found: C 57.40, H 4.31, P 9.97, Ag 21.88 
Melting point: 126-131 ºC 
IR (KBr): 3660.25, 3426.30, 3052.71, 1547.11, 1483.81, 1435.41, 1385.50, 
1100.09, 1000.04, 760.31, 736.84, 722.32, 693.77, 515.13, 480.51, 428.83 cm-1. 
Solubility: insoluble in methanol, partially soluble in water, ethanol, acetone, 
chloroform and DMSO  
 
E.7.3 [Ag2(pda)(dppm)4] (41) 
0.348 g (1.0 mmol) of [Ag2(pda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of Dppm. 
Yield: 0.9236 g (82.75%) 
% Calc: C 59.05, H 4.87, P 11.08, Ag 18.81 
% Found: C58.07, H 4.47, P 10.41, Ag 18.91 
146 
 
Melting point: 127-132 ºC 
IR (KBr): 3432.35, 3050.34, 1557.02, 1483.46, 1435.28, 1382.45, 1100.70, 
737.47, 696.16, 515.68, 480.30 cm-1. 
Solubility: insoluble in water, ethanol, acetone, DMSO, partially soluble in 
methanol, chloroform 
 
E.7.4 [Ag2(hxda)(dppm)4] (42) 
0.362 g (1.0 mmol) of [Ag2(hxda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of Dppm. 
Yield: 0.580 g (51.32%) 
% Calc: C 60.02, H 5.21, P 10.67, Ag 18.59 
% Found: C 59.00, H 4.66 , P10.26, Ag 18.83 
Melting point: 128-133 ºC 
IR (KBr): 3434.27, 3049.86, 2922.70, 1555.25, 1483.83, 1436.18, 1390.71, 
1311.50, 1142.58, 1100.20, 999.14, 784.56, 739.88, 720.78, 694.84, 516.29, 
479.92 cm-1. 
Solubility: partially soluble in ethanol, DMSO, chloroform, insoluble in 
methanol, water, acetone.  
 
E.7.5 [Ag2(hpda)(dppm)4] (43) 
0.376 g (1.0 mmol) of [Ag2(hpda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield: 0.9505 g (83.08%) 
% Calc:     C 60.32, H 5.32, P 10.55, Ag 18.36 
% Found:  C 59.46, H 4.65, P 11.02, Ag 18.78 
Melting point: 129-134 ºC 
IR (KBr): 3424.14, 3050.37, 2937.01, 1559.41, 1483.63, 1435.27, 1395.44, 
1099.57, 1026.34, 999.10, 737.88, 720.10, 693.84, 515.35, 480.02cm-1. 
Solubility: insoluble in water, ethanol, acetone, partially soluble in methanol, 
chloroform and DMSO  
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E.7.6 [Ag2(oda)(dppm)4] (44) 
0.390 g (1.0 mmol) of [Ag2(oda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield: 0.689 g (59.49%) 
% Calc: C 60.62, H 5.43, P 10.42, Ag 18.15 
% Found: C 60.47, H 4.99, P 10.00, Ag 18.76 
Melting point: 130-135 ºC 
IR (KBr): 3432.58, 3050.99, 2940.41, 1560.87, 1484.33, 1435.37, 1389.85, 
1100.00, 999.47, 740.40, 722.41, 694.79, 515.93, 482.32 cm-1. 
Solubility: insoluble in water, partially soluble in methanol, ethanol, acetone, 
chloroform and DMSO  
 
E.7.7 [Ag2(nda)(dppm)4] (45) 
0.404 g (1.0 mmol) of [Ag2(nda)] in 30 mls of  toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield: 0.9435 g (80.50%) 
% Calc: C 60.91, H 5.53, P 10.30, Ag 17.94 
% Found: C 59.67, H 4.93, P 10.82, Ag 17.62 
Melting point: 131-136 ºC 
IR (KBr): 3426.72, 3051.37, 2929.90, 1553.79, 1483.62, 1435.34, 1392.50, 
1099.21, 999.16, 740.87, 721.31, 693.97, 514.83, 480.77 cm-1. 
Solubility: partially soluble in water methanol, ethanol, acetone, chloroform and 
DMSO 
 
E.7.8 [Ag(ddaH)(dppm)3].3H2O (46) 
0.418 g (1.0 mmol) of [Ag2(dda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield: 0.5925 g (49.95%) 
% Calc: C 61.10, H 5.79, P 10.16, Ag 11.19 
% Found: C 60.61, H5.29, P 9.88, Ag 11.33 
Melting point: 132-137 ºC 
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IR (KBr): 3450.30, 3051.37, 2923.89, 2849.61, 1714.34, 1555.08, 1483.28, 
1434.92, 1386.65, 1306.68, 1183.53, 1099.85, 1026.14, 998.65, 785.21, 740.09, 
719.67, 694.71, 515.19, 481.69, 440.32 cm-1. 
Solubility: insoluble in water methanol, ethanol, acetone, chloroform and 
DMSO 
 
E.7.9 [Ag2(udda)(dppm)4] (47) 
0.432 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield:  0.730 g (60.83%) 
% Calc: C 61.48, H 5.73, P 10.07, Ag 17.53 
% Found: C 60.84, H 5.15, P 10.46, Ag 17.98 
Melting point: 133-138 ºC 
IR (KBr): 3431.91, 3050.22, 2922.36, 2850.19, 1552.42, 1483.32, 1435.08, 
1394.67, 1099.33, 999.03, 788.47, 739.67, 721.42, 693.37, 515.21, 480.47, 
442.86 cm-1. 
Solubility: Insoluble in water, partially soluble in methanol, ethanol, DMSO, 
Chloroform and acetone.  
 
E.7.10 [Ag2(ddda)(dppm)4].H2O (48) 
0.446 g (1.0 mmol) of [Ag2(ddda)] in 30 mls of toluene reacted with 0.768 g (2.0 
mmol) of dppm. 
Yield: 0.7163 g (59.03%) 
% Calc: C 61.57, H 6.32, P 9.48, Ag 17.08 
% Found: C 61.43, H 5.61, P 9.36, Ag 17.69 
Melting point: 126-131 ºC 
IR (KBr): 3431.61, 3051.65, 2923.27, 2850.51, 2359.66, 1553.15, 1484.55, 
1435.63, 1386.15, 1100.18, 999.41, 789.90, 740.27, 722.98, 694.61, 516.62, 
481.04 cm-1. 
Solubility: insoluble in water, ethanol, acetone, partially soluble in methanol, 
chloroform, DMSO 
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E.7.11 [Ag2(uddca)(dppm)4].2H2O (49) 
0.460 g (1.0 mmol) of [Ag2(uddca)] in 30 mls of toluene reacted with 0.768 g 
(2.0 mmol) of dppm. 
Yield: 0.8652 g (70.45%) 
% Calc:     C 60.29, H 6.07, P 9.57, Ag 16.66 
% Found: C 59.71, H 5.25, P 9.93, Ag 16.98 
Melting point: 127-132 ºC 
 
IR (KBr): 3423.18, 3051.30, 3019.92, 2920.52, 2850.36, 1550.73, 1484.47, 
1466.33, 1435.47, 1396.68, 1309.65, 1145.59, 1099.88, 1026.29, 999.31, 
788.47, 740.26, 723.32, 693.96, 668.79, 516.56, 479.79, 438.99 cm-1. 
Solubility: insoluble in water, partially soluble in methanol, ethanol, acetone, 
chloroform and DMSO  
 
E.8 SYNTHESIS OF    SILVERDICARBOXYLATE 
DIPHENYLPHOSPHINETHANE COMPLEXES 
 
E.8.1 [Ag2(prda)(dppe)4].H2O (50) 
0.319 g (1.0 mmol) of [Ag2(prda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of dppe. 
Yield: 0.906 g (81.18%) 
% Calc: C 59.41, H 5.41, P 10.39, Ag 18.09 
% Found: C 58.24, H 4.48, P 11.32, Ag 18.81 
Melting point: 128-133 ºC 
IR (KBr): 3431.68, 3051.61, 1556.21, 1482.77, 1434.60, 1331.95, 1175.42, 
1100.34, 1026.57, 998.93, 926.06, 742.99, 723.86, 694.59, 654.76, 509.74, 
482.64, 447.22 cm-1. 
Solubility: partially soluble in ethanol, DMSO, insoluble in methanol, acetone, 
chloroform, water 
  
E.8.2 [Ag2(bda)(dppe)4] (51) 
0.334 g (1.0 mmol) of [Ag2(bda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of  dppe. 
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Yield: 0.608 g (53.75%) 
% Calc: C 60.62, H 5.43, P 10.42, Ag 18.15 
% Found: C 59.63,  H 4.75, P 10.98, Ag 18.93 
Melting point: 129-134ºC 
IR (KBr): 3432.01, 3052.01, 1552.07, 1482.66, 1434.25, 1405.33, 1176.51, 
1100.09, 1026.42, 998.84, 744.04, 729.65, 694.70, 656.18, 511.84, 479.87 cm-1. 
Solubility: partially soluble in water, acetone, methanol, ethanol, chloroform and 
DMSO  
 
E.8.3 [Ag2(pda)(dppe)3].4H2O (52) 
0.348 g (1.0 mmol) of [Ag2(pda)] in 30 mls of toluene reacted with 0.797g (2.0 
mmol) of dppe. 
Yield: 0.7261 g (63.41%) 
% Calc:     C 53.22, H 5.61, P 8.76, Ag 20.34 
% Found: C 52.17,  H 4.21, P 9.46, Ag 20.49 
Melting point: 130-135ºC 
IR (KBr): 3418.67, 3050.54, 1552.60, 1482.99, 1434.13, 1400.26, 1311.86, 
1176.71, 1099.57, 1069.05, 1026.53, 998.82, 884.74, 740.81, 726.81, 694.68, 
511.33, 481.78, 449.11 cm-1. 
Solubility: partially soluble in methanol, chloroform, insoluble in ethanol, 
acetone, DMSO  
 
E.8.4 [Ag2(hxda)(dppe)4] (53) 
0.362 g (1.0 mmol) of [Ag2(hxda)] in 30 mls of Toluene reacted with 0.797 g 
(2.0 mmol) of dppe. 
Yield:   0.8416 g (72.56%) 
% Calc:    C 61.20, H 5.63, P 10.18, Ag 17.73 
% Found: C 61.78, H 5.10, P 10.53, Ag 17.11 
Melting point: 131-136 ºC 
IR (KBr): 3432.85, 3049.13, 2919.94, 1691.01, 1555.63, 1483.18, 1434.45, 
1403.85, 1310.76, 1239.33, 1099.39, 1069.60, 1026.86, 999.63, 881.40, 741.52, 
718.84, 692.97, 513.53, 482.10 cm-1. 
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Solubility: partially soluble in water, methanol, ethanol, DMSO, insoluble in 
acetone, chloroform.  
 
E.8.5 [Ag2(hpda)(dppe)3] (54) 
0.376 g (1.0 mmol) of [Ag2(hpda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of dppe. 
Yield:   0.6965 g (59.37%) 
% Calc:    C 57.89, H 5.45, P 9.14, Ag 21.22 
% Found: C 56.84, H 4.80, P 10.26, Ag 21.99 
Melting point: 132-137 ºC 
 
IR (KBr): 3427.21, 3049.98, 2927.69, 1548.43, 1482.84, 1434.58, 1401.36, 
1308.83, 1177.74, 1100.15, 1069.08, 1026.16, 998.58, 925.59, 743.48, 758.43, 
693.36, 509.87, 480.28, 447.93 cm-1. 
Solubility: insoluble in water methanol, ethanol, acetone, chloroform and 
DMSO 
 
E.8.6 [Ag2(oda)(dppe)4] (55) 
0.390 g (1.0 mmol) of [Ag2(oda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of dppe. 
Yield: 0.845 g (71.18%) 
% Calc: C 61.75, H 5.83, P 9.95, Ag 17.73 
% Found: C 60.13, H 5.02, P 10.25, Ag 17.86 
 Melting point: 133-138 ºC 
IR (KBr): 3441.09, 2935.88, 1545.08, 1483.44, 1434.23, 1398.45, 1175.72, 
1100.11, 1027.33, 740.83, 726.94, 693.94, 511.59, 477.76 cm-1. 
Solubility: insoluble in water methanol, ethanol, acetone, chloroform and 
 DMSO 
 
E.8.7 [Ag2(nda)(dppe)4].2H2O (56) 
0.404 g (1.0 mmol) of [Ag2(nda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of dppe. 
Yield: 0.7634 g (63.56%) 
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% Calc:    C 60.29, H 6.07, P 9.57, Ag 16.66 
% Found: C 60.43, H 5.17, P 10.71, Ag 16.88 
Melting point: 127-132ºC 
IR (KBr): 3433.58, 3050.30, 2922.85, 1560.67, 1482.99, 1434.25, 1399.80, 
1175.42, 1099.22, 1026.42, 999.34, 741.71, 723.43, 694.82, 510.84,481.90 cm-1. 
Solubility: insoluble in water methanol, ethanol, acetone, chloroform and 
DMSO. 
 
E.8.8 [Ag2(dda)(dppe)4] (57) 
0.418 g (1.0 mmol) of [Ag2(dda)] in 30 mls of toluene reacted with 0.797  (2.0 
mmol) of dppe. 
Yield: 0.8132 g (66.93%) 
% Calc:    C 62.27, H 6.02, P 9.73, Ag 16.95 
% Found: C 62.52, H 5.57, P 10.29, Ag 16.17 
Melting point: 128-133ºC 
IR (KBr): 3438.20, 3051.81, 2923.91, 2850.61, 1556.19, 1482.94, 1434.57, 
1404.53, 1233.75, 1174.62, 1099.92, 1026.53, 999.10, 744.66, 726.85, 694.85, 
510.55, 481.80 cm-1. 
Solubility: insoluble in water methanol, ethanol, acetone, chloroform, partially 
soluble in DMSO 
 
E.8.9 [Ag2(udda)(dppe)4].H2O (58) 
0.432 g (1.0 mmol) of [Ag2(udda)] in 30 mls of toluene reacted with 0.797 g  
(2.0 mmol) of dppe. 
Yield: 0.950 g (77.29%) 
% Calc:   C 61.67, H 6.18, P 9.49, Ag 16.53 
% Found: C 61.49, H 5.51, P 9.29, Ag 16.13 
Melting point: 129-134 ºC 
IR (KBr): 3439.42, 3052.04, 2923.37, 2850.50, 1550.42, 1483.01, 1434.50, 
1399.88, 1311.59, 1176.36, 1099.98, 1026.51, 999.24, 729.77, 695.28, 509.52, 
482.64 cm-1. 
Solubility: partially soluble in water, DMSO, chloroform, insoluble in methanol, 
ethanol and acetone.  
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E.8.10 [Ag2(ddda)(dppe)4] (59) 
0.446 g (1.0 mmol) of [Ag2(ddda)] in 30 mls of toluene reacted with 0.797 g (2.0 
mmol) of dppe. 
Yield: 0.5731 g (46.10%) 
% Calc: C 62.78, H 6.20, P 9.52, Ag 16.57 
% Found: C 63.62,  H 5.74 , P 9.59, Ag 16.61 
Melting point: 130-135ºC 
IR (KBr): 3442.72, 3052.64, 2920.17, 2849.27, 1697.99, 1637.97, 1555.56, 
1482.84, 1434.42, 1403.17, 1255.57, 1185.55, 1099.39, 1026.56, 999.35, 
881.87, 743.43, 695.04, 512.03, 481.54 cm-1. 
Solubility: insoluble in water methanol, ethanol, DMSO, soluble in acetone, 
chloroform. 
 
E.8.11 [Ag2(uddca)(dppe)4] (60) 
0.460 g (1.0 mmol) of [Ag2(uddca)] in 30 mls of toluene reacted with 0.797 g 
(2.0 mmol) of dppe. 
Yield: 0.681 g (54.17%) 
% Calc: C 63.02, H 6.29, P 9.42, Ag 16.41 
% Found: C62.40, H5.66, P 9.89, Ag 16.75 
Melting point: 131-136 ºC 
IR (KBr): 3439.52, 3051.83, 2922.59, 2850.66, 1741.22, 1630.31, 1551.14, 
1483.12, 1466.31, 1434.38, 1400.48, 1310.81, 1274.67, 1175.44, 1099.70, 
1069.56, 1026.98, 999.30, 881.77, 743.05, 728.98, 694.95, 510.92, 481.88 cm-1. 
Solubility: insoluble in water, DMSO, soluble in methanol, ethanol, acetone, 
chloroform.  
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E.9 BIOLOGICAL PREPARATIONS AND METHODS 
 
Fungal isolates: A Candida albicans isolate was obtained from ATCC (American 
Type Culture Collection, Maryland USA) 10231. The isolate was stored on 
Sabouraud Dextrose Agar (SDA) plates at 4C, and was sub cultured monthly from 
the initial culture received. 
 
Sterilisation: was achieved by autoclaving at 121C and 100 lbs/inch for 15mins.  
 
Cell density: 0.250 OD cells in 5mls of Phosphate Buffered Saline (PBS).  
 
R1 Minimal Media (R1MM): is a media made up of Yeast Nitrogen Base without 
amino acids (Ynb) obtained from Becton, Dickenson and Company (Ref: 291940) and 
D (+) Glucose Monohydrate obtained from Reidal-de Haën (Charge lot: 61850). Ynb 
(0.67g) was dissolved in 100 ml of cold distilled water along with D (+) Glucose 
Monohydrate (2 g) in a 200 ml duran bottle. The resulting solution was then left to 
stand for 5 mins and then autoclaved, after autoclaving the bottle was allowed to cool 
before transfer to multiwell plate. The media was stored at 4C. 
Tests were carried out on overnight cultures of candida grown in sabraud’s agar 
(Oxoid) which was made up according to manufacturing instructions. The antifungal 
experiments were carried out in R1 minimal media. 
 
Phosphate buffer saline (PBS): was obtained from Sigma (Lot 71K8201) in tablet 
form and was prepared as follows: 
1 tablet was dissolved in cold distilled water (100 ml) and the resulting solution 
autoclaved for 15 mins. 
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E.9.1 Preparation of complex solutions for antimicrobial susceptibility testing 
 
Solutions of suspensions of test complexes were prepared by dissolving (0.1 g) in 5% 
(5 ml) of DMSO and diluting to 100 cm3 using distilled water to yield a stock solution 
at a concentration of 1000 g/ml.  
 
E.9.2 Antimicrobial Susceptibility testing methods 
 
Yeast susceptibility testing: Each test complex was made into solution following the 
method, from these stock solutions a series of different concentrations were obtained 
by dilution. Concentrations of 1.0 g/ml, 0.5 g/ml, 0.25 g/ml, 0.1 g/ml, 0.09 
g/ml, 0.08 g/ml, 0.07 g/ml and 0.05 g/ml were obtained and through testing the 
IC50 (minimum inhibitory concentration) for each compound was calculated, this was 
done as follows: 
 
96 well microarray analysis plates (Figure 69) were used for yeast susceptibility 
testing. These plates contained 96 wells in which 10g/ml of each test solution could 
be added to every three consecutive wells. A Control, Blank, Amphotericin B (Amp 
B), Silver Nitrate (AgNO3) and Silver Acetate (Ag2(CH3COO)2) were also added to 
the plate. Before each experiment the candida cell density was determined and 
adjusted to OD 0.25 by diluting in PBS (Sigma Aldrich), made up according to 
manufacturer’s instructions. 
 
Control 1: This was used as a standard to which the compounds could be tested 
against. The control was a suspension of R1 minimal media containing 0.250 OD 
cells of C. albicans. 100 l of the control media was then added to the first three wells 
on the plate. 
 
Control 2: Blank; this was a solution of R1MM (100 g/ml) usually added to the last 
three wells on the plate, this was a reference to show that the media containing no 
cells and no test solution would show no growth of cells.  
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Control 3: Amphotericin B; Amp B is well known antifungal agent. This was added to 
the cells to see how good the test compounds measured against one of the best on the 
market. 100 g/ml of this solution was added to the next three consecutive wells after 
the control 1. 
 
Control 4: Silver Nitrate (AgNO3) and Silver acetate (AgAoc); were added to see how 
silver compounds containing no ligand derivative would fair against the test 
complexes containing a dicarboxylic acid. 10 g/ml of these solutions were added to 
the next wells after Amp B. Test complexes were now added at different 
concentrations to the next available wells. 
 
To the wells containing the test complexes, Amp B, AgNO3 and Ag2(CH3COO)2, 90 
g/ml of the R1MM containing C. albicans cells were added, the plate was then 
loaded onto the spectrophotometer and measured at a temp of 37 ºC and left for 24 
hrs, with readings being taken every 4 hrs. Each run was done in triplicate meaning it 
was done once a day for three days. The results were then calculated for IC50 of each 
complex. 
  
Figure 69: 96 well plate 
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E.9.2.1 Antibacterial test 
The antibacterial activity of a series of silver inorganic complexes against a selection 
of Grampositive and Gramnegative bacteria was determined using inoculated 96 well 
plates. A total of seven concentrations of each of silver complex, ligand and silver 
nitrate control were assessed for antibacterial activity. These concentrations were: 50 
ppm, 25 ppm, 10 ppm, 5 ppm, 2.5 ppm, 1 ppm and 0.1 ppm. The water insoluble 
complexes were initially dissolved in DMSO, and subsequently diluted in de-ionised 
water to give the desired concentrations. The bacterial strains tested were MRSA 
(clinical isolate), S. aureus (ATCC 25922), E. coli (ATCC 25923) and E. coli (clinical 
isolate). Stock cultures of the bacteria were grown on plate count agar (PCA-3% w/v 
tryptone, 1% w/v glucose, 2.5 % w/v yeast, 9 % w/v agar, Oxoid). These organisms 
were grown overnight in nutrient rich broth to give a concentration of approximately 
108 cfu/ml. These were diluted one in ten thousand with maximum recovery diluent 
(MRD – 1 % w/v peptone, 8.5 % w/v NaCl, Oxoid) to give working concentrations of 
approximately 104 cfu/ml. 10 l aliquots of each concentration of material was placed 
in separate wells of a 96 well plate. Each test well was inoculated with 90 l of the 
working 104 cfu/ml bacterial isolates. The resulting wells were incubated overnight at 
37°C. Wells containing the ligands, silver nitrate (reference) and bacterial blanks were 
also prepared. All tests were performed in duplicate. The optical absorbance of the 
wells was obtained using an ELISA reader at 632 nm. The resulting absorbance 
values were plotted against the concentration. 
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CONCLUSION 
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The purpose of this study was to generate a series of light stable silver complexes for 
application as potential antimicrobial agents.  The strategy employed the use of the 
aliphatic α, ω-dicarboxylic acids HOOC-(CH2)n-COOH (where n = 1-11) as primary 
ligands and counter ions.  These versatile ligands have previously been shown, in this 
laboratory, to promote variations in structure and nuclearity (chain length dependent). 
The auxiliary ligands chosen were the neutral donor phosphines PPh3, dppm and dppe 
which are known to stabilize Ag+ complexes.66 
  
The α, ω-dicarboxylic acids reacted smoothly with [Ag(CH3COO)] to yield the silver 
dicarboxylate complexes [Ag2(prda)] (1), [Ag2(bda)] (2), [Ag2(pda)] (3), [Ag2(hxda)] 
(4), [Ag2(hpda)](5), [Ag2(oda)] (6), [Ag2(nda)] (7), [Ag2(dda)] (8), [Ag2(udda)] (9), 
[Ag2(ddda)] (10) and [Ag2(uddca)] (11).  Complexes 1-11 were reacted with PPh3 in 
1:2.5, 1:4 and 1:6 molar ratios and with the dppm and dppe in 1:2 molar ratios, 
respectively. 
Thecomplexes[Ag2(prda)(PPh3)3](12),[Ag2(bda)(PPh3)3].C7H8(13), 
[Ag2(pda)(PPh3)3].2H2O  (14), [Ag(hxdaH)(PPh3)2] (15) 
{Ag(hpdaH)(PPh3)3.2H2O}n(16),{Ag2(oda)(PPh3)3.2H2O}n(17), 
[Ag(ndaH)(PPh3)2](18), [Ag2(dda)(PPh3)4].2C7H8(19), [Ag2(udda)(PPh3)2] (20), 
[Ag(ddda)(PPh3)3] (21) and [Ag(uddcaH)(PPh3)2] (22) resulted from the reaction of 
the relevant Ag(I) dicarboxylate salt with 2.5 equivalents of PPh3. 
  
The complexes [Ag2(prda)(PPh3)3].H2O (23), [Ag2(bda)(PPh3)4] (24), 
[Ag2(pda)(PPh3)4] (25), [Ag(hxda)(PPh3)4] .2H2O(26), [Ag2(hpda)(PPh3)4].C7H8(27), 
[Ag2(oda)(PPh3)4].2.C7H8(28), [Ag2(oda)(PPh3)4] (28A), [Ag2(ndaH)(PPh3)4].2H2O 
(29), [Ag2(dda)(PPh3)4].H2O (30), [Ag2 (udda) (PPh3)3] (31), [Ag2 (udda) 
(PPh3)4](31A), [Ag(ddda)(PPh3)3]n (32) and [Ag(PPh3)2(HOOC(CH2)9COO)](33) 
resulted from the reaction of the relevant Ag(I)dicarboxylate salt with 4 equivalents of 
PPh3. 
  
Attempts to react complexes 1-11 with PPh3 in a 1:6 ratio yielded the same product as 
obtained when 4 equivalent of PPh3 were employed and where the dicarboxylate 
ligands were propanedioate (prda), butanedioate (bda), pentanedioate (pda), 
nonanedioate (nda) and decanedioate (dda). The complexes [Ag(hxdaH)(PPh3)3].C7H8 
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(34), [Ag2(hpda)(PPh3)5].C7H8 (35) [Ag2(oda)(PPh3)5].2C7H8 (36) [Ag2(udda)(PPh3)4] 
(37), [Ag2(uddca)(PPh3)5] (38), [Ag2(uddca)(PPh3)6] (38A) were successfully 
generated.  
 
Complexes 1-11 were reacted with dppm in a 1:2 molar ratio to yield the complexes 
[Ag2(prda)(dppm)3]C7H8 (39), [Ag2(bda)(dppm)3].C7H8 (40), [Ag2(pda)(dppm)4] (41), 
[Ag2(hxda)(dppm)4] (42), [Ag2(hpda)(dppm)4] (43), [Ag2(oda)(dppm)4] (44), 
[Ag2(nda)(dppm)4] (45), [Ag(ddaH)(dppm)3].3H2O (46), [Ag2(udda)(dppm)4] (47), 
[Ag2(ddda)(dppm)4].H2O (48), [Ag2(uddca)(dppm)4].2H2O (49), [Ag2(dppm)2(OAc)2].3 
C7H8 (49A). 
 
Complexes 1-11 were reacted with dppe in a 1:2 molar ratio using the same procedure 
employed for the dppm reactions to yield the complexes [Ag2(prda)(dppe)4].H2O(50),  
[Ag2(bda)(dppe)4](51), [Ag2(pda)(dppe)3].4H2O(52), [Ag2(hxda)(dppe)4](53), 
[Ag2(hpda)(dppe)3](54), [Ag2(oda)(dppe)4](55), [Ag2(nda)(dppe)4].2H2O (56), 
[Ag2(dda)(dppe)4] (57), [Ag2(udda)(dppe)4].H2O (58), [Ag2(ddda)(dppe)4] (59), 
[Ag2(uddca)(dppe)4] (60). 
 
All 60 complexes were found to have limited solubilities and complexes 12-60 were 
all relatively light stable compared to simple silver salts such as AgNO3 and their 
structures were found to be diverse (the structures of complexes 16, 17, 18, 22, 28, 
31A, 32, 33, 38A and 48A were determined by X-ray crystallography) with 
mononuclear, dinuclear, polynuclear and polymeric species generated. 
 
The antimicrobial experiments have shown that all of the metal free dicarboxylic 
acids and phosphine based ligands are relatively poor antifungals and display no 
antibacterial activity. Complexes 1-11 are potent in-vitro anti-Candida agents which 
display activity superior/comparable to the clinically used AgNO3 and the state-of -
the -art organic drug Amphothericin B. Only five of the silver dicarboxylates 
(complexes 1, 4, 5, 6 and 7) displayed good antibacterial activity, although it was 
significantly less than that of AgNO3. Furthermore, unlike the the activity of AgNO3 
these five complexes displayed some discrimination in activity towards the Gram 
positive (S. aureus /MRSA) and Gramnegative (E.coli) bacteria. Therefore, it is 
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suggested that the silver dicarboxylate complexes 1-11 do not act on microbial cells in 
the same way as AgNO3.  
All 27 of the PPh3 complexes (12-38) exhibited significant antifungal activity against 
the Candida albicans cells although their activity is, on average, over ten times less 
than that of the equivalent silver dicarboxylate. Only complexes 14, 31, 33, 37 and 38 
are active against the bacterial cells tested.  Complexes 31, 37 and 38 are the only 
complexes that display higher antibacterial activity (comparable to that of AgNO3) 
than antifungal activity, a trend not previously observed.  Complexes 31, 37 and 38 
represent potential therapeutics that warrent further investigation as novel 
antibacterial agents.  
 
The dppm and dppe derivatives 39-60 all exhibited significant antifungal activity 
against the Candida albicans cells.  However, with the exception of complex 39, most 
of their activities are again significantly less than that of the equivalent silver 
dicarboxylate. Only complexes 39, 41 and 52 display any activity against the bacterial 
cells tested.  Complex 41 is interesting as it exhibits good activity against the Gram 
positive MRSA but it is inactive agaist the Gramnegative E.coli.  Complexes 39 and 
52 display some discrimination in activity towards the Grampositive (MRSA) and 
Gramnegative (E.coli) bacteria.  
 
In conclusion this research has shown that structurally diverse, light stable silver 
complexes can be synthesised easily using the aliphatic α, ω-dicarboxylic acids as 
primary, and phosphines as stabilizing donor, ligands.  All of the sixty complexes 
generated are effective antifungal agents with a variation in the degree of activity 
reflecting their structural diversity.  This variation in antifungal activity and the fact 
that only 13 of the complexes display antibacterial properties suggests that a mode of 
action other than simple silver ion release may be responsible for their antimicrobial 
properties.  This class of complex represents a very interesting group of potential 
antifungal agents and a number of the complexes (particularly 31, 37 and 38) may 
offer significant potential as broad spectrum therapeutic antibacterial drugs.     
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